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Abstract 
 
Prostate cancer is the most common male cancer in the UK. Although incidence 
is increasing, prostate cancer mortality is decreasing, mainly owing to the over 
diagnosis of disease that would not have become clinically apparent during the 
patient’s lifetime. The gold-standard for prostate cancer diagnosis is transrectal 
ultrasound guided biopsy of the prostate. Whilst prostate biopsy can inform on 
diagnosis, it’s prognostic ultiltiy is poor. Currently clinicians lack pathological 
biomarkers to differentiate between patients with prostate cancer who have 
indolent disease that can be safely managed with surveillance strategies, and 
those who will go onto develop aggressive disease which requires early radical 
curative treatment.   
 
Phosphorylation of the androgen receptor has been extensively investigated in 
relation to prostate cancer development and progression. Androgen receptor 
phosphorylation has been shown to regulate cellular localisation, transcriptional 
activity, cell growth and sensitivity to androgens in prostate cancer.  However, 
only a small number of studies have investigated the prognostic significance of 
androgen receptor phosphorylation, and only consider a limited number of serine 
residues in clinical specimens.  
 
The research presented in this thesis sought to investigate the prognostic and 
predictive significance of AR phosphorylation at serine 578 in hormone-naïve 
prostate cancer. It was hypothesised that pARS578 would be associated with poor 
outcomes in prostate cancer and may be utilised as a prognostic marker at 
diagnosis in prostate cancer and predict response to drug treatment with a PKC 
inhibitor.  It was also hypothesised that PKC, the putative kinase for 
phosphorylation at serine 578, would be associated with poor outcomes and may 
offer a potential therapeutic target in prostate cancer. 
 
In the current study, the phosphorylation site of primary interest was serine 578. 
Scansite 2.0, an online kinase search tool, predicted that PKC is the putative 
kinase mediating phosphorylation at serine 578 on the androgen receptor. 
Phosphorylation of the androgen receptor at serine 578 has been linked with 
increased AR transcriptional activity, cell growth, nuclear cytoplasmic shuttling, 
3 
 
modulation of other AR phosphorylation sites and DNA-repair mechanisms. The 
prognostic significance of androgen receptor phosphorylation at serine 81 was 
also investigated in this study. Serine 81 is phosphorylated in response to DHT 
via an alternative pathway to that of serine 578. Serine 81 phosphorylation is 
associated with increased androgen receptor transcriptional activity and 
increased cell growth in prostate cancer. It was therefore hypothesised that 
androgen receptor phosphorylation at serine 578 and serine 81 would be 
associated with poor outcome measures in prostate cancer.  
 
Immunohistochemical analysis was performed in a cohort of 105 hormone-naïve 
prostate cancer patients undergoing active surveillance, representing a cohort of 
patients with low-risk disease, as defined by current clinical markers such as PSA 
and Gleason score at diagnosis. Nuclear PKC expression was significantly 
associated with pARS578 expression in the clinical specimens, supporting the 
prediction of Scnasite 2.0 that PKC is the kinase responsible for phosphorylation 
of the AR at this site. High cytoplasmic expression of pARS81 was associated with 
decreased time to intervention (HR 2.76 (95% CI 1.1-7.3), p=0.032). There was 
no association between pARS578 and time to intervention in this cohort. Analysis 
of combined expression of both phosphorylation sites revealed an association 
between high dual expression of cytoplasmic pARS81 and cytoplasmic pARS578 and 
decreased time to treatment intervention (HR 2.35 (95% CI 1.2-4.6), p=0.031). 
These results suggest a synergistic prognostic effect when these two 
phosphorylation sites are combined and identifies a sub-population of low-risk 
prostate cancer patients who are at increased risk of disease progression. 
 
A second study was conducted to investigate if these results could be replicated 
in a cohort of prostate cancer patients with all stages of disease at diagnosis. 
Immunohistochemical analysis in 90 hormone-naïve prostate cancer patients 
found that high expression of nuclear pARS81 (HR 2.1 (95% CI 1.1 – 4.2), p=0.030), 
nuclear pARS578 (HR 2.24 (95% CI 1.0-4.9), p=0.036) and cytoplasmic pARS578 (HR 
4.54 (95% CI 2.0-10.4), p=<0.001) was associated with decreased disease 
survival. Furthermore, high expression of cytoplasmic pARS578 was associated with 
decreased time to biochemical relapse (HR 2.1 (95% CI 1.0-4.2), p=0.034) and 
decreased disease-specific survival following biochemical relapse (HR 3.2 (95% CI 
1.0-9.9), p=0.034). Dual expression of nuclear, cytoplasmic and total pARS81 and 
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pARS578 were all associated with decreased-disease specific survival, suggesting 
that there is a sub-population of prostate cancer patients who may benefit from 
dual targeted therapy with androgen deprivation therapy and PKC inhibitors.   
 
A validation cohort of 243 hormone-naïve prostate cancer patients with all 
stages of disease was utilised to verify the results of the second cohort. 
Unfortunately, due to technical issues and time constraints, IHC could not be 
completed for the phosphorylation sites of interest in all patients. Despite this, 
high expression of cytoplasmic pARS578 was significantly associated with 
decreased time to biochemical relapse (HR 2.9 (95% CI 1.0-8.2), p=0.037) and 
trended towards an association with decreased overall survival (p=0.076). 
Interestingly, dual expression of high cytoplasmic pARS81 and cytoplasmic pARS578 
was associated with decreased overall survival (HR 2.1 (95% CI 1.3-3.3) p=0.001) 
despite neither phosphorylation site independently predicting decreased overall 
survival.  
 
Lastly, a study to develop a technique for isolation, propagation and 
characterisation of primary prostate cancer cells from TRUS biopsy specimens 
was undertaken. Two primary prostate cell cultures were developed which were 
confirmed to have a malignant luminal epithelial cell phenotype with a 
functional AR using flow cytometry, RT-PCR and immunofluorescence. This 
technique is of high translational relevance, as it provides a model with 
potential to identify biomarkers to predict individual patient’s response to 
prostate cancer therapies.  
 
Overall these results suggest that androgen receptor phosphorylated at serine 81 
and serine 578 are associated with poor outcomes in prostate cancer and are 
potential targets for new drug therapies. Additional studies are required to 
validate these results in a larger multi-centre cohort of prostate cancer patients 
before either of these phosphorylation sites can be utilised as a biomarker in 
clinical practice.  
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Chapter 1 Introduction 
 
1.1 Prostate cancer epidemiology, pathology and prognostic factors 
 
1.1.1 Prostate cancer incidence, mortality and survival 
 
Prostate cancer is the most common male cancer in the UK, with 46,690 new 
cases diagnosed in 2014. (1) The incidence of prostate cancer has been 
increasing in the UK for the past 40 years (Figure 1.1). Although currently the 
second most common cancer overall, it is predicted that by 2035 there will be 
more than 75,000 new cases of prostate cancer each year, making it the most 
common cancer overall. (2) The increased incidence of prostate cancer is mainly 
due to the introduction of the prostate specific antigen (PSA) blood test in the 
late 1970s and the increased use of transurethral resection of the prostate 
(TURP) as a treatment for benign prostatic hyperplasia (BPH). This has resulted 
not only in the earlier detection of prostate cancer but also diagnosis of disease 
that may not have become clinically apparent during the patient’s life time.  
This over-diagnosis has resulted in over-treatment, with significant associated 
healthcare costs and unnecessary side effects related to treatment. (3) 
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Figure 1.1 Incidence of prostate cancer in the UK over time 
 
 
Age-standardised incidence rates per 100,000 men from 1993-2014. (1) 
 
 
In the UK, prostate cancer-associated mortality has increased since the 1970s. 
Mortality rates have increased by more than 50% between the early 1970s and 
early 1990s. In the last decade, however, prostate cancer mortality has fallen by 
13% and is projected to decrease by a further 16% in the next twenty years. (1) 
There is ongoing debate as to why mortality rates have decreased in the UK but 
it is thought that this is mainly due to increased use of the PSA test resulting in 
over-detection of low risk, localised prostate cancer and more aggressive 
treatment in prostate cancer patients. (4-7)  
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1.1.2 Prostate cancer risk factors 
 
No definite modifiable risk factors have been identified for the development of 
prostate cancer. Whilst obesity appears to be linked to aggressiveness of 
prostate cancer, further evidence is required before it can be determined that 
obesity is a definite risk factor. (8, 9)  
 
A number of non-modifiable risk factors have been identified that are thought to 
increase the probability of developing prostate cancer. 
 
1.1.2.1 Age 
 
Advancing age is the most common risk factor associated with prostate cancer 
development. Greater than half of all cases diagnosed are in those aged 70 years 
and over. The peak rate of incidence of prostate cancer is in the 90 years and 
over age group. (1) 
1.1.2.2 Ethnicity 
 
Whilst the overall life-time risk of prostate cancer in men in the UK is 1 in 8, 
there is significant variation amongst men of different ethnicity. (1) In England, 
it is estimated that 1 in 4 black men will be diagnosed with prostate cancer, 
double the estimated rate in white men. Asian men have the lowest life-time 
risk, estimated to occur in 1 in 13 men. (10) Similar trends are observed in the 
USA. (11) 
1.1.2.3 Family History 
 
 
Men with a first degree relative with prostate cancer are at least twice as likely 
to develop prostate cancer themselves. The risk increases further with two first 
degree relatives affected. (12, 13) Family history of a mother with breast cancer 
is associated with a 1.24-fold increased risk of prostate cancer. (14) A further 
study has shown that a family history of both prostate and breast cancer 
increases the risk of prostate cancer development by 89% than compared to a 
family history of prostate cancer alone. (15) 
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1.1.2.4 Genetic factors 
 
 
Genome wide association studies have identified more than 70 genetic variations 
associated with an increased risk of prostate cancer. Although the majority of 
these variations have low prevalence, combined they account for approximately 
30% of hereditary prostate cancer risk. (16) 
 
The BRCA1 and BRCA2 genes, well recognised for their role in the increased risk 
of breast cancer, are also associated with increased incidence of prostate 
cancer. It is estimated that 2% of men diagnosed with early onset prostate 
cancer have a BRCA2 mutation, compared to 1 in 300 in the general population. 
(17, 18) Germline BRCA2 mutations are associated with an 8.6-fold increased risk 
of prostate cancer development at or before 65 years of age, whilst germline 
BRCA1 mutation is associated with a more modest increased risk of 3.75-fold. 
(19, 20) In men with BRCA2 mutation and an elevated PSA, 48% were found to 
have prostate cancer on subsequent biopsy and were more likely to have 
intermediate or high-risk disease, suggesting that targeted PSA screening in this 
population is likely to be of benefit. (21)  
 
1.1.3 Normal Prostate Anatomy and Histology 
 
1.1.3.1 Prostate Anatomy  
 
 
The prostate is a tubulo-alveolar exocrine gland that forms part of the male 
reproductive system. It surrounds the prostatic urethra, sitting inferior to the 
bladder neck and anterior to the rectum and is of similar size to a walnut (Figure 
1.2).   
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Figure 1.2 The anatomical relations of the prostate gland (22) 
 
 
The prostate gland is approximately the size of a walnut and sits inferior to 
the bladder and anterior to the rectum 
 
McNeal described four histologically distinct zones within the prostate (Figure 
1.3). (23) The peripheral zone is found postero-laterally and forms 70% of the 
prostate. Approximately 70-80% of prostate cancers arise in the peripheral zone. 
The central zone forms 25% of the prostate and is positioned anterior to the 
peripheral zone. Fewer than 5% of prostate cancers arise in the central zone. 
The transitional zone surrounds the prostatic urethra and is the exclusive site of 
origin of BPH. It forms only 5% of the prostate but approximately 10% of prostate 
cancers arise here.  Finally, the anterior fibro-muscular zone is devoid of 
glandular components, and forms the anterior surface of the prostate.  
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Figure 1.3 Sagittal image of the zonal anatomy of the prostate (24) 
 
 
 
The prostate is made up of four histologically distinct zones. The peripheral 
zone, located postero-laterally, is the largest zone and most common site of 
prostate cancer, with 70-80% of prostate cancers arising here.  
 
1.1.3.2 Prostate Histology 
 
 
The normal prostate is composed of glands surrounded by stroma (Figure 1.4). 
The glandular lumen is lined by secretory luminal epithelial cells which express 
the androgen receptor (AR). These tall, columnar epithelial cells secrete 
prostatic acid phosphatase (PAP), PSA and human kallikrein-2 into the lumen of 
the gland to form seminal fluid. Basal epithelial cells separate luminal epithelial 
cells from the basement membrane and are thought to secrete components of 
the basement membrane. These low, cuboidal epithelial cells have low 
expression of AR. Amongst the basal cell population, it is proposed that 
progenitor stem cells produce prostatic epithelial cells via intermediate cell 
stages. (25) Neuroendocrine cells, the third epithelial cell type found within the 
prostate, are irregularly distributed throughout the glands. They do not express 
AR and their role is not fully understood.  
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The fibromuscular stroma of the prostate surrounds the glands and is composed 
of fibroblasts, smooth muscle cells, endothelial cells, dendritic cells, nerve cells 
and inflammatory infiltrates.   
Figure 1.4 Normal histology of the prostate (26) 
 
 
Glandular lumens within the prostate are lined with secretory epithelial 
cells on a basement membrane/ basal lamina. Basal cells separate the 
secretory epithelial cells from the basement membrane and secrete 
components of the basement membrane. Neuroendocrine cells are 
irregularly dispersed throughout the gland. 
 
1.1.4 Prostate Pathology 
 
1.1.4.1 Benign Prostatic Hyperplasia 
 
 
The prostate is the only internal organ in men that continues to grow throughout 
adulthood. In BPH, there is benign proliferation of both stromal and epithelial 
components of the prostate, occurring exclusively in the transitional zone 
(Figure 1.5).  
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Figure 1.5 Histopathology of normal prostate tissue and BPH (27) 
 
 
 
(A) Normal prostate tissue and (B) BPH characterised by epithelial and stromal 
hyperplasia. 
 
As the transitional zone enlarges, there is compression of the peripheral zone. 
Androgens are known to play a role in BPH; castrated pre-pubescent males do 
not develop BPH in later life. BPH is so common in men, that it is viewed by 
many as a normal part of the ageing process. It is estimated that 20% of men in 
their 40s will have BPH rising to 80-90% of men in their 70s and 80s. (28) The 
clinical manifestation of BPH is with bothersome lower urinary tract symptoms 
(LUTS) comprised of urinary frequency, urinary urgency, hesitancy and 
incomplete bladder emptying. Complications of BPH include recurrent urinary 
tract infection (UTI), bladder calculi and acute urinary retention. There is no 
association between BPH and the later development of prostate cancer. (29) 
Treatment for BPH includes conservative management with lifestyle advice 
initially where appropriate, before progressing to medical treatment and/or 
surgery if required. Medical management is with 5-alpha reductase inhibitors, 
which inhibits the conversion of testosterone to the more potent 
dihydrotestosterone (DHT), and alpha-blockers, which cause prostatic smooth 
muscle relaxation. The mainstay of surgical management in BPH is TURP, 
however this is becoming less common with the success of medical management.  
1.1.4.2 High-grade Prostatic Intraepithelial Neoplasia 
 
High-grade prostatic intraepithelial neoplasia (HGPIN) is an asymptomatic, 
pathological entity that is a premalignant lesion of prostate adenocarcinoma. It 
is characterised by the presence of atypical epithelial cells with prominent 
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nucleoli, increased nuclear-to-cytoplasmic ratio and increased nuclear size. In 
addition, there is increased proliferation of luminal epithelial cells, with 
complete or partial preservation of the basal cell layer but no invasion into the 
surrounding stroma (Figure 1.6). As with prostate cancer, HGPIN is most 
commonly identified in the peripheral zone and can be multifocal. HGPIN is 
more common with advancing age. (30) There is no evidence that HGPIN causes 
elevation of serum PSA. HGPIN has been found to be independently associated 
with increased risk of developing prostate cancer, particularly if multifocal. (31) 
As such, patients with HGPIN in ≥3 biopsy sites on an otherwise negative prostate 
biopsy are recommended to have repeat biopsy. (32) 
 
Figure 1.6 Histopathology of high-grade prostatic intraepithelial neoplasia 
(30) 
 
 
 
(A) Haematoxylin and eosin (H&E) stained section of HGPIN with luminal 
epithelial cell proliferation and prominent nuclei and nucleoli (B) Prostate 
biopsy section stained for high molecular weight keratin, a basal cell marker, 
showing HGPIN with disruption of the basal cell layer 
 
 
1.1.4.3 Atypical small acinar proliferation 
 
 
Atypical small acinar proliferation (ASAP) is a histological entity by which 
prostate needle biopsy specimens contain suspicious foci with features of 
malignancy but is insufficient for definitive diagnosis or exclusion of prostate 
cancer.  Approximately 5% of prostate needle biopsies performed are found to 
contain a focus of ASAP. (33) The presence of ASAP on an initial prostate biopsy 
is associated with a 40% risk of prostate adenocarcinoma on subsequent biopsy. 
(33) It is therefore recommended that patients with ASAP on an otherwise 
negative biopsy should have a repeat biopsy performed. (32) 
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1.1.4.4 Prostate Cancer 
 
 
Acinar adenocarcinoma of the prostate is the most common malignancy of the 
prostate, accounting for more than 90% of prostate cancers. As earlier 
described, it most commonly occurs in the peripheral zone of the prostate but 
can also arise in the transitional and central zones to a lesser extent. Acinar 
adenocarcinoma is characterised by the presence of large nuclei with prominent 
nucleoli, luminal mucin, crystalloids and amorphous eosinophilic secretions and 
most importantly the absence of basal cells. Further pathognomonic features 
include glomerulation, mucinous fibroplasia and perineural invasion (Figure 1.7).  
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Figure 1.7 Histopathology of acinar adenocarcinoma of the prostate (27) 
 
 
H&E stained sections of acinar adenocarcinoma of the prostate with (A) luminal 
mucin and (B) crystalloids, features which are pathognomonic for prostate 
cancer.   
 
 
Non-acinar prostate cancer forms the remaining 5-10% of prostate cancers. 
Subtypes include ductal adenocarcinoma, the most common non-acinar prostate 
cancer, sarcomatoid carcinoma, squamous cell and adenosquamous carcinoma, 
transitional cell carcinoma, small cell carcinoma, basal cell carcinoma and clear 
cell carcinoma. Each subtype has specific histological and clinical features, with 
varying incidence and prognosis. (34) 
 
The main focus of this thesis will be acinar adenocarcinoma of the prostate. 
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1.2 Management principles of prostate cancer 
 
1.2.1 Presentation 
 
 
Currently, there are no recognised signs or symptoms that are reliable predictors 
of prostate cancer. (35) Localised prostate cancer is often asymptomatic, 
whereas locally advanced prostate cancer may produce LUTS, and are difficult 
to distinguish between those secondary to BPH. Less frequently, and only with 
metastatic disease, patients may present with bone pain, fatigue and 
unintentional weight loss.  
 
Most patients are diagnosed with prostate cancer in the UK following 
investigation for LUTS in primary care. (36) Patients who present with LUTS are 
frequently offered a serum PSA test and clinical examination, including digital 
rectal examination (DRE) of the prostate. An elevated PSA and/or abnormal DRE 
should prompt referral for further investigation.  
 
A further small subpopulation of patients will be diagnosed with prostate cancer 
following an incidental finding of malignancy in prostate tissue resected for 
other diseases, such as BPH and bladder cancer.  
 
1.2.2 Diagnosis 
 
 
Definitive diagnosis of prostate cancer is made following histological 
examination of prostate tissue, most commonly obtained via trans rectal 
ultrasound (TRUS) guided biopsy of the prostate. The decision to perform 
prostate biopsy should be made based on PSA level, DRE findings, risk factors 
and co-morbidities. Biopsy is not routinely recommended in patients with a high 
clinical suspicion of prostate cancer and evidence of bone metastases unless 
entering a clinical trial. The Royal College of Pathologists has set out 
recommendations for the reporting of TRUS biopsies to ensure standardisation in 
practice and includes the number and location of the cores obtained, 
histological tumour type, histological grading using both the Gleason grading 
system and grade group, the number of cores involved, an estimate of tumour 
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extent, the presence of perineural invasion and evidence of extra-prostatic 
extension. (37) 
 
Traditionally, TRUS biopsy was offered before cross-sectional imaging had 
confirmed the presence of tumour, however with increasing availability of MRI 
many patients now have an MRI prior to TRUS biopsy. TRUS biopsies are not 
without complication – side effects include discomfort, bleeding, transient 
impotence, urinary retention and rarely, life-threatening sepsis. Despite the use 
of MRI many biopsies are still non-targeted. It is estimated that in non-targeted 
TRUS biopsy 2-10% of patients will have a malignancy that is not detected on the 
initial biopsy. Furthermore, non-targeted TRUS biopsy has been found to detect 
a higher rate of clinically insignificant prostate cancers compared to targeted 
techniques with the use of multi-parametric magnetic resonance imaging (MP-
MRI). The Prostate Imaging-Reporting and Data System version 2 (PI-RADS v2) is 
used to score findings on prostate mpMRI and assign a risk category for the 
likelihood of the presence of clinically significant prostate cancer. Patients are 
assigned a score of 1 to 5, where a score of PI-RADS 1 is associated with a very 
low risk of clinically significant prostate cancer and a score of PI-RADS 5 is 
associated with a very high risk of clinically significant prostate cancer. (38) The 
use of MP-MRI to guide biopsy has been shown to be more specific and less 
sensitive than non-targeted TRUS biopsy in the detection of clinically significant 
prostate cancer. It is estimated that MP-MRI performed before prostate biopsy 
could therefore reduce the number of TRUS biopsies performed by up to 25%. 
(39, 40) Inter-observer variability is a major limitation of mpMRI, (41)  which PI-
RADS v2 aims to overcome. Whilst recent studies of the reproducibility of PI-
RADS v2  has demonstrated ongoing moderate inter-observer variability(42, 43), 
a meta-analysis has shown this scoring system to perform well in terms of 
sensitivity and specificity for prostate cancer detection. (44) As such, the 
National Institute for Clinical Excellence (NICE) is currently considering the 
introduction of MP-MRI before TRUS biopsy.  
 
Following histological confirmation of prostate cancer, clinical staging should be 
completed if the patient is suitable for radical treatment. MP-MRI, or computed 
tomography (CT) if MRI is contraindicated, is recommended to obtain a 
radiological tumour node metastasis (TNM) stage. Once staging is complete, 
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patients should be discussed by a urological cancer multi-disciplinary team 
(MDT) to decide further management.  
 
1.2.3 Current prognostic markers 
 
1.2.3.1 PSA 
 
PSA is a serine protease produced by luminal epithelial cells in the prostate in 
response to androgens. It is encoded by the kallikrein-3 (KLK3) gene in an 
androgen-dependent manner in the normal prostate. PSA forms a major 
component of seminal fluid. It is the protease responsible for cleavage of 
semenogelin I and II, resulting in liquefaction of ejaculate, thus increasing sperm 
motility and aiding fertilisation. (45, 46) 
 
In the normal prostate, the basal cell layer and basement membrane surrounding 
luminal epithelial cells forms a barrier preventing PSA from entering the 
circulation. Prostate cancer causes disruption of this barrier with associated loss 
of the normal glandular architecture, allowing PSA to enter the systemic 
circulation, resulting in an elevated concentration of serum PSA.   
 
PSA is a useful prognostic biomarker in prostate cancer. Increased pre-operative 
PSA levels in patients treated with radical prostatectomy are associated with 
higher Gleason scores, increased risk of extracapsular extension, positive 
surgical margins, seminal vesicle invasion and decreased time to biochemical 
progression. (47) Furthermore, PSA has been shown to predict pathological stage 
in prostate cancer, even when allowing for the increased diagnosis of low-risk, 
localised prostate cancers. (48) PSA is currently used in the NICE guidelines for 
risk stratification for men with localised prostate cancer (Table 1.1). PSA has 
also been used in assessing response to treatment and disease progression. 
 
The 4K panel, a blood test that measures total PSA, free PSA, intact PSA and 
human kallikrein 2 in combination with patient age, can improve prediction of 
reclassification at the first surveillance biopsy in men entering active 
surveillance program. (49) 
 
33 
 
The role of PSA as a screening tool in prostate cancer remains highly 
controversial. Conflicting results have been reported from large population 
studies in the USA and Europe with regards to PSA screening. (6, 50) The Cluster 
Randomized Trial of PSA Testing for Prostate Cancer (CAP) recently reported on 
the effectiveness of a single PSA measurement as a screening tool in the UK. 
There was an increased diagnosis of low-risk prostate cancer in the intervention 
group with no significant difference in prostate cancer mortality at 10 years 
compared to the control group. These findings do not support single PSA testing 
as a screening program for prostate cancer in the UK. (7) Currently, there is no 
screening programme for prostate cancer in the UK. 
Table 1.1 Risk stratification of men with localised prostate cancer (51) 
 
 
Risk category Serum PSA  Gleason score  Clinical stage 
Low <10 ng/ml and ≤6  and T1-T2a 
Intermediate 10-20 ng/ml or 7 or T2b 
High >20 ng/ml or 8-10 or ≥T2c 
 
NICE recommends using serum PSA, Gleason score and clinical stage at diagnosis 
to assign men with localised prostate cancer a risk category. This can aid 
clinicians in deciding the most appropriate management for the patient.  
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1.2.3.2 Gleason  
 
Gleason grading has been well established as a strong predictor of prostate 
cancer prognosis. Along with PSA, Gleason score is used in the NICE guidelines 
for risk stratification for men with localised prostate cancer (Table 1.1).  
Gleason grading was developed in the 1960s and 1970s as a histological grading 
system based on the architectural patterns of malignant cells on H&E stained 
prostate tissue specimens. (52) Traditionally, a score was assigned based on five 
basic grade patterns ranging from 1 to 5, with Gleason Pattern 1 showing very 
well differentiated prostate cancer and Gleason Pattern 5 being the most poorly 
differentiated pattern of prostate cancer. The two predominant Gleason 
patterns were added together to give a score of 2-10. (53) Since its inception, 
several modifications have been made to Gleason grading. Notably, in 2005 the 
International Society of Urological Pathology (ISUP) made a number of 
recommendations for changes to the Gleason grading system. They 
recommended discarding the use of patterns 1-2 and only reporting Gleason 
score 6 and above on needle biopsy specimens. Furthermore, they also 
recommend that should a tertiary pattern be identified on needle biopsy, that is 
the presence of patterns 3, 4 and 5, the tumour should be considered high 
grade. In this instance, the primary pattern and highest grade should be used to 
formulate the overall Gleason score. (54) Since the introduction of the modified 
criteria, there has been an overall upgrading of Gleason score with improvement 
in prognostic value of Gleason grading. (55, 56) In 2014, the ISUP made further 
recommendations to assign new grade groups based on Gleason score, as 
outlined in Table 1.2, and has been approved for use by the World Health 
Organisation (WHO). A recent study of more than 10,500 prostate cancer 
patients enrolled in the CaPSURE registry found the new prognostsic Gleason 
grade groups were associated with prostate cancer-specific mortality and 
development of metastases. (57) It is anticipated that the new grade groups will 
allow more accurate risk stratification, simplify the grading system and 
hopefully reduce the overtreatment of indolent prostate cancers. (58)  
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Table 1.2 Gleason Score Prognostic Grade Groups (58) 
 
Prognostic Grade Group Gleason score 
1 ≤6 
2 3+4 = 7 
3 4+3 = 7 
4 8 
5 9-10 
 
In 2014, the ISUP made recommendations for the new Gleason Score Prognostic 
Grade groups, made up of five prognostically distinct grade groups, and is based 
on the 2005 Gleason score grading criteria.   
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1.2.3.3 TNM stage 
 
The TNM classification is used in the staging of prostate cancer (Table 1.3). The 
T stage can be estimated pre-operatively based on clinical examination, needle 
biopsy results and MRI findings, whilst distant nodal and metastatic disease can 
be detected using CT and bone scans. Clinical T stage has consistently been 
shown to be associated with pathological stage at radical prostatectomy. (59) 
Based on the T stage, patients can be classified as having localised, locally 
advanced or advanced prostate cancer. Furthermore, T stage is an important 
component of the risk stratification system in localised prostate cancer (Table 
1.1). T stage therefore has important implications for the management of 
patients with prostate cancer. TNM stage at diagnosis is associated with survival 
in prostate cancer, with the presence of nodal or metastatic disease associated 
with poor survival outcomes. (51, 60) 
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Table 1.3 The TNM classification system in Prostate Cancer (51) 
 
Stage Sub-stage Definition 
Tumour  Primary Tumour 
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour  
 T1a Tumour incidental histological finding in 5% or less of tissue 
resected 
T1b Tumour incidental histological finding in more than 5% of 
tissue resected  
T1c Tumour identified by needle biopsy, e.g., because of elevated 
PSA  
T2  Tumour confined within prostate 
 T2a Tumour involves one-half of one lobe or less 
T2b Tumour involves more than one-half of one lobe, but not both 
lobes 
T2c Tumour involves both lobes 
T3   Tumour extends through the prostatic capsule 
 T3a Extracapsular extension (unilateral or bilateral) including 
microscopic bladder neck improvement  
T3b Tumour invades seminal vesicle(s)  
T4  Tumour is fixed or invades adjacent structures other than 
seminal vesicles: external sphincter, rectum, levator muscles, 
and/or pelvic wall  
Node  Regional lymph nodes 
 NX Regional lymph nodes cannot be assessed  
N0 No regional lymph nodes metastasis  
N1 Regional lymph node metastasis 
Metastasis  Distant metastasis 
 M0  No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Metastasis at other site(s) 
 
Prostate cancer staging is based on the extent of the primary tumour (T), lymph 
node involvement (N) and the absence or presence of metastases (M). 
 
1.2.4 Management of prostate cancer 
 
 
The management principles of prostate cancer are based predominantly on 
whether the disease is localised, locally advanced or advanced. Localised 
prostate cancer is defined as prostate cancer that is confined to the prostate. 
Locally advanced disease includes T3 and T4 tumours and any tumour that has 
metastasised to local lymph nodes. Advanced prostate cancer denotes distant 
metastatic spread of disease. Radical treatment options should be considered in 
all patients with localised and locally advanced disease whilst taking into 
consideration co-morbidities and patient age. Radical treatment options include 
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active surveillance (AS), radical prostatectomy and radical radiotherapy. Non-
radical treatment options including watchful waiting, hormonal treatment and 
chemotherapy are reserved for those with advanced disease or those who are 
not suitable for radical treatment.  
 
1.2.4.1 Active Surveillance 
 
AS is an observational treatment strategy with curative intent by which patients 
with low to intermediate risk localised prostate cancer are intensively followed 
up and offered radical treatment if there is evidence of disease progression. 
Studies in both the USA and UK comparing surveillance strategies against radical 
treatment in localised prostate cancer have found no significant difference in 
prostate cancer-specific and all cause mortality. (61, 62) AS is a useful strategy 
to avoid overtreatment of indolent disease, thus minimising side-effects of 
radical treatment and the associated health care costs. Only patients who would 
tolerate radical treatment should be offered AS. The recommended protocol for 
AS as per the current NICE guidelines is outlined in Table 1.4. 
Table 1.4 Suggested AS protocol (51) 
 
Timing Tests 
Enrolment MP-MRI (if not already performed) 
Year 1 Serum PSA every 3-4 months 
DRE every 6-12 months 
Prostate re-biopsy at 12 months 
Year 2-4 PSA every 3-6 months 
DRE every 6-12 months 
Year 5 and every subsequent 
year until AS ends 
PSA every 6 months 
DRE every 12 months 
 
Active surveillance involves intensive follow-up of patients with low to 
intermediate risk prostate cancer with regular serum PSA testing, clinical 
examination and repeat biopsy for histological examination. DRE = digitial 
rectal examination 
 
Patients should be offered radical treatment if there is any biochemical, 
histological or clinical evidence of disease progression. No set criteria have been 
recommended to indicate disease progression but it is generally accepted that a 
39 
 
rapidly rising PSA, high-grade disease on repeat biopsy or an increase in tumour 
clinical stage should warrant consideration for radical treatment. Again, the 
decision to proceed to radical treatment should take patient wishes, co-
morbidities and life expectancy into account. The main risks associated with AS 
are development of advanced disease whilst on AS, psychological impact of non-
treatment of a known cancer and developing a co-morbidity during AS which 
would make the patient ineligible for radical treatment.  
 
1.2.4.2 Radical Prostatectomy 
 
Radical prostatectomy is a major surgical procedure that was traditionally 
performed as an open surgical procedure but is increasingly performed using 
robotically assisted techniques. It involves the excision of the entire prostate 
gland and seminal vesicles. Radical prostatectomy should be offered to men with 
intermediate risk disease without co-morbidities and to those patients with low-
risk disease who do not wish to delay treatment by entering AS. In high-risk 
disease and locally advanced prostate cancer, radical prostatectomy with 
extended lymph node dissection can be used as part of a multi-modal approach 
so long as the tumour is not fixed nor invading the urethral sphincter. (32) 
Furthermore, recent studies have found a survival benefit to offering radical 
prostatectomy and lymph node dissection to patients with a low burden of 
metastatic disease. (63-65) The TRoMbone trial, a pilot study to investigate the 
survival benefit of radical prostatectomy in patients with oligometastatic disease 
(1-3 skeletal metastatses without visceral metastases) is currently recruiting 
patients and will soon report their findings with a view to conducting a full 
study. (66) The findings of this study has potential to significantly change the 
current management of early metastatic prostate cancer. Significant risks 
associated with radical prostatectomy include urinary incontinence, erectile 
dysfunction, involved surgical margins and, in rare cases, death.    
1.2.4.3 Radical radiotherapy 
 
Radical radiotherapy can be delivered to the prostate by external beam x-rays 
(external beam radiotherapy, EBRT) or via radiation sources implanted directly 
into the prostate gland (brachytherapy).  
40 
 
 
Brachytherapy should only be offered to patients with low to intermediate risk 
localised disease. Low-dose rate brachytherapy with permanent radioactive 
seeds is the most commonly used protocol for brachytherapy. High-dose rate 
brachytherapy monotherapy has been shown to provide good local control and 
progression-free survival in low to intermediate risk prostate cancer with low 
toxicity and few side effects, however an optimal treatment schedule has not 
been agreed as yet.(67) A recent study has suggested that low-dose rate 
brachytherapy can be effective at controlling even high-risk localised prostate 
cancer and could benefit patients unable to tolerate radical prostatectomy or 
EBRT. (68)  
 
EBRT can be offered to all patients with localised and locally advanced prostate 
cancer. Androgen deprivation therapy (ADT) is offered to patients with 
intermediate risk disease for 6 months prior to, during or after EBRT and for up 
to 3 years in patients with high-risk disease. Patients with high-risk disease 
unsuitable for ADT should be given EBRT at an increased dose or in combination 
with brachytherapy.(32) Risks associated with radical radiotherapy include 
urinary incontinence, erectile dysfunction, radiation induced enteropathy and 
radiation-induced bowel cancer. 
 
1.2.4.4 High-intensity focused ultrasound and cryotherapy 
 
Focal therapies have been developed for potential radical treatment of patients 
with localised prostate cancer.  
 
High-intensity focused ultrasound (HIFU) is a technique that induces coagulative 
necrosis in malignant tissue by mechanical and thermal damage through the use 
of focused ultrasound waves. Cryotherapy involves the delivery of argon gas via 
cryoprobes inserted directly into malignant tissue under image guidance. The 
aim of cryotherapy is to induce local temperatures of -40 °C resulting in 
destruction of malignant cells.  
 
Whilst HIFU and cryotherapy have shown promising results in the management of 
localised prostate cancer (69, 70), they are not currently recommended as a 
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radical treatment in prostate cancer unless enrolled in a clinical trial comparing 
their use to standard radical therapies. (71) 
1.2.4.5 Watchful waiting 
 
Watchful waiting is a conservative management strategy by which patients who 
are unsuitable for radical treatment either due to disease stage, life expectancy 
or co-morbidities, are offered treatment for symptomatic relief rather than 
curative intent. This approach is most commonly used in patients who are 
thought unlikely to have significant disease burden during their lifetime. 
Treatments may include hormonal therapy and palliative radiotherapy. 
 
1.2.4.6 Hormonal therapy 
 
The aim of hormonal therapy in prostate cancer is prevention of the androgen-
dependent growth of prostate cancer. This can be achieved by androgen 
deprivation and/or AR blockade.  
 
Androgen deprivation was first described in the management of prostate cancer 
by Huggins et al in 1941, who discovered disease activity in prostate cancer 
decreased following surgical or medical castration. (72) Bilateral orchidectomy is 
still offered today as an alternative to medical androgen deprivation. Bilateral 
orchidectomy achieves lower mean testosterone levels than compared to 
luteinising hormone-releasing hormone (LHRH) agonists . (73, 74) The advantage 
of orchidectomy over LHRH agonists is the avoidance of medical treatment with 
its associated side effects whilst being more cost-effective. (75) Orchidectomy is 
an irreversible procedure however, and patients should be counselled 
appropriately before proceeding.  
 
LHRH agonists are recommended as monotherapy in the first line treatment of 
advanced prostate cancer. LHRH agonists downregulate the gonadotrophin-
releasing hormone (GnRH) receptors in the pituitary, producing a hypogonadal 
effect by reducing the secretion of luteinising hormone (LH) and follicle-
stimulating hormone (FSH), and subsequently reducing androgen levels. The use 
of LHRH agonists are associated with an ‘androgen-flare’ by initially stimulating 
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release of LH and FSH when it binds to the GnRH receptors, and therefore many 
patients are offered a short course of anti-androgens to overcome this. Side 
effects of LHRH agonists include cardiovascular morbidity, hot flushes, sexual 
dysfunction, osteoporosis and fatigue. 
 
Anti-androgens act peripherally to reduce the effect of endogenous androgens by 
competitively binding to the AR. Anti-androgens are not as effective as LHRH 
agonists in terms of overall survival, however, as the levels of circulating 
testosterone are not diminished, they have a more acceptable side effect profile 
than LHRH agonists. Side effects include gynaecomastia, liver dysfunction and 
diarrhoea and vomiting. As a result, anti-androgens may be offered as 
monotherapy to men with advanced prostate cancer who are unable to tolerate 
the side effects of LHRH agonists and are willing to accept the adverse impact 
on overall survival. Anti-androgens and LHRH agonists may be used in 
combination to produce maximum androgen blockade in patients who show early 
signs of biochemical relapse after initial monotherapy with LHRH agonists or 
bilateral orchidectomy. 
 
Unfortunately, all men with advanced prostate cancer will eventually have 
disease progression despite hormonal therapy, signalling the development of 
castration-resistant prostate cancer (CRPC). This usually occurs after 2-3 years 
of ADT. CRPC has a poor prognosis, with a median survival time of 9-30 months. 
(76) 
 
1.2.4.7 Chemotherapy 
 
Traditionally, chemotherapy was reserved for patients with castrate-resistant 
prostate cancer. The primary chemotherapy agent used in CRPC is docetaxel, an 
anti-neoplastic taxane agent and is used in combination with prednisolone. 
Docetaxel treatment is associated with increased median survival of 2.4 months 
compared to the previous standard chemotherapeutic agent. (77) Side effects of 
docetaxel include neutropenia, anaemia, fatigue, gastro-intestinal upset and 
peripheral sensory neuropathy. As such, docetaxel is restricted for use in 
patients with good performance status.  
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Several recent studies have found that earlier treatment with docetaxel in 
combination with ADT in patients with hormone-sensitive metastatic prostate 
cancer is associated with decreased time to disease progression and improved 
overall survival. (78, 79) It is now recommended that men with metastatic 
disease at presentation should be offered combined ADT and docetaxel as first 
line treatment, provided they are fit enough to receive this treatment. (80)  
 
1.2.4.8 Abiraterone acetate 
 
Abiraterone acetate is an androgen biosynthesis inhibitor that prevents the 
production of androgens by the adrenals and testes. Two recent studies have 
shown addition of abiraterone and prednisolone to ADT provides a significant 
overall survival and progression-free survival benefit for newly diagnosed 
hormone-sensitive metastatic prostate cancer compared to treatment with ADT 
alone. (81, 82) Treatment with the addition of either docetaxel or abiraterone 
was compared in the STAMPEDE trial for patients with hormone-sensitive 
metatstatic prostate cancer. No significant overall or disease-specific survival 
benefit was identified between the two treatment arms. Whilst neither 
treatment arm had significantly worse toxicity, each treatment was associated 
with different toxicities. (83) It has therefore been suggested that both 
treatment arms should be considered in patients with newly diagnosed hormone 
sensitive metastatic prostate cancer taking treatment-spceific side effects and 
patient preference into account.  
 
Abiraterone is also recommended for use as a first-line treatment in metastatic 
CRPC and in patients with disease progression whilst on docetaxel therapy. (80)  
 
1.2.4.9 Enzalutamide 
 
Enzalutamide is a new AR antagonist that is licensed for use in patients with 
metastatic CRPC who are asymptomatic and docetaxel is not yet clinically 
indicated. In this patient cohort, it has been shown to decrease the risk of 
radiological progression and improve overall survival. (84) The AFFIRM study 
found improved overall survival when using enzalutamide for treatment of 
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disease progression following docetaxel treatment in patients with metastatic 
CRPC. (85) As such, enzalutamide is recommended as a second-line treatment 
for metastatic CRPC in patients treated with docetaxel. (80) 
 
1.2.4.10  Immunotherapy 
 
Immunotherapy is a treatment that aims to assist the patients immune system to 
identify and destroy malignant cells. Sipuleucel-T, an autologous vaccine, was 
approved by the US Food and Drug Administration to treat asymptomatic or 
minimally symptomatic metastatic castrate resistant prostate cancer in 2010. 
The vaccine consists of autologous peripheral-blood mononuclear cells activated 
ex vivo with a recombinant fusion protein consisting of prostatic acid 
phosphatase antigen fused to granulocyte-macrophage colony-stimulating 
factor.(86)The IMPACT study found a 4.1 month median overall survival benefit 
in metastatic CRPC patients treated with Sipuleucel-T compared to the control 
group. (87) It is not currently licensed for use in Europe. 
 
1.2.4.11 Pharmacoeconomics of prostate cancer treatment 
 
Prostate cancer treatment is expensive. The diagnosis, treatment and 5 year 
follow-up cost of prostate cancer in the UK was estimated at £136, 278, 237 in 
2010. (3) Since then, new treatments have been introduced for the treatment of  
advanced and castrate-resistant prostate cancer, including abiraterone and 
enzalutamide, with high associated costs. In the UK, abiraterone was initially 
deemed to not be cost-effective and was only recommended for use once the 
manufacturer agreed to a significant cost-reduction. This economic burden is 
expected to continue to rise as prostate cancer incidence increases, potentially 
making prostate cancer treatment in UK unsustainable. For example, NICE does 
not recommend the use of Sipuleucel-T for use in patients with metastatic CRPC 
due to its high incremental cost-effectiveness ratio, despite the findings of the 
IMPACT study as discussed above. As such, it is crucial that new tools such as 
predictive biomarkers are developed to assist clinicians in directing prostate 
cancer treatment to those patients who would gain most benefit.  
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1.3 Androgen Receptor 
  
The AR is a class I nuclear receptor and forms part of the nuclear receptor 
superfamily. It is encoded by the AR gene, located on the X chromosome at 
position Xq11-12, producing a 110 kDa protein. AR is activated in response to 
androgens, causing translocation of the AR from the cytoplasm to the nucleus, 
where it acts as an intracellular ligand-dependent transcription factor capable of 
regulating the expression of many thousands of androgen-regulated genes.  
 
In humans, AR is expressed in all organs with the exception of the spleen and 
bone marrow. It is essential for the development of male reproductive organs, 
puberty, male fertility and male sexual function. In the prostate, androgens are 
essential for normal development and function. AR is expressed in both 
epithelial cells and stromal cells. In epithelial cells, AR has a role in cellular 
differentiation, survival and the expression of secretory proteins. (88, 89) 
Stromal AR has a role in embryonic prostate development, epithelial 
differentiation and determining secretory protein expression. (90) 
 
Prostate cancer development is androgen-dependent in approximately 90% of 
cases at diagnosis. (91) Increased AR expression in hormone-naïve prostate 
cancer is associated with markers of aggressive disease and poor prognosis. (92, 
93) 
 
1.3.1 AR structure 
 
The AR is a 919-amino acid protein with three major functional domains, as 
demonstrated in Figure 1.8. The largest domain, the N-terminal domain (NTD) 
has a transcriptional modulatory function, controlled by the constitutively active 
activation function 1 (AF-1), independent of the interaction with ligands. (94) 
The DNA-binding domain (DBD) is adjacent to the NTD and is the smallest 
domain. It consists of two zinc fingers, the first containing the P-box, a 
recognition helix that binds to DNA, and the second containing the D-box which 
allows AR dimerization. The DBD therefore has a role in nuclear localisation, 
receptor dimerization and DNA binding to target genes. (95, 96) The ligand-
binding domain (LBD) varies in size and is separated from the DBD by a hinge 
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region. It contains the ligand dependent C-terminal activation function 2 (AF-2), 
a surface hydrophobic groove, thought to be critical to co-activator recruitment. 
(97) Binding of ligand to the LBD leads to a conformational change allowing 
exposure of AF-2 to AR co-activators and co-repressors. (98) 
 
Figure 1.8 Androgen receptor structure with functional domains (99) 
 
 
The AR contains three major functional domains and a hinge region. Each 
domain has a specific function. The NTD modulates transcriptional activity, 
controlled by AF-1. The DBD binds to target genes and is the site of AR 
dimerization. The LBD contains AF-2, which is activated by binding of ligand. 
Serine 81 is located within the NTD. Serine 578 is located in the DBD. NTD = N-
terminal domain, DBD = DNA-binding domain, LBD = ligand binding domain, AF-1 
= activation function 1, AF-2 = activation function 2.  
 
1.3.2 Genomic AR signalling 
 
In the absence of androgens, the AR is located in the cytoplasm bound to heat-
shock proteins (HSP), cytoskeletal proteins and co-chaperones. Upon androgen 
binding to the LBD, AR undergoes conformational change, dissociates from HSPs 
and becomes phosphorylated. The AR subsequently interacts with co-regulators 
that facilitate translocation of the AR/androgen complex to the nucleus. Within 
the nucleus, AR dimerises and binds to androgen response elements (ARE) in 
promoter regions of its target genes. Binding of AR homodimers to AREs results 
in transcription of androgen-dependent genes including PSA (Figure 1.9). This 
process is modulated by co-regulators that can either enhance (co-activate) or 
repress AR transcription through chromatin remodelling and histone 
modifications.  When the ligand dissociates from AR, the AR translocates back to 
the cytoplasm where it is again bound to HSPs awaiting further ligand binding.  
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Figure 1.9 Genomic androgen receptor signalling in the prostate (100) 
 
 
Schematic diagram illustrating genomic AR signalling. In the absence of ligand, 
AR is in its inactive state within the cytoplasm, bound to HSPs, cytoskeletal 
proteins and co-chaperones. Testosterone enters the prostate cell and is 
converted to DHT by 5a-reductase. DHT binds to AR in the cytoplasm causing 
conformational changes resulting in the dissocation of AR from HSPs and co-
chaperones, allowing AR to enter the nucleus. Within the nucleus, AR dimerises 
and binds to AREs of target genes in the presence of co-activators, resulting in 
gene transcription. AR = androgen receptor, HSP = heat shock protein, DHT = 
dihydrotestosterone, ARE = androgen response element 
 
1.3.3 Non-genomic AR signalling 
 
Non-genomic AR signalling is the interaction of activated AR with intracellular 
signalling molecules within the cytoplasm, independent of genomic AR signalling. 
Activated AR can bind to non-receptor tyrosine kinase Src, activating the 
mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated kinases 
(ERK) cascade and enhances cell proliferation. (101)  AR can also interact with 
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the phosphoinositide 3-kinase (PI3K)/Akt pathway by binding of the AR NTD to 
the SH2 domain of p85a regulatory subunit of PI3K. (102) This results in 
activation of Akt, with resultant inhibition of apoptosis and increased cell 
survival through regulation of transcription factors.   
 
Both MAPK/ERK cascade and PI3K/Akt pathway have been implicated in prostate 
carcinogenesis and development of CRPC.  
 
1.3.4 Post-translational modification of AR 
 
The AR can undergo post-translational modification by phosphorylation, 
acetylation, SUMOylation, methylation and ubiquitination at 23 known sites on 
the receptor and is associated with regulation of AR structure, activity and 
stability. 
 
Phosphorylation of the AR was the first reported, and most common, post-
translational modification of AR. To date, 18 phosphorylation sites have been 
identified that include serine, threonine and tyrosine residues, each with 
differing biological effects. AR phosphorylation will be discussed in more depth 
in the following section. 
 
Acetylation occurs at three known lysine residues on the AR – Lys 630, Lys 632 
and Lys 633 located in the hinge region. (103) Deacetylation downregulates AR 
transcriptional activity, whilst acetylation enhances transcription and increases 
cell growth. (103-105)  
 
In addition to acetylation, methylation can also occur at Lys 630 and Lys 632. 
SET9 is the methyltransferase responsible for methylation at these sites, and 
studies have shown it is responsible for AR regulation of androgen-target genes 
and enhances cell growth and survival in prostate cancer cells. (106, 107) 
 
SUMOylation occurs at Lys 386 and Lys 520 within the NTD. SUMOylation is the 
attachment of the small ubiquitin-like modifier (SUMO) to lysine side chains. This 
has been shown to occur in response to the presence of androgens in the AR, and 
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is associated with enhancement of androgen-dependent gene transcription and 
cell proliferation in prostate cancer cells. (108, 109)  
 
Finally, ubiquitination occurs at Lys 845 and Lys 847 in LBD of AR, (110) which is 
the attachment of ubiquitin chains to lysine residues. Ubiquitination of the AR 
has been linked with both the degradation of the receptor and enhanced 
transcription. (110, 111) 
 
1.3.5 Post-translational serine phosphorylation of AR 
 
AR phosphorylation was first reported in 1984 by Goueli et al who discovered 
that AR was phosphorylated in the presence of nuclear cAMP-independent 
protein kinase in rat prostates. (112) Since then, there has been extensive 
research in relation to AR phosphorylation.   
 
AR is phosphorylated at 18 known serine, threonine and tyrosine residues, with 
phosphorylation occurring in all the three major domains and hinge region. The 
vast majority of phospho-sites are identified in the NTD, which includes the 
constitutively active AF1 domain (Figure 1.10). AR phosphorylation regulates AR 
cellular localisation, transcriptional activity, cell growth and sensitivity to 
androgens. Furthermore, AR can be phosphorylated in both the presence and 
absence of androgen, implicating AR phosphorylation in prostate cancer 
progression and development of CRPC.  Serine phosphorylation is the most 
extensively researched area of post-translational phosphorylation, and will be 
the focus of this section going forwards. 
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Figure 1.10 Distribution of phospho-sites within AR (113) 
 
 
Eighteen phospho-sites have been identified on the AR and include serine (S), 
tyrosine (T) and threonine (Y) residues, with the majority located within NTD of 
AR. Serine 81 is located within the NTD. Serine 578 is located in the DBD. DBD = 
DNA-binding domain, NTD = N-terminal domain 
 
Serine 81 (Ser-81) is the phospho-site most phosphorylated on the AR in the 
presence of androgens. Gioeli et al investigated the phosphorylation status at 
several serine residues on the AR in prostate cancer cells in response to 
androgens. Mass spectrometry results identified that Ser-81 had the highest 
stoichiometric phosphorylation in response to androgens, whilst other serine 
residues including serines 16, 256, 308, 424, and 650 had varying increased 
levels of androgen-dependent phosphorylation also. (114). Chen et al identified 
that Ser-81 phosphorylation was reduced in LNCaP cells cultured in androgen-
depleted medium, whilst DHT stimulated phosphorylation at Ser-81. In addition, 
expression of PSA, an androgen-regulated protein, increased in line with 
increased phosphorylation at Ser-81, further supporting Ser-81 phosphorylation 
to be androgen-dependent. (115) Several kinases from the cyclin-dependent 
kinase family have been linked to phosphorylation at this site, including Cdk 1, 
Cdk 5 and Cdk 9. (115-117) Ser-81 phosphorylation is associated with increased 
AR transcriptional activity and expression of androgen-dependent proteins such 
as PSA, chromatin-binding of AR to AREs, nuclear localisation of AR and 
enhanced cell growth in prostate cancer cells. (116-118) 
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Serine 16 (Ser-16) phosphorylation can occur in both an androgen-dependent and 
independent manner. Phosphorylation increases at Ser-16 on the AR upon 
treatment with androgens, however, it remains phosphorylated in the absence of 
the LBD. It has therefore been suggested that Ser-16 may have a role in 
androgen-independent prostate cancer (114, 119) 
 
Serine 94 (Ser-94), located in the NTD, is constitutively active. Phosphorylation 
at Ser-94 was not altered by the deletion of the LBD, confirming phosphorylation 
status at this serine residue is independent of androgen. (114, 119) No biological 
function of Ser-94 phosphorylation on the AR has been identified.  
 
Serine 213 (Ser-213), is phosphorylated by a number of different kinases, with 
Akt and PIM-1 the most studied. Effects of phosphorylation at Ser-213 in prostate 
cancer are kinase dependent. Phosphorylation by Akt at Ser-213 is associated 
with increased transcriptional activity, protein stability and nuclear localisation 
of AR and promotes cell survival in prostate cancer cells, (120, 121) whilst 
phosphorylation by PIM-1 is associated with destabilisation of AR, varying effects 
on AR transcriptional activity in different prostate cancer cell lines and 
increased prostate cancer cell growth in low androgen conditions.(122, 123) In 
clinical specimens, increased pARS213 expression is associated with a shorter 
disease-free interval and decreased disease-specific survival in CRPC. 
Furthermore, increased expression of pARS213 is seen as prostate cancers progress 
from hormone-sensitive to castrate-resistant disease. (123, 124) 
 
As discussed above, serine 256 and serine 424 are phosphorylated in an 
androgen-dependent manner. Serine 293 phosphorylation occurs in an androgen-
independent manner. The biological function of AR phosphorylated at serines 
256, 424 and 293 is currently unknown.    
 
AR phosphorylated at Serine 308 (pARS308) by cyclin D3/CDK11p58 negatively 
regulates AR transcriptional activity in prostate cancer cells, resulting in 
decreased cellular proliferation in androgen-dependent prostate cancer cells. 
(125) Increased expression of pARS308 confers a survival advantage in patients 
with CRPC, further supporting the role of pARS308 in decreased transcriptional 
activity. (126)   
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Serine 515 (Ser-515) is phosphorylated by a number of kinases including Cdk1, 
Cdk7 and MAPK. (127-129) Whilst Ser-515 does not appear to have a role in AR 
localisation, it does have a role in AR transactivation.  Upon ligand binding, 
pARS515 recruits components required for transactivation of AR target genes 
through signalling cascades.(127) Epidermal growth factor (EGF) stimulated 
MAPK-dependent phosphorylation of Ser-515 resulted in increased transcriptional 
activity in both the presence and absence of androgens in CRPC cells. (129) In 
hormone-naïve prostate cancer patients, increased pARS515 is associated with 
poor outcome measures including decreased time to biochemical relapse, 
decreased survival following biochemical relapse and decreased disease-specific 
survival. (128) 
 
Serine 578, located in the DBD on AR, is predicted to be phosphorylated by 
protein kinase C (PKC). (130) EGF signalling via PKC-dependent phosphorylation 
at Ser-578 increases AR transcriptional activity, cell growth, nuclear-cytoplasmic 
shuttling, modulates phosphorylation at serine 515 and regulates AR interaction 
with Ku-70/80, a protein complex involved with DNA-repair in castrate resistant 
prostate cancer cells.(129) PAK6, a member of the p21-activated kinase (PAK) 
family and known tumour suppressor, also phosphorylates AR at serine 578. 
Phosphorylation by PAK6 at serine 578 is associated with inhibition of nuclear 
translocation and increased AR degradation. (131) 
   
AR phosphorylation at serine 650, located in the hinge region, occurs through 
both androgen-dependent and independent processes. The stress kinases, 
protein kinase A and PKC are all linked to phosphorylation at this site. (114, 132) 
Serine 650 phosphorylation is associated with decreased transcriptional activity 
in prostate cancer cells by exporting AR from the nucleus. (132) 
 
Finally, phosphorylation of the AR at serine 791 (Ser-791) is Akt-dependent. Ser-
791 is located in the LBD of AR. Phosphorylation at this serine residue is 
associated with increased ligand-binding, ligand-dependent nuclear translocation 
and decreased AR stability.(133) In hormone naïve prostate cancer clinical 
specimens, increased pARS791 is associated with improved outcomes, with 
patients with high expression having longer time to disease recurrence. 
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Increased pARS791 expression in CRPC clinical specimens is also associated with a 
good prognosis, with increased disease-specific survival following relapse. (126)  
Overall, high expression of pARS791 seems to have a protective role in prostate 
cancer.  
 
It can be concluded that AR phosphorylation has an important role not only in 
prostate cancer progression but in the development of castrate-resistance. 
Interestingly, individual phosphorylation sites have differing effects with 
phosphorylation at certain sites being associated with poor prognosis whilst 
being protective at others. Furthermore, the individual kinases responsible for 
phosphorylation also appears to play a role in the effect of phosphorylation at 
the same serine residue in some cases. Phosphorylation status may be utilised in 
future as a prognostic marker in prostate cancer.  
 
1.3.6 PKC and serine phosphorylation of AR 
 
As described above, several kinases are known to phosphorylate serine residues 
on the AR in androgen-dependent and independent processes, including Akt, 
MAPK, Cdks and PKC. Some kinases phosphorylate the AR at more than one 
serine residue, resulting in differing biological effects depending on the serine 
site phosphorylated and are the target of new drug therapies in prostate cancer. 
The focus of this thesis is the role of AR phosphorylation at serine 578 in 
prostate cancer.  PKC is the predicted kinase to phosphorylate the AR at this site 
(130), and will therefore be discussed in more detail below.  
 
Protein kinase C is a family of serine/threonine kinases, comprised of at least 12 
isozymes categorised into three sub groups according to their biochemical and 
structural properties.  PKC isozymes are single polypeptides containing an N-
terminal regulatory region and a catalytic C-terminal region, separated by a 
hinge region (Figure 1.11). (134) Conventional PKCs are calcium-dependent and 
are activated by phorbol esters or diacylglycerol (DAG) and includes PKC α, β1, 
β2 and γ. Novel PKCs (PKC δ, ε, η, and θ) lack a calcium-binding region and are 
therefore calcium-independent but require phorbol esters or DAG for activation. 
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Finally, the atypical PKCs (PKC ζ, λ, µ and ι) are calcium-independent and are 
activated independently of phorbol esters and DAG. (135) 
Figure 1.11 Structure of conventional, novel and atypical PKC isozymes 
(134) 
 
 
 
Schematic diagram illustrating the primary structure of conventional, novel and 
atypical PKC isozymes. Conventional PKCs are composed of four domains (C1-4), 
are calcium-dependent and are activated by phorbol esters or diacylglycerol. 
Novel PKCs lack a calcium binding region in the C2 domain but still require 
activation with phorbol esters or diacylglycerol. Atypical PKCs are calcium-
independent and are activated independently of phorbol esters and DAG.  
 
Newly synthesised PKC is dephosphorylated and in an inactive state. (136) The 
first step in PKC activation is phosphorylation by 3-phosphoinositide-dependent 
protein kinase 1 (PDPK1), a master kinase that phosphorylates and activates a 
number of protein kinases. This initial phosphorylation step is followed by two 
auto-phosphorylation steps, completing PKC activation. Activated PKC is 
released into cytosol where it can respond to lipid secondary messengers. (137) 
 
Activated PKC isozymes have a variety of roles in both normal cell function and 
disease. The intracellular effects of PKC include proliferation, differentiation, 
cell to cell interaction, secretion, cytoskeletal functions, gene transcription and 
apoptosis. PKC is implicated in a number of disease processes including 
cardiovascular disease, metabolic disorders and carcinogenesis.  
 
PKC was first linked to tumorigenesis in 1982 when Castagna and colleagues 
identified that PKC was directly activated by tumour-promoting phorbol esters. 
(138) Since then, the role of PKC in carcinogenesis has been extensively 
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investigated in many cancer types. Total PKC expression is elevated in both 
breast and lung cancer and reduced in colon cancer. (139-141) It has been found 
that individual PKC isozymes have varying levels of expression and biological 
effects in different cancer diseases. For example, PKCa enhances cell 
proliferation in lung, bladder, breast and gastric cancers, but has an anti-
proliferative effect in colon cancer. (142-146)  
 
PKC has previously been linked to prostate cancer development and progression. 
Expression of total PKC is elevated in CRPC compared to hormone-sensitive 
disease. Furthermore, patients who had increased expression of PKC with the 
development of CRPC had shorter survival following biochemical relapse. (147) 
Increased PKC expression secondary to phorbol 12-myristate 13-acetate (PMA) 
treatment, a potent PKC activator,  in androgen-dependent LNCaP prostate 
cancer cells promotes PKC induced apoptosis through activation of down-stream 
signalling cascades. (148) Previous studies have demonstrated that PMA-induced 
apoptosis in LNCaP cells is mediated by PKC α and PKCδ. (149, 150) Conversely, 
PKCε has been linked to development of castrate-resistance with ongoing 
proliferation of LNCaP cells in androgen-deficient conditions, suggesting PKCε 
may have a role in tumour progression. (151) This suggests that in common with 
other malignancies, different PKC isozymes have varying biological effects in 
prostate cancer.  
 
PKC is known to phosphorylate the AR in prostate cancer. In LNCaP cells, PMA 
increases phosphorylation of the AR at Serine 650. (114, 129) Scansite 2.0, an 
online kinase search tool, predicts that PKC is the putative kinase mediating 
phosphorylation at serine 578. (130) Phosphorylation at serine 578 has been 
shown to be PKC-dependent in CWR-R1 cells, a CRPC cell line. Introduction of a 
serine 578 mutation on the AR in CWR-R1 cells resulted in a 50% decrease in 
PKC-dependent AR phosphorylation compared to wild-type cells. (129) 
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1.4 Statement of research aims 
 
The research presented in this thesis is a proof of concept study that sought to 
investigate the prognostic and predictive significance of AR phosphorylation at 
serine 578 and serine 81 in patients with hormone-naïve prostate cancer. This 
work was conducted with a view to identify new prognostic and predicitive 
biomarkers that can assist clinicians in the management of patients with 
prostate cancer. 
 
Phosphorylation at Ser-578 is associated with increased AR transcriptional 
activity, cell growth, nuclear-cytoplasmic shuttling, modulates phosphorylation 
at serine 515 and regulates AR interaction with Ku-70/80, a protein complex 
involved with DNA-repair in castrate resistant prostate cancer cells in in vitro 
studies. As such, it was speculated that pARS578 expression in clinical specimens 
would be increased in advanced disease and would be associated with poor 
outcomes in prostate cancer. It was therefore hypothesised that pARS578 may be 
utilised as a prognostic biomarker at diagnosis in prostate cancer. Furthermore 
PKC, the putative kinase for phosphorylation at serine 578, would be associated 
with poor outcomes and may offer a potential therapeutic target in prostate 
cancer.  
 
Ser-81 is the serine residue most commonly phosphorylated in response to DHT. 
Ser-81 phosphorylation is associated with increased AR transcriptional activity 
and expression of androgen-dependent proteins such as PSA, chromatin-binding 
of AR to AREs, nuclear localisation of AR and enhanced cell growth in prostate 
cancer cells. It was hypothesised that pARS81 expression in clinical specimens 
would also be associated with poor outcomes in prostate cancer. 
 
As serine 81 and serine 578 are predicted to be phosphorylated via alternative 
pathways, it was hypothesised that expression of AR phosphorylated at these 
sites may have a cumulative prognostic effect. Therefore, the prognostic 
significance of dual expression of AR phosphorylated at Ser-578 and Ser-81 was 
investigated in relation to outcome measures. 
 
57 
 
Using archival tissue from prostate cancer patients, the expression of androgen 
receptor phosphorylated at serine 578 and serine 81 was assessed in three 
clinical cohorts in relations to clinical outcome measures. Firstly a cohort of 
patients with ‘low-risk’ prostate cancer, managed with active surveillance was 
utilised to assess the significance of androgen receptor phosphorylation in a 
patients with early prostate cancer. It was anticipated that phosphorylation 
status of the androgen receptor may identify patients that may require early 
definitive treatment. A second ‘discovery’ cohort of hormone-naïve prostate 
cancer patients with all stages of disease was utilised to assess the significance 
of androgen receptor phosphorylation in relation to clinical outcome measures 
with a view to using phosphorylation status in clinical specimens as a prognostic 
biomarker. A third, larger cohort of hormone naïve prostate cancer patients was 
collated and assessed for androgen receptor phosphorylation to validate the 
findings of the second cohort of patients.  
 
The main objectives of this study were to: 
1. Assess the clinical significance of AR phosphorylation at serine 81,serine 
578 and PKC expression in a cohort of early prostate cancer patients 
treated with AS 
2. Assess the clinical significance of AR phosphorylation at serine 81, serine 
578 and PKC expression in a discovery cohort of hormone-naïve prostate 
cancer patients 
3. Verify the clinical significance of AR phosphorylation at serine 81, serine 
578 and PKC expression in the discovery cohort in a larger, consecutive 
cohort of hormone-naïve prostate cancer patients 
4. Develop a technique for the culture and characterisation of patient-
derived cells from prostate needle biopsy specimens 
5. Assess the impact of PKC inhibitors on expression of pARS578 in patient 
derived cells to establish if pARS578 may be utilised as a predictive 
biomarker for response to treatment 
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Chapter 2 Materials and Methods 
 
2.1 Patients 
 
 
2.1.1 Active surveillance prostate cancer cohort 
 
 
A prospective cohort of one hundred and five consecutive prostate cancer 
patients treated with AS were recruited in NHS Ayrshire and Arran between 
13/11/1998 and 17/03/2011. Clinical information was available for all patients, 
of which 84 patients had diagnostic tissue for use in this study. An anonymised 
database containing clinical, biochemical and pathological data for patients 
included in the cohort was created using electronic and paper medical records. 
Ethical approval was obtained from the West of Scotland Research and Ethics 
Committee (ref. 12/WS/0087). The clinical outcome measure for this cohort was 
time to intervention.  
2.1.2 Discovery cohort 
 
Ninety patients with hormone naïve prostate cancer were recruited from 
Glasgow Royal Infirmary between 1992 and 2000. Patients were included if they 
had tissue appropriate for use in a tissue micro-array (TMA) available. An 
anonymised database containing clinical, biochemical and pathological data for 
patients included in the cohort was created using electronic and paper medical 
records.  Written consent was obtained for participation in the study. Ethical 
approval was obtained from the West of Scotland Research and Ethics 
Committee (ref. 05/S0704/94). Clinical outcome measures for this cohort was 
time to biochemical relapse, disease-specific survival following biochemical 
relapse and disease-specific survival. Biochemical relapse is treatment 
dependent. Patients were considered to have biochemical relapse with serum 
PSA >0.2 ng/ml following radical prostatectomy, serum PSA of 2.0 ng/ml above 
the post treatment nadir level following radical radiotherapy or 2-3 consecutive 
elevations of serum PSA above the nadir over intervals greater than 2 weeks 
following hormone treatment.  
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2.1.3 Validation cohort 
 
A retrospective cohort of consecutive prostate cancer patients diagnosed in 2009 
was identified using the NHS Greater Glasgow and Clyde Urology MDT records. 
423 patients were identified.  Patients were included if they had clinical 
information available on Clinical Portal. Clinical information was available for 
361 patients, of which 243 had diagnostic tissue suitable for use in this study. An 
anonymised database containing clinical, biochemical and pathological data for 
patients included in the cohort was created using electronic medical records. 
While date of death was recorded in the electronic medical records, cause of 
death was not. Paper records could not be obtained for these patients. As a 
consequence, disease-specific survival could not be used as a clinical outcome 
measure in this cohort. Overall survival was therefore used as a clinical end 
point in this study. Ethical approval for tissue collection was obtained from 
Biorepository. Data collection was under NHS Greater Glasgow and Clyde Safe 
Haven ethical approval (GSH/16/ON/001). Clinical outcome measures for this 
cohort was time to biochemical relapse, overall survival following biochemical 
relapse and overall survival. 
2.1.4 Primary prostate cell culture cohort 
 
Thirty-six patients undergoing investigation for prostate cancer were 
prospectively recruited from a single institution in 2016. Patients were eligible 
for the study if they were undergoing investigation for prostate cancer. Patients 
were ineligible if they had previously received treatment for prostate cancer. 
Written consent was obtained for participation in the study. Primary prostate 
cell cultures were successfully grown from only two patients. Clinical 
information was available for all patients. An anonymised database containing 
clinical, biochemical and pathological data for patients included in the cohort 
was created using electronic medical records. Ethical approval was obtained 
from West of Scotland Research and Ethics Committee (ref. 16/WS/0015).  
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2.2 Tissue preparation 
 
2.2.1 Tissue microarray construction 
 
A TMA allows analysis of tissue from multiple patients on one slide. A TMA is 
constructed using cores of tissue from multiple patients. Cores 0.6 mm in 
diameter are obtained from tissue from a paraffin embedded block from 
individual patients.  Each core is seeded into a second paraffin block along with 
cores from numerous other patients obtained in the same manner. This allows 
comparative analysis of multiple patients under the same conditions.  
 
A TMA was constructed for the discovery study cohort. A uropathologist 
identified and marked tumour rich areas on the H&E slide. Cores from the 
corresponding area in the paraffin embedded tissue block were obtained for 
each patient. Three cores were obtained to allow the TMA to be constructed in 
triplicate. Three micrometer sections were cut and placed onto Superfrost Plus 
microscope slides (Fischer Scientific, Loughborough, UK). Sections were stored 
at 4°C until use. 
 
2.2.2 Tissue section preparation 
 
Both the AS cohort and validation cancer cohort utilise diagnostic prostate tissue 
for experimentation. The majority of patients have histological diagnosis of 
prostate cancer confirmed by TRUS-guided biopsy of the prostate.  TRUS biopsy 
takes several cores from each side of the prostate. Each core measures less than 
1mm and would not be sufficient tissue for construction of a TMA. A minority of 
patients are diagnosed with tissue obtained from other routes. TURP is a 
treatment for bladder outflow obstruction (BOO) secondary to BPH. Multiple 
chips of tissue are resected to widen the prostatic urethra and relieve bladder 
obstruction. Prostate cancer may be identified on histological examination of 
these prostatic chips. The AS cohorts and validation cohort did not have enough 
patients diagnosed via TURP to warrant construction of a TMA and therefore full 
tissue sections were used. 
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TRUS biopsy cores from the diagnostic specimen for each patient were obtained. 
Three micrometre sections were cut from the corresponding paraffin embedded 
tissue block and placed onto Superfrost Plus microscope slides. Sections were 
stored at 4°C until use. In the active surveillance cohort, tumour area was 
marked on a H&E section for each patient by a uropathologist, and the tumour 
area was then marked on the corresponding slides for each antibody. In the 
validation cohort, a uropathologist was not available to identify tumour area on 
the H&E sections. Therefore, three different areas suspicious for malignancy 
were identified in each slide and analysed. The median score was then 
calculated as a representative score for each patient’s sample.  
 
2.3 Immunohistochemistry 
 
Immunohistochemistry (IHC) is a technique that is employed to allow 
visualisation of a specific antigen within a tissue section or fixed cells using 
antibodies directed against the antigen of interest. When IHC was introduced in 
the 1930s, a direct method of visualisation was used.  The direct method of IHC 
uses a primary antibody pre-labelled with a fluorophore or enzyme that allows 
visualisation of the antigen. The indirect method of IHC was first described in 
1970 (152), with the introduction of a secondary antibody labelled with 
peroxidase antiperoxidase complex. The indirect method of IHC uses a primary 
antibody directed against the antigen of interest, and a labelled secondary 
antibody that binds to the primary antibody. The indirect method is employed in 
this study. EnVision (Dako) is a secondary antibody directed against rabbit or 
mouse immunoglobulins present on the primary antibody of interest. The 
secondary antibody is conjugated to horseradish peroxidase (HRP). HRP is only 
visible on oxidation, producing an insoluble brown precipitate. 3,3’-
diaminobenzidine (DAB) was used to oxidise HRP, thus allowing visualisation of 
the antigen of interest. 
 
2.3.1 Tissue preparation 
 
IHC was performed on tissue sections described in sections 2.2.1 and 2.2.2. 
Tissue sections were baked at 56°C for twenty minutes and cooled for twenty 
minutes prior to use.   
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2.3.2 Tissue dewaxing and rehydration 
 
Sections were dewaxed in xylene (2 x 3 min). The sections were rehydrated by 
immersion in serial graded alcohol solution washes; 100% ethanol (2 x 2 min), 
90% ethanol (2 min) and 70% ethanol (2 min). Finally, the sections were rinsed in 
running water. 
 
2.3.3 Antigen retrieval 
 
Antigen retrieval is a process necessary to allow binding of the primary antibody 
to the antigen within the tissue. Formalin fixation of tissues is used almost 
universally in histopathology. During the fixation process, cross-links form 
between formalin and proteins (antigens). This adversely affects the availability 
of the antigen for binding of the primary antibody. A number of different 
techniques have been described for antigen retrieval in IHC, the majority of 
which involve heating the specimens in various solutions.  
 
Two different methods of heat-based antigen retrieval were employed in this 
study. Antigen retrieval buffer for detection of AR was DakoCytomation Target 
Retrieval Solution 10x (DAKO). The retrieval solution was diluted 1:10. The 
buffer was preheated to 96°C in a water bath. Sections were incubated in the 
buffer for twenty minutes at 96°C before being cooled for twenty minutes.   
Antigen retrieval buffer for the remaining antigens was either tris-EDTA buffer 
(1mM EDTA and 5mM Tris) at pH 8 or sodium citrate buffer (8mM tri-sodium 
citrate and 2mM anhydrous citric acid) at pH 6. One litre of the specified buffer 
(Table 2.1) was pre-heated to 96°C in a microwave for 13.5 minutes. The 
sections were added to the pre-heated buffer and heated under pressure for 5 
minutes before being cooled for twenty minutes. All sections were rinsed in 
distilled water after antigen retrieval. 
 
2.3.4 Blocking of non-specific staining 
 
The main cause of non-specific staining in IHC is thought to be due to binding of 
the Fc region of the antibody (both primary and secondary) to endogenous Fc 
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receptors present on cells within the tissue. Another cause of non-specific 
staining is the presence of endogenous peroxidases within the tissue section. 
DAB can react with endogenous peroxidases producing non-specific brown 
staining. (153)  To overcome this, endogenous peroxidase activity was 
inactivated by treating sections with 3% hydrogen peroxide for ten minutes. 
Sections were rinsed in distilled water before being incubated in 5% horse serum 
(Vector) in tris buffered saline (TBS) (0.1M Tris/HCl, 1.5M NaCl) for twenty 
minutes to prevent non-specific binding of the antibody. 
 
2.3.5 Incubation with primary antibody 
 
Sections were incubated in the primary antibody as listed in Table 2.1. Antibody 
specificity was previously validated in the host laboratory.(154) Each antibody 
was optimised prior to use to ensure the correct antibody dilution, incubation 
time and conditions were used to give the best staining results. Antibodies were 
diluted to the desired concentration in antibody diluent (DAKO). A positive and 
negative control was included in each run of IHC to ensure consistency across 
the stained sections. The positive control ensured that the IHC method had 
worked and the negative control ensured there was no non-specific staining. 
Once the incubation period was complete, the sections were washed in TBS 
buffer (2 x 5 minutes). 
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Table 2.1 Antibody conditions for IHC 
 
Protein Antigen 
Retrieval 
Method 
Antibody Antibody dilution Antibody incubation 
conditions 
AR High pH antigen 
retrieval solution 
20 min at 96°C 
Mouse 
Dako 
AR441 
AS 
Discovery 
Validation 
1:100 
1:100 
1:100 
Overnight 
4°C 
pARS81 EDTA pH 8 
5 min under 
pressure 
Rabbit 
Millipore 
#07-1375 
AS 
Discovery 
Validation 
1:4000 
1:4000 
1:1000 
Overnight 
4°C 
pARS578 EDTA pH 8 
5 min under 
pressure 
Rabbit  
Eurogentec 
AS 
Discovery 
Validation 
1:1000 
1:1000 
1:400 
Overnight 
4°C 
PKC Citrate pH 6 
5 min under 
pressure 
Rabbit 
Abcam 
ab59363 
AS 
Discovery 
Validation 
1:500 
1:500 
1:500 
Overnight 
4°C 
The details of the antigen retrieval method, antibody name, antibody dilution 
and incubation conditions for each protein of interest.  
 
2.3.6 Incubation with secondary antibody 
 
Sections were incubated in secondary antibody (EnVision+ detection system) for 
thirty minutes at room temperature. Once the incubation period was complete, 
the sections were washed in TBS buffer (2 x 5 minutes). 
 
2.3.7 Detection of secondary antibody 
 
As described above, DAB oxidises HRP bound to the secondary antibody, 
producing a brown insoluble precipitate. DAB peroxidase substrate kit (Vector 
Laboratories) was used to detect the secondary antibody in this study. Four 
drops of DAB stock, two drops of buffer stock and two drops of hydrogen 
peroxide were added to 5ml distilled water and mixed well. Sections were 
incubated with the DAB substrate at room temperature until a brown colour 
developed (up to ten minutes). The sections were then rinsed in running water 
for ten minutes.  
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2.3.8 Counterstaining 
 
Counterstaining allows better visualisation of the antigen-antibody complex by 
staining the remaining tissue a contrasting colour to the principal stain. This 
makes the principal stain stand out more against the rest of the tissue. In this 
study, haematoxylin and Scott’s tap water substitute were used to counterstain 
the sections. Haematoxylin is a cationic basic dye that binds to negatively 
charged nucleic acids within the nucleus, resulting in blue staining of the 
nucleus.  The sections were soaked in haematoxylin for thirty seconds, before 
being quickly dipped in acid alcohol to remove excess haematoxylin stain. 
Scott’s tap water substitute is a blueing counterstain solution that blues 
haematoxylin stained tissue. The sections were bathed in Scott’s tap water 
substitute for thirty seconds before being washed in running water for one 
minute. 
  
2.3.9 Dehydration and mounting 
 
The sections were dehydrated by immersion in several graded alcohol solutions; 
70% ethanol for one minute, 90% ethanol for one minute and 100% ethanol for 2 
x one minute. The sections are submerged in xylene, an organic solvent, for 2 x 
1 minute to further dehydrate the specimens. Finally, the slides were mounted 
using DPX and glass coverslips. 
 
2.3.10 Analysis of protein expression 
 
2.3.10.1 Slide visualisation 
 
After IHC, slides were digitally scanned and uploaded to Slidepath Digital Image 
Hub (Leica Biosystems). Slidepath is a virtual microscopy system that allows 
visualisation and analysis of tissue sections on a computer.   
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2.3.10.2 Histoscoring 
 
The weighted histoscore (WHS) method (155) was employed to assess tissue 
staining intensity in the sections. It relies on the subjective scoring of the 
intensity of staining in cells and an estimate of the percentage of cells staining 
at a particular intensity. The final histoscore is calculated using the following 
formula: (0 x % negative cells) + (1 x %weakly stained cells) + (2 x % moderately 
stained cells) + (3 x strongly stained cells). The total histoscore can range for 0 
to 300. Where staining was conducted in triplicate, a mean histoscore was used 
for analysis. 
 
In this study, the staining of the nuclei and cytoplasm of tumour epithelial cells 
was scored by two independent blinded observers. Sections were viewed on 
Slidepath at 20x magnification. Interclass correlation coefficients (ICCC) were 
calculated to ensure there was no significant variation between the two 
observers. Prior to calculating the ICCC, any sections with scores discordant by 
more than 50 were re-evaluated. Both observers reviewed the section in 
question on the same computer screen and a new score assigned that both 
observers agreed on. An ICCC score of >0.74 was considered excellent (155). 
For the purposes of statistical analysis, protein expression levels were grouped 
into low (≤median) and high (>median) expression.   
 
2.4 In-vitro Studies 
 
2.4.1 Culture of established prostate cell lines 
 
Three established prostate cell lines were utilised in this study. Two prostate 
cancer cell lines, LNCaP and VCaP, and one benign prostate epithelial cell line, 
PNT2 were used.  
 
LNCaP cells are a metastatic androgen-sensitive prostate cancer cell line that is 
epithelial in origin. LNCaP cells were first isolated in 1979 from a supraclavicular 
lymph node containing metastatic prostate cancer in a 50 year old Caucasian 
male (156). The LNCaP cell line is one of the most commonly used in prostate 
cancer research owing to its expression of the AR and its sensitivity to 
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androgens. LNCaP cells were cultured in RPMI 1640 (Invitrogen, UK) 
supplemented with 10% foetal calf serum (Invitrogen, UK), 2mM L-glutamine 
(Invitrogen, UK) and penicillin/ streptomycin (50 units/ml, 50 µg/ml (Invitrogen, 
UK)). Cells were cultured in T-75 flasks and incubated in 5% CO2 at 37°C. Media 
was exchanged twice weekly. Cells were split when they reached 70% 
confluency. 
 
VCaP cells are a metastatic prostate cancer cell line, epithelial in origin and 
derived from a vertebral metastasis. The cells were originally obtained from a 
59-year-old Caucasian male with castrate resistant metastatic prostate cancer. 
VCaP cells express wild-type AR, CK-8 and 18 and PSA. VCaP cells can grow in 
androgen-independent conditions. (157) VCaP cells were cultured in DMEM/F12 
(Invitrogen, UK) supplemented with 10% foetal calf serum (Invitrogen, UK), 2mM 
L-glutamine (Invitrogen, UK) and penicillin/ streptomycin (50 units/ml, 50 µg/ml 
(Invitrogen, UK)). Cells were cultured in T-75 flasks and incubated in 5% CO2 at 
37°C. Media was exchanged twice weekly. Cells were split when they reached 
70% confluency. 
 
PNT2 cells originate from benign prostate tissue obtained from a cadaver of a 
33-year old male. The cells are epithelial in origin and express CK-8 and 18, 
indicating a luminal epithelial type. PNT2 cells were cultured in RPMI 1640 
(Invitrogen, UK) supplemented with 10% foetal calf serum (Invitrogen, UK), 2mM 
L-glutamine (Invitrogen, UK) and penicillin/ streptomycin (50 units/ml, 50 µg/ml 
(Invitrogen, UK)). Cells were cultured in T-75 flasks and incubated in 5% CO2 at 
37°C. Media was exchanged twice weekly. Cells were split when they reached 
70% confluency. 
 
All cell lines were passaged at a ratio of 1:4 by trypsinisation to maintain the 
monolayer growth pattern and prevent overcrowding. Media was removed from 
the flasks and the cells were washed twice with phosphate-buffered saline (PBS) 
(Invitrogen, UK) heated to 37°C. This step is performed to remove traces of 
foetal calf serum that inactivates trypsin. Cells were incubated in 3 ml of trypsin 
(Invitrogen, UK) for 5 minutes in 5% CO2 at 37°C. Once cells were detached from 
the flask, 3 ml of cell line specific media was added to inactivate trypsin. Cells 
were gently pipetted against the side of the flask to disaggregate any clusters of 
 68 
cells before seeding into new T-75 flasks containing 10 ml of fresh cell line 
specific media. Cells were incubated in 5% CO2 at 37°C undisturbed for 48 hours 
to allow reattachment of cells to the flask.  
 
2.4.2 Culture of primary prostate cells 
 
2.4.2.1 Collection of human prostate tissue 
 
Human prostate samples were obtained from patients undergoing TRUS biopsy 
for investigation of prostate cancer (Figure 1). Samples were stored in a serum-
free RPMI (Invitrogen, UK) at 4°C overnight.  
 
Figure 2.1 TRUS guided core biopsy of the prostate  
 
 
Two trans rectal ultrasound guided prostate core biopsies were obtained for 
each patient.  
 
2.4.2.2 Processing of prostatic tissue obtained at TRUS guided core 
biopsy  
 
Biopsies were minced and suspended in serum-free RPMI (Invitrogen, UK) and 
incubated at 37°C in 5% CO2 overnight. A cell strainer was used to remove 
fibroblasts from the cell suspension. The cell suspension was washed three times 
in 10ml of PBS (Invitrogen, UK). The remaining tissue clumps and cells were re-
suspended in 5 ml of primary prostate cell media (Advanced DMEM/F12 
(Invitrogen, UK) supplemented with Amphotericin B 2.5µg/ml (Invitrogen, UK), 
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Penicillin/Streptomycin (50 units/ml, 50 µg/ml (Invitrogen, UK)), 2mM L-
glutamine (Invitrogen, UK) and B-27 (50X) supplement (20ml/L) (Invitrogen, UK) 
and the following growth factors: EGF 1µM (Sigma), N-acetyl-cysteine-L 1.25mM 
(Sigma), Human R-spondin-1 10 ng/ml  (PeproTech), Human Noggin 10 ng/ml 
(PeproTech), DHT 1nM (Sigma), FGF-10 1 ng/ml  (BioVision), FGF-2 0.1 ng/ml 
(BioVision), SB202190 10 µM  (Sigma), Y27632 10 µM (USBiological Life Sciences) 
and Cholera Toxin 1 µg/ml (Sigma)).  
 
The cell suspension was cultured in a T-25 Matrigel-coated flask at 37°C in 5% 
CO2 undisturbed for 7 days to allow attachment of the cells/tissue clumps to the 
flask. Media was renewed after 7 days, and every 2-3 days thereafter.  
 
Cells were passaged at approximately 70% confluency to maintain a monolayer 
and prevent overcrowding. Cells were washed twice in PBS heated to 37°C to 
remove any traces of media. Cells were incubated in 3 ml of trypsin (Invitrogen, 
UK) for 5 minutes in 5% CO2 at 37°C. Once cells were detached from the flask, 
cells were washed three times in PBS. Finally, the cells were re-suspended in 
10ml of primary prostate cell media and cultured in a T-75 flask at 37°C in 5% 
CO2. Again, cells were cultured to approximately 70% confluency before being 
passaged 1:4 into four T75 flasks. All experiments were conducted at passage 2 
when the cells had reached approximately 70% confluency.  
 
2.4.3 Cell treatments 
 
Expression of AR and pARS578 in the cell lines and one primary prostate cell 
culture was assessed in response to treatment with PMA and BIM-1.  
 
2.4.3.1 PMA 
 
PMA is a potent PKC activator. Cells were treated with 10nM PMA for one hour. A 
stock solution of 3µM PMA was prepared in dimethyl sulfoxide (DMSO). 
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2.4.3.2 BIM-1 
 
Bisindolylmaleimide-1 (BIM-1) is a highly selective, reversible inhibitor of PKC. 
Cells were treated with 10µM BIM-1 for one hour. A stock solution of 6mM BIM-1 
was prepared in DMSO. 
 
2.4.4 Inhibition of PKC using BIM-1 
 
Cells were trypsinised as described above at passage 2. Cells were seeded at 1 x 
104 in 8 well chamber slides. Each cell line was incubated in the cell-specific 
media for 72 hours. Cells were incubated in serum/additive free media 
overnight. The media was removed and the cells were washed in warmed PBS. 
Cells were incubated in the presence or absence of 10µM BIM-1 for one hour, 
followed by stimulation with 10 nM PMA for one hour. At the end of the 
treatment, cells were washed twice using ice-cold PBS and fixed using 4% 
paraformaldehyde (PFA) as described in the immunofluorescence (IF) section 
below. 
 
2.5 Immunofluorescence 
 
IF is an imaging technique that utilises antibodies labelled with a fluorophore 
directed against a specific antigen. A fluorophore is a fluorescent marker that 
emits light on excitation with light. This technique can be used in both tissue 
sections and cells to visualise specific proteins or antigens of interest using a 
fluorescent microscope.  
 
There are two methods of IF: direct and indirect. The direct method uses a 
primary antibody labelled with a fluorophore. The primary antibody binds to the 
antigen and the attached fluorophore can then be visualised under the 
microscope. The indirect method uses a primary antibody directed against the 
antigen of interest, and a secondary antibody labelled with a fluorophore that 
binds to the primary antibody. Although the indirect method is more complex 
than direct IF, it is preferable as signal intensity is higher as multiple secondary 
antibodies can bind to the primary antibody. The indirect method of IF was used 
in this study to characterise LNCaP, VCaP, and PNT2 cell lines as well as two 
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primary prostate cell cultures. IF was also performed on the cell lines treated as 
described above. 
 
2.5.1 Cell culture for characterisation  
 
Cells were seeded at 2.5 x 104 cells per well in 6 well chamber slides. Each cell 
line was incubated in the cell-specific media for 72 hours. Media was aspirated 
and cells were washed twice in ice-cold PBS. 
 
2.5.2 Fixation of cells 
 
Cells were fixed using 200µl of 4% PFA per well in a fume hood and incubated at 
4°C for thirty minutes. PFA was removed and PBS was added to each well. The 
cells were stored in PBS in the chamber slides at 4°C until use.  
 
2.5.3 Permeabilisation of cells 
 
Intracellular antigens are inaccessible to the antibody if the cell membrane 
remains intact. There are two reagent types that can be used to permeabilise 
the cell membrane. Organic solvents such as methanol or acetone dissolve lipids 
within the cell membrane, and have the additional benefit of also being a 
fixative agent. A disadvantage of using organic solvents is that lipid antigens may 
be leached from the cell during this process. Detergents, such as Tween20 or 
Triton X-100, are uncharged hydrophilic molecules that interact with membrane 
proteins and create pores in the membrane, thus rendering the cell membrane 
permeable.  
 
Excess PFA was removed by washing the cells twice in PBS at room temperature 
for five minutes on an orbital shaker.  Cell membranes were permeabilised with 
200µl of permeabilisation buffer (0.1% TritonX-100/PBS), applied twice for ten 
minutes at room temperature on an orbital shaker.  
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2.5.4 Blocking of non-specific staining 
 
Non-specific staining can result in a false positive result. In order to reduce non-
specific staining, cells were incubated in 200µl of blocking buffer (1.5% horse 
serum (Vector Laboratories) in 0.1% TBS-tween) for thirty minutes at room 
temperature on an orbital shaker. 
 
2.5.5 Incubation with primary antibody 
 
Various primary antibodies were used in this study as listed in Table 2.2 The 
primary antibody was diluted in blocking buffer described above. Cells were 
incubated in 100µl of the appropriate antibody per well for one hour at room 
temperature on an orbital shaker.  
 
Cells were then washed three times in TBS for ten minutes at room temperature 
on an orbital shaker.   
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Table 2.2 Antibody conditions for IF 
 
Protein Primary 
antibody 
Primary 
Antibody 
concentration 
Secondary 
antibody 
Secondary 
antibody 
concentration 
AR Mouse 
Dako 
AR441 
1:200 Goat anti-mouse 
IgG Alexa-Fluor 
488 
1:500 
PSA Rabbit 
Dako 
1:100 Goat anti-rabbit 
IgG Alexa-Fluor 
488 
1:500 
pARS578 Rabbit 
Eurogentec 
1:100 Goat anti-rabbit 
IgG Alexa-Fluor 
488 
1:500 
 
The primary antibody name and concentration and its associated secondary 
antibody name and concentration are listed for each protein of interest.  
 
2.5.6 Incubation with secondary antibody 
 
Cells were incubated in 200µl of the appropriate secondary antibody labelled 
with Alexa Fluor-488 fluorophore at a concentration on 1:500 for one hour at 
room temperature protected from light. All subsequent steps were performed in 
semi-darkness to avoid excitation, and subsequent bleaching of the fluorophore. 
Cells were washed three times in TBS for ten minutes at room temperature.   
 
2.5.7 Counterstaining and mounting 
 
4',6-diamidino-2-phenylindole (DAPI) is a blue fluorescent stain that binds to 
double stranded DNA and is therefore a useful nuclear counterstain in IF. 
Vectorshield mounting media with DAPI (Vector Laboratories) was used to mount 
the chamber slides onto coverslips. Coverslips were sealed with clear nail 
varnish to prevent movement of the coverslips whilst viewing cells with the 
microscope and also to prevent drying out of the cells. The slides were then 
stored protected from light at 4°C. 
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2.5.8 Visualisation of immunofluorescent staining 
 
Zeiss Confocal microscope was used to visualise the protein of interest. Cells 
were viewed and images obtained at x63 magnification. Zen software was used 
to process the images.   
 
2.6 Gene expression profiling 
 
2.6.1 RNA extraction 
 
RNA was extracted from LNCaP, VCaP, PNT2, and the two primary prostate cell 
cultures described above using the RNeasy Mini kit (Qiagen, Manchester, UK). 
Cells were cultured in appropriate growth medium in a T75 flask to 
approximately 70% confluency. 
 
2.6.1.1 Harvesting cells 
 
Cells were trypsinised and neutralised with appropriate growth media. Cells 
were transferred to a corning tube, and centrifuged at 1200rpm for 3 mins. The 
supernatant was aspirated. Cells were re-suspended in 1ml of PBS and 
transferred to a nuclease free tube. Cells were centrifuged again at 1200rpm for 
3 minutes and supernatant aspirated.  
 
2.6.1.2 Lysing cells 
 
To allow all RNA to be made available, cell membranes were disrupted and the 
cells homogenised. Cells were lysed using 350µl of RLT lysis buffer. Cells were 
homogenised by repeatedly aspirating the cell suspension through a 26G needle 
and 1ml syringe. 350µl of 70% ethanol was added before immediately 
transferring the homogenised cell sample to a spin column and centrifuged for 
15 seconds at 8000 x g. Flow through was discarded. 
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2.6.1.3 Washing cells 
 
 
Firstly, the cell sample was washed in RW1 buffer to remove large biomolecules 
that were not attached to the spin column membrane. RW1(700µl) was applied 
to the spin column membrane and centrifuged for 15 seconds at 8000 x g. Flow 
through was discarded. The cell sample was washed again with a mild washing 
buffer (RPE buffer) that removes any residual salts from the RNA extraction 
process. Two washes with 500µl RPE buffer were performed, centrifuging for 15 
seconds at 8000 x g after the first wash and two minutes at 8000 x g. Flow 
through was discarded after each wash. Finally, the spin column was centrifuged 
for one minute at 8000 x g to dry the membrane. 
 
2.6.1.4 Eluting RNA 
 
The spin column was placed into a new collecting tube. RNase free water (30 µl) 
was added directly to the spin column and centrifuged for one minute at 8000 x 
g to elute RNA. The spin column was discarded and the RNA was stored at -80°C 
until use.  
 
2.6.2 cDNA Synthesis 
 
2.6.2.1 DNA elimination 
 
DNA should be removed from the sample prior to cDNA synthesis as even small 
amounts of residual DNA can be amplified in quantitative real time-PCR (RT-
qPCR). Firstly, the quantity and purity of the RNA before the DNA extraction 
step was quantified using the Nanodrop. To 2µg RNA, 2µl 10x DNase I reaction 
buffer (Promega, Southampton, UK), 1ul DNase I (Promega, Southampton, UK), 
1ul RNase OUT (Life Technologies, Paisley, UK) and nuclease free water to a 
volume of 20ul was added. The mixture was incubated at room temperature for 
15 minutes, before inactivating the DNase solution by the addition of 1µl of Stop 
solution (Promega, Southampton, UK). The solution was then heated to 65°C for 
ten minutes. After heating, the solution was stored on ice and transferred to the 
Nanodrop to determine the quantity and purity of the RNA post-DNA elimination. 
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2.6.2.2 cDNA synthesis 
 
For a 100 µl cDNA synthesis reaction, 1 µg RNA from the cell line of interest was 
added to 5 µl random primers (Life Technologies, UK) and topped up with 
nuclease-free water to a volume of 62 µl. The RNA solution was heated to 65°C 
for ten minutes. After heating, 20 µl of 5x FS buffer, 
2.5 µl of RNase OUT, 2.5 µl of Superscript II reverse transcriptase, 10 µl of 10nM 
dNTP and 3.5 µl of DMSO was added to the RNA solution to make a final volume 
of 100 µl. The RNA solution was heated for 10 minutes at 25°C, then 30 minutes 
at 50°C before heating to 85°C for 5 minutes to inactivate the transcriptor. 
cDNA was stored at -20°C until use. 
 
2.6.3 Quantitative Real Time-PCR 
 
RT-qPCR was performed to allow comparison between gene expression in the 
control sample (PNT2 benign cell line) and the prostate cancer cell lines and 
primary prostate cells. A 96 well optical fast PCR plate was used. To each well 
40 ng cDNA from the cell line of interest, 10 µl of master mix (Life 
Technologies), 5 µl nuclease-free water and 1 µl of gene expression assay was 
added. The gene expression assays used in this study were all Taqman Gene 
Expression Assays and included ActB (housekeeping gene), AR, FASN, KLK-3, 
GOLM1 and AMACR. Blank control wells containing only the mixture and no cDNA 
were included in each plate to exclude contamination. Plates were sealed and 
centrifuged at 1200 rpm for 3 minutes. Air bubbles were removed using a 
Microlance needle. RT-qPCR was performed using an ABI 7500 real time PCR 
machine (Applied Biosystems).  Samples were heated at 50°C for two minutes, 
95°C for 10 minutes then 40 cycles of 95°C for 15 seconds and 60°C for one 
minute. Gene expression was normalised to the ActB housekeeping gene. The 
comparative cycle threshold (DDCt) method was used to quantify relative gene 
expression.   
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2.7 Flow cytometry 
 
Flow cytometry is a method for characterising mixed cell populations based on 
the expression of cell surface and intracellular molecules detected on individual 
cells by fluorescent-labelled antibodies. A cell suspension is incubated with 
fluorochrome-labelled antibodies and analysed using a flow cytometer. 
 
2.7.1 Harvesting Cells 
 
Cells were trypsinised and neutralised with appropriate growth media. Cells 
were counted and 5 x 105 cells were placed in a 10 ml falcon tube per test. Cells 
were washed twice in 3 ml of warmed PBS for 3 minutes. Cells were treated with 
750 g/ml DAPI for 10 minutes as a live/dead stain.  
 
2.7.2 Fixation of cells 
 
Cells were fixed in a mixture of 125 µl of cold 2% PFA and 875 µl of cold PBS. 
Cells were vortexed and incubated in the fridge for one hour. Cells were washed 
in twice in PBS for five minutes. Cells can be stored in PBS at 4°C until use. 
 
2.7.3 Permeabilisation of cells 
 
Cells were washed twice in permeabilisation buffer (0.1% TritonX-100/PBS), 
applied twice for ten minutes at room temperature. 
 
2.7.4 Incubation in primary antibody 
  
Cells were stained using both CK-18-FITC conjugated antibody (1:100) and CD-
90-APC conjugated antibody (1:100) for one hour at 4°C protected from light. 
Antibodies were diluted in a flow cytometry buffer (PBS, 1% BSA) to a volume of 
100 µl. A negative control and APC and FITC control cells were included for each 
cell line. Cells were washed twice in 3 ml of PBS-T for three minutes and re-
suspended in 1ml of flow cytometry buffer.  Cells were analysed using the BD 
FACSVerse flow cytometer (BD Biosciences).  
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Chapter 3 Active Surveillance Prostate Cancer Cohort 
 
In 2013, the majority of patients diagnosed with prostate cancer presented with 
Stage I disease, and more than half had localised prostate cancer. (158) NICE 
recommends that patients with low risk, localised prostate cancer should be 
offered AS as an alternative to immediate radical intervention. (51) The PIVOT 
trial comparing observation startegies against radical prostatectomy found no 
significant difference in all-cause or prostate cancer mortality in patients with 
localised prostate cancer. (61) AS is a delayed treatment strategy that aims to 
avoid over-treatment of low-risk prostate cancer, and thus unnecessary side 
effects, arising from over-diagnosis of indolent tumours. The PRIAS study found 
pathological evidence of progression in 28% of men with low-risk, localised 
prostate cancer undergoing AS. (159) There is a risk that the delay in treatment 
in these patients may result in prostate cancer progressing to an advanced stage, 
resulting in them being ineligible for radical treatment. Clinicians currently lack 
the tools to predict which patients that fulfil low risk criteria at diagnosis will 
progress to more advanced disease or remain with indolent disease. Therefore, 
biomarkers that can predict which patients will progress, and require radical 
treatment, and those patients whose disease will remain indolent and can 
therefore safely remain on AS, would be a useful tool to the urologist.   
 
The aim of the current study was to determine whether AR phosphorylation at 
Ser-578 and Ser-81 and PKC expression is associated with clinico-pathological 
factors and time to intervention in an AS cohort. In addition, as phosphorylation 
of AR at Ser-578 and Ser-81 has been predicted to occur via different pathways, 
it was hypothesised that expression of AR phosphorylated at these sites may 
have a cumulative prognostic effect. Therefore, the prognostic significance of 
dual expression of AR phosphorylated at Ser-578 and Ser-81 was investigated in 
relation to time to intervention.  
3.1 Cohort Demographics 
 
Analysis was based on one hundred and five prospectively identified, consecutive 
prostate cancer patients under AS. Patient characteristics recorded included 
age, Gleason score at diagnosis, serum PSA at diagnosis, perineural invasion 
(PNI) and treatment for prostate cancer whilst on AS (Table 3.1). Median age at 
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diagnosis was 67.5 years (IQR 63.3- 72.0 years). Median PSA at diagnosis was 
7.0ng/mL (IQR 4.5-10.2ng/mL). Median follow-up was 30.0 months (IQR 19.1-
49.6 months).  
 
Table 3.1 Clinico-pathological characteristics of the cohort 
 
 
 Clinical Parameter Patients, n (%) 
Age (<70/ ≥70 years) 63 (60)/ 42 (40) 
Diagnosis PSA (<10/ ≥10 ng/ml) 77 (73.3)/ 27 (25.7) 
Diagnostic procedure (TRUS/TURP) 81 (77.1)/ 24 (22.9) 
Gleason score (6/>6) 98 (93.3)/ 7 (6.7) 
Peri neural invasion (no/yes) 80 (76.2)/ 8 (7.6) 
Prostatic intraepithelial neoplasia (no/yes) 77 (73.3)/ 12 (11.4) 
Percentage tissue containing cancer (<50/ ≥50) 87 (82.9)/ 1 (1) 
Intervention (no/yes) 78 (74.3)/ 27 (25.7) 
 
Number of patients with missing data is not displayed. Values that do not give a 
sum of 100% is due to data being unavailable 
 
TRUS biopsy was the most common procedure at diagnosis with eighty-one 
(77.1%) patients having diagnostic tissue obtained at TRUS biopsy. The remaining 
twenty-four (22.9%) patients had diagnostic tissue available from TURP. Ninety-
eight (93.3%) patients had a Gleason 6 tumour and seven (7%) patients had 
Gleason 7. Eight (7.6%) patients had perineural invasion at diagnosis. Twelve 
(11.4%) patients had high grade PIN in their diagnostic specimen. Only one 
patient had greater than 50% of the diagnostic tissue positive for cancer.   
Twenty-seven (25.7%) patients required treatment for prostate cancer whilst on 
AS. Eighteen patients (17.1%) required treatment due to biochemical 
progression. The remaining nine (8.6%) patients had treatment for other reasons 
such as clinical or histological progression. Twenty-five patients received radical 
therapy, and two patients received hormonal therapy. The median time to 
treatment intervention was 21.9 months (IQR 18.7-35.8).  
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3.2 Protein expression analysis 
 
Eighty-one patients had diagnostic prostate cancer specimens available for IHC. 
Protein expression in the nucleus and cytoplasm was recorded in epithelial 
tumour cells only. Expression of all proteins was heterogeneous throughout the 
cells. Representative specimens of high and low expression for each protein are 
displayed in Figure 3.1. 
 
Figure 3.1 IHC of prostate cancer tissue for AR, pARS81, pARS578 and PKC 
 
 
Representative tissue specimens that were categorised as high and low 
expression of AR, pARS81, pARS578 and PKC. Expression of all proteins was 
heterogeneous throughout the cells. 
 
Protein expression in the specimens was divided into low (≤median) and high 
(>median) for purposes of analysis (Table 3.2). All ICCC values were >0.90.  
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Table 3.2 Protein expression in patients with tissue available 
 
 Patients, n(%) Median 
Histoscore 
(Histoscore 
units) 
Interquartile 
range 
(Histoscore 
units) 
AR Nuclear (low/high) 41 (39)/ 40 (38.1) 120 95 – 165 
AR Cytoplasmic (low/high) 42 (40)/ 39 (37.1) 80 50 – 100 
pARS81 Nuclear (low/high) 43 (41)/ 35 (33.3) 185 140 – 205 
pARS81 cytoplasmic (low/high) 40 (38.1)/ 38 (36.2) 100 80 – 125 
pARS578 Nuclear (low/high)  29 (27.6)/ 28 (26.7) 95 56 – 120 
pAR S578 Cytoplasmic (low/high) 34 (32.4)/ 23 (21.9) 90 110 - 135 
PKC Nuclear (low/high) 35 (33.3)/ 33 (31.4) 70 35 – 95 
PKC Cytoplasmic (low/high) 39(37.1)/29 (27.6) 110 92.5 – 120 
 
The median histoscore for each protein of interest was calculated. Patients 
were grouped into low (≤median) and high expression (>median). The number of 
patients in each group is displayed for each protein.  
Number of patients with missing data is not displayed. Values that do not give a 
sum of 100% is due to data being unavailable  
 
3.3 Association between PKC expression and expression of pARS578 in 
clinical specimens 
 
In the clinical specimens, nuclear PKC expression was significantly associated 
with pARS578 expression both in the nucleus (c.c. 0.452, p=0.001) and cytoplasm 
(c.c. 0.442, p=0.001). In addition, cytoplasmic PKC expression was significantly 
associated with pARS578 expression in the nucleus (c.c. 0.36, p=0.007) and 
cytoplasm (c.c. 0.492, p=<0.001). Table 3.3 demonstrates the association 
between PKC expression and pARS578. 
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Table 3.3 Association between PKC expression and expression of pARS578 at 
both cellular locations in the clinical specimens 
 
 
 PKC 
 Nuclear 
p value, C.C 
Cytoplasmic 
p value, C.C 
pAR578 Nuclear 0.001, 0.452 0.007, 0.36 
pAR578 Cytoplasmic 0.001, 0.442 <0.001, 0.492 
 
Pearson’s correlation coefficient was used to assess the association between 
PKC expression and expression of pARS578 in the nucleus and cytoplasm. 
Expression of PKC was significantly associated with pARS578 expression at both 
locations.  
C.C. denotes Pearson’s correlation co-efficient.Values highlighted in red 
denotes associations with a p value < 0.05.  
 
3.4 Clinico-pathological parameters related to intervention 
 
Serum PSA at diagnosis was associated with decreased time to intervention 
(proportion of patients receiving intervention at 2 years, PSA ≥10 ng/ml 32% vs 
PSA < 10 ng/ml 12%, HR 2.7 (95% CI 1.2-6.3) p=0.015) (Figure 3.2 A). The 
percentage of tissue containing cancer was associated with decreased time to 
intervention (proportion of patients receiving intervention at 2 years, ≥ 50% 
tissue contains cancer 100% vs <50% tissue contains cancer 12%, HR 17.5 (95% CI 
2.0-157.0) p=<0.001) (Figure 3.2 B).  
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Figure 3.2 Kaplan Meier Graph showing PSA at diagnosis (A) and percentage 
of tissue positive for cancer (B) as related to time to intervention 
 
 
 
 
Kaplan Meier plots showing High PSA (dashed line) (A) and high tumour volume 
(dashed line) (B) at diagnosis are significantly associated with decreased time to 
intervention 
 
No other clinico-pathological parameters were associated with time to 
intervention. The univariate analysis of clinico-pathological parameters related 
to time to intervention are displayed in Table 3.4.  
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Table 3.4 Univariate analysis of clinico-pathological parameters related to 
time to intervention  
 
Univariate analysis 
Clinico-pathological characteristic Time to intervention 
P value Hazard Ratio (95% CI) 
Age (<70/ ≥70 years) 0.823, 0.91, 0.4-2.0 
Diagnosis PSA (<10/ ≥10 ng/ml) 0.015, 2.72, 1.8-6.3  
Gleason score (6/>6) 0.100, 2.69, 0.8-9.2 
Peri neural invasion (no/yes) 0.443, 1.60, 0.5-5.4 
Prostatic intraepithelial neoplasia (no/yes) 0.361, 0.57, 0.2-1.9 
Percentage tissue containing cancer (<50/≥50) <0.001, 17.5, 2.0-157.0 
 
The clinico-pathological variables were grouped and analysed by Kaplan-Meier 
methods and Cox regression with reference to time to treatment for prostate 
cancer. High PSA and high tumour volume are significantly associated with 
decreased time to intervention. Significant results (p = £0.05) are highlighted in 
red.  
 
3.5 Expression of phosphorylated AR related to clinico-pathological 
parameters 
 
High expression of nuclear pARS578 was associated with increased PSA level at 
diagnosis (p=0.014). High nuclear and cytoplasmic pARS578 expression was 
associated with presence of perineural invasion (PNI) (p=0.034 and p=0.008 
respectively). Expression of pARS81 or PKC in the clinical specimens was not 
associated with clinico-pathological parameters. Table 3.5 shows the univariate 
analysis of expression of pARS81, pARS578 and PKC at both cellular locations 
related to clinico-pathological parameters. 
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Table 3.5 Expression of pARS81, pARS578 and PKC related to clinico-pathological parameters  
 
Expression of pARS81, pARS578 and PKC in the nucleus and cytoplasm was examined for significant relationships with clinical variables as 
shown. Protein expression was divided into high and low groups. Clinical variables were divided into groups and the Mann-Whitney U 
test was performed for statistical analysis. High PSA at diagnosis and presence of perineural invasion in pathological specimens are 
significantly associated with high expression of pARS578.  Statistically significant results are highlighted in red.
  Nuclear AR S81 Cytoplasmic AR S81 Nuclear AR S578 Cytoplasmic AR  S578 Nuclear PKC Cytoplasmic PKC 
  Low expression High expression p-value Low expression High expression p-value Low expression High expression p-value Low expression High expression p-value Low expression High expression p-value Low expression High expression p-value 
Age                
(<70/>70) 
23/20 23/12 0.278 22/18 24/14 0.467 16/13 15/13 0.904 17/17 14/9 0.423 22/13 17/16 0.348 23/16 16/13 0.756 
Gleason        
(6/>6) 
39/4 34/1 0.251 38/2 35/3 0.604 28/1 26/2 0.536 32/2 22/1 0.801 32/3 31/2 0.694 35/4 28/1 0.291 
PSA at 
diagnosis 
(<10/>10) 
31/12 25/9 0.889 28/12 28/9 0.579 25/3 17/11 0.014 27/6 15/8 0.162 25/9 23/10 0.730 28/10 20/9 0.673 
Perineural 
invasion 
(no/yes) 
29/3 29/2 0.670 28/1 30/4 0.227 18/0 21/6 0.034 23/0 16/6 0.008 24/2 25/4 0.473 30/2 19/4 0.195 
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3.6 Expression of pARS81, pARS578 and PKC related to time to 
intervention 
 
High cytoplasmic pARS81 expression was associated with decreased time to 
treatment intervention (proportion of patients receiving treatment intervention 
at 2 years, >median expression 28.5% vs <median expression 7.1%, HR 2.76 (95% 
CI 1.1-7.3)), p=0.032 (Figure 3.3).  
  
Figure 3.3 Kaplan Meier Graph showing expression of cytoplasmic 
pARS81related to time to intervention 
 
 
 
Kaplan Meier plot showing time to intervention in patients with high expression 
of cytoplasmic pARS81 (dashed line) and low expression of cytoplasmic pARS81 
(solid line). High expression of cytoplasmic pARS81 was associated with 
decreased time to intervention.  
 
Nuclear pARS81 was not associated with time to treatment intervention. There 
was no significant association between pARS578 or PKC at either cellular location 
and time to intervention. The univariate analysis of expression of pARS81, pARS578 
and PKC at both cellular locations related to time to intervention is outlined in 
Table 3.6. 
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Table 3.6 Univariate analysis of expression of pARS81, pARS578 and PKC 
related to time to intervention 
 
Univariate analysis 
Protein expression 
(<median/>median) 
Time to intervention 
P value Hazard Ratio (95% CI) 
pARS81 Nuclear  0.748, 1.16, 0.5-2.8 
pARS81 cytoplasmic  0.032, 2.76, 1.1-7.3 
pARS578 Nuclear  0.419, 0.42, 0.5-4.2 
pAR S578 Cytoplasmic  0.242, 1.82, 0.7-5.1 
PKC Nuclear  0.987, 0.99, 0.3-2.9 
PKC Cytoplasmic  0.704, 1.23, 0.4-3.5 
 
Expression of pARS81, pARS578 and PKC in the nucleus and cytoplasm was analysed 
by Kaplan-Meier methods and Cox regression in relation to time to intervention 
from diagnosis. Protein expression was divided into high and low groups. High 
expression of cytoplasmic pARS81 expression was associated with decreased time 
to intervention. Significant results (p = £0.05) are highlighted in red.  
 
3.7 Expression of dual phosphorylation sites on the AR related to 
outcome measures 
 
Phosphorylation of AR at Ser-578 and Ser-81 is predicted to occur in response to 
different kinases via separate pathways. It was therefore investigated if there is 
a cumulative predictive effect when expression at these sites are combined in 
relation to time to intervention. The two phosphorylation sites were combined 
as follows: (i) High expression (high pAR
S81 and high pAR
S578) and (ii) Low 
expression (low pAR
S81 and low pAR
S578 expression).  
  
High dual expression of cytoplasmic pARS81 and cytoplasmic pARS578 was 
associated with decreased time to treatment intervention (proportion of 
patients receiving treatment intervention at 2 years, high expression of both 
proteins 46% vs low expression of both proteins 0%, HR 6.4 (95% CI 1.3-31.0), 
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p=0.008) (Figure 3.4). There was no significant association between dual 
expression of nuclear pARS81 and pARS578 or total expression of pARS81 and pARS578 
and time to treatment intervention.  
 
Table 3.7 demonstrates the univariate analysis of dual expression of pARS81 and 
pARS578 as related to time to intervention. 
 
Figure 3.4  Kaplan Meier Graph showing dual expression of cytoplasmic 
pARS81 and pARS578 related to time to intervention 
 
 
 
Kaplan Meier plot showing time to intervention in patients with low expression 
of both cytoplasmic pARS81 and pARS578 (solid line) and high expression of both 
cytoplasmic pARS81 and pARS578 (dashed line). High expression of both 
cytoplasmic pARS81 and pARS578 is associated with decreased time to intervention 
than compared to low expression of both phosphosites. 
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Table 3.7 Univariate analysis of dual expression of pARS81 and pARS578 as 
related to time to intervention 
 
Univariate analysis 
Protein expression Time to intervention  
P value Hazard Ratio (95% CI) 
pARS578 cytoplasmic + pARS81 cytoplasmic 
 
0.008, 6.4, 1.3-31.0 
pARS578 nuclear + pARS81 nuclear 
 
0.233, 2.2, 0.6-8.4 
Total cytoplasmic pARS81 and pARS578 + 
total nuclear pARS81 and pARS578 
  
0.089, 3.9, 0.7-21.9 
 
Dual expression of pARS81 and pARS578 was analysed by Kaplan-Meier methods and 
Cox regression in relation to time to intervention. Protein expression was 
divided into high and low groups. High expression of both cytoplasmic pARS81 
and pARS578 is associated with decreased time to intervention than compared to 
low expression of both phosphosites. Significant results (p = £0.05) are 
highlighted in red.  
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3.8 Discussion 
 
 
This study investigated the role of AR phosphorylation at Ser-81 and Ser-578 in 
an AS cohort. The cohort was a prospectively identified group of consecutive 
patients who were undergoing AS. NICE recommends that patients selected for 
AS should have features of low risk localised prostate cancer, as indicated by 
PSA <10 ng/ml, a Gleason score ≤6 and a clinical stage of T1-2a (51). As would 
be expected, the cohort had features suggestive of low risk prostate cancer, 
with a median PSA at diagnosis of 7.0 ng/ml and >90% of the patients having 
Gleason 6 tumour. Clinical stage was poorly recorded and therefore was not used 
in this study. Some patients in this cohort, however, did have features indicative 
of moderate risk disease. Although it is not common in European countries to 
treat patients with features of moderate risk disease with AS, entry into AS 
programmes in the UK is less stringent. A survey of UK urologists found that 75% 
of respondents would consider patients with Gleason 7 disease and 53% would 
consider patients with a PSA >10 ng/ml for AS (160). This cohort is therefore 
reflective of common UK practice. 
 
During the follow-up period (median follow-up 30.0 months), 25.7% patients had 
treatment whilst on AS for either biochemical, histological or radiological 
progression. This is in keeping with findings of previous studies. A study of 238 
patients in the US who met AS inclusion criteria found 27% of patients progressed 
within 2 years (161). A further study of pathological specimens from 7,333 
patients who met the low risk active criteria for AS but went on to have radical 
prostatectomy rather than enter an AS programme found that 21.8% of patients 
had an upgraded Gleason score and 23.1% had non-organ confined disease on 
final pathology (162). These findings suggest that whilst AS can be used as a tool 
to reduce over treatment in low risk prostate cancer, there is still a sub-cohort 
of patients that are at risk of disease progression. Biomarkers that are able to 
predict those at risk of progression are desperately needed.  
 
In the current study, serum PSA ≥10 ng/ml at diagnosis was significantly 
associated with decreased time to intervention. This is to be expected, as PSA 
≥10 ng/ml is included in the intermediate risk criteria for localised prostate 
cancer (51). Surprisingly, Gleason score was not significantly associated with 
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time to intervention. Diagnostic specimens with ≥ 50% of tissue containing 
cancer was also significantly associated with decreased time to intervention. 
This is in keeping with another study of AS patients, who found that patients 
with more than 3 prostate biopsy cores positive for cancer at diagnosis is 
significantly associated with decreased time to disease progression (161), thus 
supporting tumour volume at diagnosis as a predictor of disease progression 
amongst an otherwise relatively homogeneous group of patients.  
 
PKC is predicted to be the kinase responsible for phosphorylation of AR at Ser-
578 by Scansite 2.0. (130) Ponguta et al demonstrated that PKC mediated 
phosphorylation was approximately 50% less in mutant S578A recurrent prostate 
cancer cells than compared to wild-type, suggesting that Ser-578 is the 
consensus site for PKC. (129) In the current study, it was observed that PKC 
expression significantly correlates with phosphorylation of AR at Ser-578 in 
hormone-naïve low risk prostate cancer specimens. This supports the role of PKC 
as the kinase responsible for phosphorylation of AR at Ser-578 in both hormone 
naïve prostate cancer and castrate resistant prostate cancer.  
 
The relationship between clinico-pathological parameters and expression of 
pARS81, pARS578 and PKC was investigated. High expression of nuclear pARS578 was 
associated with increased PSA level at diagnosis. High serum levels of PSA at 
diagnosis has been shown to be associated with other markers of high risk 
disease including high Gleason score, increased disease stage, and disease 
specific survival (163, 164). High expression of both nuclear and cytoplasmic 
pARS578 is associated with the presence of perineural invasion in diagnostic 
specimens. PNI is a recognised mechanism for the development of extra-
prostatic extension in prostate cancer (163). PNI has been associated with poorer 
outcomes following radical surgery (165, 166). This suggests that pARS578 may 
have a role in the development of PNI, and thus may be a marker for high risk 
disease. These findings support the research hypothesis that high expression of 
pARS578  is associated with advanced disease. Phosphorylation status at serine 578 
could therefore be a surrogate marker of disease severity. 
 
AR is known to be pivotal in growth and progression of prostate cancer and is 
therefore the main target in medical management of prostate cancer. It is well 
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established that the AR is activated in response to DHT. (167, 168) 
Phosphorylation of the AR occurs at a number of phosphosites in response to 
DHT, with Ser-81 being the most commonly phosphorylated site. (114) We found 
that high expression of pARS81 was associated with shorter time to treatment 
intervention. This is in spite of pARS81 expression not being associated with any 
of the clinical markers currently used to assess risk in localised disease.  This 
supports the research hypothesis that pARS81 expression would be associated with 
poor outcomes in prostate cancer. pARS81 may be a useful independent marker of 
overall poorer prognosis in low-risk localised prostate cancer.  
 
Phosphorylation of the AR can also occur at other serine residues and has been 
shown to regulate AR activity and cellular localisation. Our group has previously 
investigated the effect of AR phosphorylation at a number of serine residues on 
the AR on clinical outcome measures. Phosphorylation at serine 213 is associated 
with decreased disease specific survival in castrate resistant prostate cancer and 
phosphorylation at serine 515 is associated with decreased time to biochemical 
relapse and decreased disease specific survival in hormone naïve prostate cancer 
(124, 128). Phosphorylation of the AR is not always associated with poorer 
outcome however. Phosphorylation of the AR at serine 791 is associated with 
increased time to biochemical relapse and increased time to death in castrate 
resistant prostate cancers (126). It was hypothesised that pARS578 may also be of 
prognostic significance in prostate cancer. It has previously been demonstrated 
that the PKC inhibitor, Calphostin, reduced both EGF-dependent and 
independent cell growth in a recurrent prostate cancer cell line. (129) 
Phosphorylation of the AR at Ser-578 has been linked to nuclear-cytoplasmic 
shuttling, DNA binding and modulation of other phosphosites on the AR. In the 
present study, there was no association between phosphorylation of the AR at 
Ser-578 and time to treatment intervention, despite a significant association 
with high PSA at diagnosis, an established marker of increased disease severity.  
pARS578 expression is unable to predict which patients will require earlier 
intervention amongst a relatively homogeneous group of low risk prostate cancer 
patients.  
 
Classical AR phosphorylation occurs via DHT binding, resulting in phosphorylation 
of AR at Ser-81. As we demonstrated earlier, Ser-578 is likely to be 
 93 
phosphorylated in response to PKC. Phosphorylation of the AR in response to PKC 
occurs via an alternative pathway to that of classical AR phosphorylation 
secondary to DHT. We hypothesised that when combined, the phosphorylation 
status on the AR at these two serine residues may have a cumulative adverse 
prognostic effect. In this study, we demonstrated a cumulative prognostic effect 
when expression of cytoplasmic pARS81 and pARS578 were combined in relation to 
time to treatment intervention. This is in spite of pARS578 having no independent 
significant association with time to intervention in this cohort.  Patients who had 
high expression of both pARS81 and pARS578 required treatment sooner than those 
with low expression of both. The observed cumulative effect had greater 
prognostic power than expression of pARS81 alone. These striking results suggest 
that there is a sub-population of patients who despite fulfilling the traditional 
criteria of low risk prostate cancer at diagnosis are more likely to progress and 
require treatment at an earlier stage.  
 
A limitation of this study was the small cohort sample size. However, despite the 
small sample size, this study has demonstrated that pARS81 alone and in 
combination with pARS578 can predict earlier treatment intervention in low risk 
prostate cancer patients. This may provide clinicians with a much-needed 
prognostic biomarker to identify those patients who are more likely to require 
early intervention, and those patients that can safely remain on AS and avoid the 
harms of unnecessary treatment. These results should be validated in a larger, 
independent cohort of low-risk prostate cancer patients.  
 
A pilot study will now be conducted in a group of consecutive hormone-naïve 
prostate cancer patients with all stages of disease at diagnosis to investigate if 
these findings can be replicated in a more heterogeneous group of patients.  
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Chapter 4 Discovery Prostate Cancer Cohort 
 
 
Prostate cancer is the most common male cancer in the UK. (1) Following the 
introduction of the PSA test in the early 1990s, the incidence of prostate cancer 
has increased by 44% and is projected to rise by a further 12% by 2035. (1, 2) 
Many patients are diagnosed with low risk, indolent prostate cancer which would 
otherwise remain undetected in their lifetime. The reported rates of over-
diagnosis vary widely (169), however, it remains clear that over-treatment of 
low-risk disease should be avoided to not only reduce unnecessary side effects 
but also to reduce the associated economic burden. Current methods for risk 
stratification are poor and rely on basic parameters such as PSA at diagnosis and 
Gleason score obtained from TRUS biopsy, which does not always represent the 
true pathological nature of the tumour. Recently, the Genomic Prostate Score 
has been developed, which utilises a panel of 17 genes grouped into four 
categories (AR signalling, stromal response, cellular organisation and 
proliferation) to predict prostate cancer aggressiveness using the initial 
diagnostic pathological specimen. (170) Whilst this score can assist clinicians in 
treatment recommendations, the test is expensive and there is dubiety over it’s 
cost-effectiveness in clinical practice. Prostate cancer management is certainly 
moving towards individualised medicine and there is much need for new 
prognostic biomarkers that can easily translate into the clinic, be cost effective 
and ultimately aid clinicians in deciding which patients will gain most benefit 
from treatment or indeed if they require treatment at all.  
 
In this study, we investigate the use of IHC to assess pARS578 and pARS81 status 
both as individual and combined biomarkers for prognosis in a cohort of patients 
with hormone-naïve prostate cancer of all stages of disease.  
4.1 Patient Demographics 
 
Ninety hormone-naïve prostate cancer patients, recruited between 1992 and 
2002, were included in this study.  Median follow up period was 11.7 years (IQR 
9.9 – 14.0 years). Patient demographics including age at diagnosis, Gleason 
score, PSA at diagnosis and PSA at relapse were recorded and are summarised in 
Table 4.1. 
  
 95 
Table 4.1 Clinico-pathological characteristics of the cohort 
 
 Clinical Parameter Patients, n (%) 
Age (<70/ ≥70 years) 34 (37.0)/ 56 (60.9) 
Diagnosis PSA (<10/ 10 – 20/ ≥20 ng/ml) 19 (20.7)/ 14 (15.2)/ 36 (39.1) 
Gleason score (<7/7/>7) 24 (26.1)/ 25 (27.2)/ 28 (30.4) 
Lymphovascular invasion (no/yes) 84 (91.3)/ 6 (6.5) 
Perineural invasion (no/yes) 72 (78.3)/ 18 (19.6) 
Prostatic intraepithelial neoplasia (no/yes) 79 (85.9)/ 11 (12.0) 
 
Number of patients with missing data is not displayed. Values that do not give a 
sum of 100% is due to data being unavailable 
 
Median age at diagnosis was 70.1 years (IQR 63.3 – 75.4 years). Median PSA at 
diagnosis was 22 ng/ml (IQR 7.7 – 60.5 ng/ml). Median PSA at biochemical 
relapse was 2.2 ng/ml (IQR 1.0 – 7.3 ng/ml). At diagnosis, twenty-three patients 
had metastatic disease to local lymph nodes (3), bone (13) or both sites (7). 
Forty-seven patients developed biochemical relapse following treatment. The 
median time to biochemical relapse was 2.7 years (IQR 1.5-3.8 years). Sixty-six 
patients died during the follow-up period. Forty-six patients died from prostate 
cancer (median time to death 4 years, IQR 1.9-7.2 years). Twenty patients died 
due to non-prostate cancer causes (median time to death 4.1 years, IQR 0.9-5.5 
years).  
4.2 Protein expression analysis 
 
Eighty-nine patients had hormone-naïve prostate cancer specimens available for 
IHC. Protein expression in the nucleus and cytoplasm was recorded in epithelial 
tumour cells only. Expression of all proteins was heterogeneous throughout the 
cells.  
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Protein expression in the specimens was divided into low (≤median) and high 
(>median) for purposes of analysis. (Table 4.2) All ICCC values were >0.80. 
 
Table 4.2 Protein expression in patients with tissue available 
 
 Patients, n (%) Median 
Histoscore 
(Histoscore units) 
Interquartile 
range 
(Histoscore units) 
AR Nuclear (low/high) 44 (47.8)/ 45 (48.9) 68 44 – 83 
AR Cytoplasmic (low/high) 45 (48.9)/44 (47.8) 63 50 – 81 
pARS81 Nuclear (low/high) 34 (37.0)/ 31 (33.7) 140 74 – 207 
pARS81 cytoplasmic (low/high) 34 (37.0)/ 31 (33.7) 50 20 – 100 
pARS578 Nuclear (low/high)  30 (32.6)/ 30 (32.6) 169 130 – 206 
pAR S578 Cytoplasmic (low/high) 32 (34.8)/ 28 (30.4) 50 31 – 100 
PKC Nuclear (low/high) 30 (32.6)/ 28 (30.4) 205 174 – 223 
PKC Cytoplasmic (low/high) 29 (31.5)/ 29 (31.5) 138 100 – 163 
 
The median histoscore for each protein of interest was calculated. Patients 
were grouped into low (≤median) and high expression (>median). The number of 
patients in each group is displayed for each protein.  
Number of patients with missing data is not displayed. Values that do not give a 
sum of 100% is due to data being unavailable  
 
4.3 Association between PKC expression and expression of pARS578 in 
clinical specimens 
 
In the clinical specimens, nuclear PKC expression was significantly associated 
with pARS578 expression both in the nucleus (c.c. 0.426, p=0.002) and cytoplasm 
(c.c. 0.469, p=0.001). Cytoplasmic PKC expression was associated with nuclear 
pARS578 expression (c.c. 0.284, p=0.044). Table 4.3 demonstrates the association 
between PKC expression and pARS578. 
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Table 4.3 Association between PKC expression and expression of pARS578 at 
both cellular locations in the clinical specimens 
 
 PKC 
 Nuclear 
p value, C.C 
Cytoplasmic 
p value, C.C 
pAR578 Nuclear 0.001, 0.469 0.044, 0.284 
pAR578 Cytoplasmic 0.002, 0.426 0.894, 0.019 
 
Pearson’s correlation coefficient was used to assess the association between 
PKC expression and expression of pARS578 in the nucleus and cytoplasm. 
Expression of nuclear PKC was significantly associated with pARS578 expression at 
both locations. Expression of cytoplasmic PKC was significantly associated with 
nuclear pARS578 expression only. 
C.C. denotes Pearson’s correlation co-efficient.Values highlighted in red 
denotes associations with a p value < 0.05
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4.4 Clinico-pathological parameters related to outcome measures 
 
Time to biochemical relapse was calculated from diagnosis to biochemical 
relapse. Patients were considered to have biochemical relapse if serum PSA >0.2 
ng/ml following radical prostatectomy, serum PSA of 2.0 ng/ml above the post 
treatment nadir level following radical radiotherapy or 2-3 consecutive 
elevations of serum PSA above the nadir over intervals greater than 2 weeks 
following hormone treatment. High Gleason score at diagnosis (proportion of 
patients relapsed at 5 years, <7 44% vs 7 74% vs >7 88%, HR 1.9, (95% CI 1.3-2.9) 
p=0.004) increased PSA at diagnosis (proportion of patients relapsed at 5 years, 
<10 ng/ml 44% vs 10 – 20 ng/ml 65% vs ≥20 ng/ml 81%), HR 2.0, (95% CI 1.3-2.9) 
p=0.002) presence of metastases (proportion of patients relapsed at 5 years, 
absence of metastases 37% vs presence of metastases 79%, HR 3.7, (95% CI 1.7-
8.0) p=0.001) and LVI (proportion of patients relapsed at 5 years, absence of LVI 
61% vs presence of LVI 0%, HR 4.6, (95% CI 1.7-12.0) p=0.001) are significantly 
associated with decreased time to biochemical relapse. 
 
Survival following disease recurrence was calculated from biochemical relapse 
till death or last follow-up using cancer-specific deaths. Presence of metastases 
(10-year survival, absence of metastases 66% vs presence of metastases 17%, HR 
4.8, (95% CI 1.4-17.4) p=0.008) and increased PSA at biochemical relapse (10-
year survival, <20 ng/ml  41% vs ≥20 ng/ml 0%, HR 5.9, (95% CI 2.8-12.2) 
p=<0.001) are associated with shorter time to death following biochemical 
relapse. Presence of PNI is associated with increased survival following 
biochemical relapse (10-year survival, absence of PNI 19% vs presence of PNI 
61%, HR 0.3, (95% CI 0.1-0.9) p=0.030). 
 
Disease-specific survival was calculated from diagnosis till death or last follow-
up using cancer-specific deaths. High Gleason score at diagnosis (10 year 
survival, <7 81% vs 7 41% vs >7 21%, HR 1.9, (95% CI 1.3-2.9) p=0.007) high PSA at 
diagnosis (10 year survival, <10 ng/ml 70% vs 10-20 ng/ml 79% vs >20 ng/ml 25%, 
HR 2.0, (95% CI 1.3-3.3) p=0.001), increased age at diagnosis (10 year survival, 
<70 years 58% vs >70 years 31%, HR 2.1, (95% CI 1.1-4.0) p=0.020), high PSA at 
biochemical relapse (10 year survival, <10 ng/ml 50% vs 10-20 ng/ml 0% vs >20 
ng/ml 0%, HR 2.8, (95% CI 1.9-4.2) p=<0.001) and presence of metastases (10 
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year survival, absence of metastases 70% vs presence of metastases 30%, HR 5.0, 
(95% CI 2.0-12.4) p=<0.001) are associated with decreased disease-specific 
survival. Presence of PNI is associated with increased disease specific survival 
(10-year survival, absence of PNI 36% vs presence of PNI 62%, HR 0.4, (95% CI 0.2 
– 1.0) p=0.036). 
 
Clinico-pathological parameters as related to clinical outcome measures are 
summarised in Table 4.4.  
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Table 4.4 Univariate analysis of clinico-pathological parameters as related 
to clinical outcome measures 
 
Univariate analysis 
Clinico-pathological 
parameter 
Time to biochemical 
relapse 
 
 
P value Hazard Ratio 
(95% CI) 
Disease-specific 
survival from 
biochemical relapse 
 
P value Hazard Ratio 
(95% CI) 
Disease-specific 
survival 
 
 
P value Hazard Ratio 
(95% CI) 
Age  
(<70/ ≥70 years) 
0.260, 1.4, 0.8 – 2.5 0.385, 1.4, 0.6 – 3.3  0.020, 2.1, 1.1 – 4.0 
Diagnosis PSA  
(<10/ 10 – 20/ ≥20 
ng/ml) 
0.002, 2.0, 1.3 – 2.9 0.078, 1.5, 0.8 – 2.7 0.001, 2.0, 1.3 – 3.3 
Gleason score  
(<7/7/>7) 
0.004, 1.9, 1.3 – 2.9 0.060, 1.5, 0.8 – 2.6 0.007, 1.9, 1.3 – 2.9 
Lymphovascular 
invasion (no/yes) 
0.001, 4.6, 1.7 – 12.0 0.612, 1.3, 0.5 – 3.9 0.114, 2.1, 0.8 – 5.3 
Presence of PIN  
(no/yes) 
0.720, 0.8, 0.4 – 1.9 0.026, 0.2, 0.0 – 0.9 0.014, 0.2, 0.1 – 0.8 
Presence of PNI   
(no/yes) 
0.561, 1.2, 0.6 – 2.4 0.030, 0.3, 0.1 – 0.9 0.036, 0.4, 0.2 – 1.0 
Presence of 
metastases (no/yes) 
0.001, 3.7, 1.7 – 8.0 0.008, 4.8, 1.4 – 17.4 <0.001, 5.0, 2.0 – 12.4 
PSA at biochemical 
relapse  
(<10/ 10 – 20/ ≥20 
ng/ml) 
N/a <0.001, 5.9, 2.8 – 12.2 <0.001, 2.8, 1.9 – 4.2 
The clinico-pathological variables were grouped and analysed by Kaplan-Meier 
methods and Cox regression with reference to time to biochemical relapse from 
diagnosis, disease-specific survival from biochemical relapse and disease-
specific survival. Patients were considered to have biochemical relapse with 
serum PSA >0.2 ng/ml following radical prostatectomy, serum PSA of 2.0 ng/ml 
above the post treatment nadir level following radical radiotherapy or 2-3 
consecutive elevations of serum PSA above the nadir over intervals greater than 
2 weeks following hormone treatment. Significant results (p = £0.05) are 
highlighted in red.  
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4.5 Expression of pARS81, pARS578 and PKC related to clinico-
pathological parameters 
 
High expression of both nuclear and cytoplasmic pARS81 was associated with the 
presence of perineural invasion (p = 0.028 and p = 0.028). High nuclear pARS81 
expression was associated with Ki67 expression (p = 0.027). High expression of 
nuclear pARS578 was associated with increased PSA level at diagnosis (p = 0.015).  
High expression of cytoplasmic pARS578 was associated with high Gleason score (p 
= 0.008).  High expression of both nuclear and cytoplasmic PKC was associated 
with increased age (p = 0.032 and p = 0.018). High nuclear PKC expression was 
associated with increased PSA at diagnosis (p = 0.009). Table 4.5 demonstrates 
the expression of   pARS81, pARS578 and PKC as related to clinico-pathological 
parameters. 
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Table 4.5 Expression of pARS81, pARS578 and PKC related to clinico-pathological parameters 
 
Expression of pARS81, pARS578 and PKC in the nucleus and cytoplasm was examined for significant relationships with clinical variables as 
shown. Protein expression was divided into high and low groups. Clinical variables were divided into groups and the Mann-Whitney U 
test was performed for statistical analysis. Statistically significant results (p = £0.05) are highlighted in red.
  Nuclear AR S81 Cytoplasmic AR S81 Nuclear AR S578 Cytoplasmic AR S578 Nuclear PKC Cytoplasmic PKC 
  Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Age               
(<70/>70) 
15/19 12/19 0.661 18/16 9/22 0.053 14/16 10/20 0.296 16/16 8/20 0.94 17/13 8/20 0.032 17/12 8/21 0.018 
Gleason        
(<7/7/>7) 
13/8/9 6/8/12 0.111 10/10/11 9/6/10 0.973 9/10/7 8/7/12 0.324 13/9/6 4/8/13 0.008 10/10/7 10/3/12 0.431 10/7/8 10/6/11 0.630 
Diagnosis PSA 
(<10/10-20/>20) 
8/7/15 4/5/13 0.450 9/6/16 3/6/12 0.387 9/4/11 2/5/19 0.015 8/5/13 3/4/17 0.096 9/8/9 3/3/18 0.009 7/7/13 5/4/14 0.478 
LVI                  
(no/yes) 
32/2 27/4 0.332 32/2 27/4 0.332 27/3 27/3 1.000 30/2 24/4 0.305 27/3 26/2 0.701 26/3 27/2 0.643 
PNI                         
(no/yes) 
23/11 28/3 0.028 23/11 28/3 0.028 21/9 23/7 0.563 25/7 19/9 0.374 21/9 24/4 0.155 22/7 23/6 0.755 
PIN                 
(no/yes) 
27/7 28/3 0.227 26/8 29/2 0.059 25/5 26/4 0.720 26/6 25/3 0.388 24/6 25/3 0.333 23/6 26/3 0.281 
Metastases 
(no/yes) 
13/8 8/8 0.475 15/9 6/7 0.345 11/6 8/10 0.236 12/9 7/7 0.682 9/7 11/6 0.625 13/5 7/8 0.141 
Ki67 
(≤median/>median) 
22/8 14/17 0.027 19/12 17/13 0.716 17/10 18/10 0.920 16/12 19/8 0.312 17/9 16/12 0.539 17/9 16/12 0.539 
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4.6 Expression of pARS81, pARS578 and PKC related to clinical outcome 
measures 
 
Table 4.6 shows the univariate analysis of expression of pARS81, pARS578 and PKC 
related to clinical outcome measures. 
  
Table 4.6 Univariate analysis of expression of pARS81, pARS578 and PKC related 
to clinical outcome measures 
 
Univariate analysis 
Protein expression 
(<median/>median) 
Time to biochemical 
relapse 
 
 
P value Hazard Ratio 
(95% CI) 
Disease-specific 
survival from 
biochemical relapse 
 
P value Hazard Ratio 
(95% CI) 
Disease-specific 
survival 
 
 
P value Hazard Ratio 
(95% CI) 
pARS81 Nuclear  
 
0.594, 0.8, (0.4-1.6) 0.407, 1.5, (0.6-3.5) 0.030, 2.1, (1.1–4.2) 
pARS81 Cytoplasmic  
 
0.166, 1.6, (0.8-3.1) 0.578, 1.3, (0.5–3.1) 0.057, 1.9, (1.0-3.8) 
pARS578 Nuclear  
 
0.461, 1.3, (0.6-2.6) 0.347, 1.6, (0.6-4.5) 0.036, 2.2, (1.0-4.9) 
pAR S578 Cytoplasmic  
 
0.034, 2.1, (1.0-4.2) 0.034, 3.2, (1.0-9.9) <0.001, 4.5, (2.0-10.4) 
PKC Nuclear  
 
0.712, 0.9, (0.4-1.8) 0.450, 1.5, (0.5-3.9) 0.203, 1.7, (0.8-3.7) 
PKC Cytoplasmic  
 
0.938, 1.0, (0.5-2.1) 0.799, 1.1, (0.4-3.1) 0.269, 1.6, (0.7-3.5) 
 
Expression of pARS81, pARS578 and PKC in the nucleus and cytoplasm was analysed 
by Kaplan-Meier methods and Cox regression in relation to time to biochemical 
relapse from diagnosis, disease-specific survival from biochemical relapse and 
disease-specific survival. Patients were considered to have biochemical relapse 
with serum PSA >0.2 ng/ml following radical prostatectomy, serum PSA of 2.0 
ng/ml above the post treatment nadir level following radical radiotherapy or 2-3 
consecutive elevations of serum PSA above the nadir over intervals greater than 2 
weeks following hormone treatment. Protein expression was divided into high and 
low groups by the median value. High expression of cytoplasmic pARS578 was 
associated with all three outcome measures. High expression of nuclear pARS81  
and pARS578 were both associated with decreased disease-specific survival. 
Significant results (p = £0.05) are highlighted in red. 
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High expression of cytoplasmic pARS578 was associated with shorter time to 
biochemical relapse (proportion of patients relapsed at 5 years < median 
expression 51.9%   vs > median expression 82.1%, HR 2.1 (95% CI 1.0-4.2), p=0.034) 
(Figure 4.1 A). No association was observed between PKC or pARS81 and time to 
biochemical relapse.  
 
High expression of cytoplasmic pARS578 was associated with decreased survival 
following biochemical relapse (10-year survival, < median expression 58.3% vs > 
median expression 24.3% HR 3.2 (95% CI 1.0-9.9), p=0.034) (Figure 4.1 B). No 
association was observed between pARS81 or PKC and survival from biochemical 
relapse.  
 
Expression of both pARS81 and pARS578 were found to be significantly associated with 
disease-specific survival. High expression of nuclear pARS81 was associated with 
decreased disease-specific survival (10-year survival, <median expression 55% vs > 
median expression 24%, HR 2.1 (95% CI 1.1 – 4.2), p=0.030. High cytoplasmic 
pARS578 was associated with decreased disease-specific survival (10-year survival 
<median expression 71.3% vs >median expression 19.7% HR 4.54 (95% CI 2.0-10.4), 
p=<0.001) (Figure 4.1 C). High nuclear pARS578 was associated with decreased 
disease-specific survival (10-year survival, <median expression 63.8% vs >median 
expression 30.5%, HR 2.24 (95% CI 1.0-4.9), p=0.036) (Figure 4.1 D).  
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Figure 4.1 Kaplan Meier Graph showing expression of pARS578 related to 
clinical outcome measures 
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A. Kaplan-Meier survival plot showing expression of cytoplasmic pARS578 as related to time to 
biochemical relapse. High cytoplasmic pARS578 (dashed line) is significantly associated with 
decreased time to biochemical relapse.  
B. Kaplan-Meier survival plot showing expression of cytoplasmic pARS578 as related to disease-
specific survival following biochemical relapse. High cytoplasmic pARS578 (dashed line) is 
significantly associated with decreased disease-specific survival following biochemical 
relapse.  
C. Kaplan-Meier survival plot showing expression of cytoplasmic pARS578 as related to disease-
specific survival. High cytoplasmic pARS578 (dashed line) is significantly associated with 
decreased disease-specific survival.  
D. Kaplan-Meier survival plot showing expression of nuclear pARS578 as related to disease-
specific survival. High nuclear pARS578 (dashed line) is significantly associated with decreased 
disease-specific survival.  
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4.7 Expression of dual phosphorylation sites on the AR related to 
outcome measures 
 
The two phosphorylation sites were combined as follows: (i) high pARS81 and high 
pARS578 and (ii) low pARS81 and low pARS578 expression.  
 
High cytoplasmic pARS81 and cytoplasmic pARS578 was associated with decreased 
disease-specific survival (10-year survival, high expression of both proteins 15% vs 
low expression of both proteins 88%, HR 10.0, (95% CI 2.2-46.0) p=<0.001). (Figure 
4.2 A) High nuclear pARS81 and nuclear pARS578 was associated with decreased 
disease-specific survival (10-year survival, high expression of both proteins 20% vs 
low expression of both proteins 73%, HR 3.9, (95% CI 1.3-11.2) p=0.007) (Figure 4.2 
B).  
 
Lastly, the expression of total cytoplasmic pARS81 and pARS578 and total nuclear 
pARS81 and pARS578 was investigated in relation to clinical outcome measures. 
Patients were grouped as follows: (i) high total cytoplasmic expression of pARS81 
and pARS578 and high total nuclear expression of pARS81 and pARS578 and (ii) low 
total cytoplasmic expression of pARS81 and pARS578 and low total nuclear expression 
of pARS81 and pARS578.  Combined high expression of total cytoplasmic pARS81 and 
pARS578 and high total nuclear expression of pARS81 and pARS578 was associated with 
decreased disease-specific survival (10-year survival, high total expression of both 
proteins 0% vs low total expression of both proteins 86%, HR 10.6, (95% CI 2.0-54.4) 
p=0.001) (Figure 4.2 C). 
 
Dual expression of pARS81 and pARS578 was not associated with time to biochemical 
relapse or disease-specific survival from biochemical relapse.  
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Table 4.7 Univariate analysis of dual expression of pARS81 and pARS578 related 
to clinical outcome measures 
 
Univariate analysis 
 Time to biochemical 
relapse 
 
 
P value Hazard Ratio 
(95% CI) 
Disease-specific 
survival from 
biochemical relapse 
 
P value Hazard Ratio 
(95% CI) 
Disease-specific 
survival 
 
 
P value Hazard Ratio 
(95% CI) 
pARS578 cytoplasmic + 
pARS81 cytoplasmic 
 
0.091, 2.3, 0.9-5.9 0.069, .3.9, 0.8-19.0 <0.001, 10.0, 2.2-46.0 
pARS578 nuclear + 
pARS81 nuclear 
 
0.909, 1.0, 0.4-2.2 0.250, 2.0, 0.6-6.6 0.007, 3.9, 1.3-11.2 
Total cytoplasmic 
pARS81 and pARS578 + 
total nuclear pARS81 
and pARS578 
  
0.480, 1.5, 0.5-5.4 0.106, 3.7, 0.7-20.7 0.001, 10.6, 2.0-54.4 
 
Dual expression of pARS81and pARS578 was analysed by Kaplan-Meier methods and 
Cox regression in relation to time to biochemical relapse from diagnosis, disease-
specific survival from biochemical relapse and disease-specific survival. Patients 
were considered to have biochemical relapse with serum PSA >0.2 ng/ml following 
radical prostatectomy, serum PSA of 2.0 ng/ml above the post treatment nadir 
level following radical radiotherapy or 2-3 consecutive elevations of serum PSA 
above the nadir over intervals greater than 2 weeks following hormone 
treatment. Protein expression was divided into high and low groups. Dual 
expression of pARS81and pARS578in all three groupings was significantly associated 
with decreased disease-specific survival. Significant results (p = £0.05) are 
highlighted in red. 
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Figure 4.2 Kaplan Meier Graph showing dual expression of pARS81 and pARS578 
related to disease-specific survival 
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A. Kaplan Meier survival plot showing disease-specific survival in patients with 
low expression of both cytoplasmic pARS81 and pARS578 (solid line) and high 
expression of both cytoplasmic pARS81 and pARS578 (dashed line). High 
expression of both cytoplasmic pARS81 and pARS578 is associated with 
decreased disease-specific survival than compared low expression of both 
phosphosites 
B.  Kaplan Meier survival plot showing disease-specific survival in patients with 
low expression of both nuclear pARS81 and pARS578 (solid line) and high 
expression of both nuclear pARS81 and pARS578 (dashed line). High expression of 
both nuclear pARS81 and pARS578 is associated with decreased disease-specific 
survival than compared low expression of both phosphosites 
C. Kaplan Meier survival plot showing disease-specific survival in patients with 
low expression of total pARS81 and pARS578 (solid line) and high expression of 
total pARS81 and pARS578 (dashed line). High total expression of pARS81 and 
pARS578 is associated with decreased disease-specific survival than compared to 
low total expression of pARS81 and pARS578 
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4.8 Discussion 
 
The current study investigates the use of the AR phosphorylated at Ser-81 and Ser-
578 in a cohort of patients with hormone-naïve prostate cancer with a 
heterogeneous mix of disease severity at presentation. The clinico-pathological 
characteristics of this cohort reflect urological practice at the time when these 
patients were recruited. This is an elderly cohort, with 60.9% of patients aged >70 
years. The PSA at diagnosis was >20 ng/ml in 39.1% of patients and 30.4% of 
patients had a Gleason score of >7, indicating that the majority of patients had at 
least one marker of high risk disease as defined by the current NICE guidelines 
(51).  
 
As is expected, clinico-pathological markers of high risk disease were found to be 
significantly associated with poor clinical outcome measures. High Gleason score 
and increased PSA at diagnosis were found to be significantly associated with both 
shorter time to biochemical relapse and decreased disease-specific survival. This is 
in keeping with previous reports. (47, 171-173) Surprisingly, the presence of PNI 
was found to be associated increased disease-specific survival and longer survival 
following biochemical relapse. PNI is associated with other adverse clinico-
pathological markers of prostate cancer including extra-prostatic extension, higher 
PSA at diagnosis and higher Gleason grade, and there has been increasing evidence 
regarding its role as a negative prognostic marker in prostate cancer. (165, 174) 
Our results should be interpreted with caution, as this is a small cohort from a 
single institution and differences in pathological interpretation of PNI may account 
for our findings. (175)  
 
Protein expression in the discovery prostate cancer cohort differs to that of the AS 
cohort. The median expression of almost all of the AR proteins was less in the 
discovery prostate cancer cohort than compared to the AS. An exception was that 
of nuclear pARS578 which was found to have higher median expression in the 
discovery prostate cancer cohort. Kinase expression was more intense in the 
discovery prostate cancer cohort, with the median expression of PKC higher than 
that observed in the AS cohort. This variation in staining intensity observed 
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between the two cohorts likely reflects the differences in the clinico-pathological 
parameters of these two cohorts and is in keeping with studies that demonstrate 
differences in the molecular profile of low and high-risk disease. (176, 177) 
  
PKC expression strongly correlated with pARS578 expression in this cohort. This is in 
agreement with the findings in the AS cohort and with that of previous castrate 
resistant prostate cancer cell line work and Scansite prediction(129, 130). The 
current study adds to this by suggesting that the link between PKC and AR 
phosphorylation at Ser-578 is also present in hormone naïve prostate cancer tissue 
and therefore may have important implications in not only high and low risk 
disease but also early and late stages of the disease too.  Similar site directed 
mutagenesis studies are necessary in prostate cancer cell lines established from 
localised disease in order to confirm this finding. 
 
AR phosphorylation status has previously been associated with markers of high risk 
disease in hormone-naïve prostate cancer. Willder et al found that cytoplasmic 
pARS515 expression was associated with the presence of LVI and high expression of 
nuclear pARS308 was associated with high PSA levels at diagnosis in hormone-naïve 
prostate cancer (128). In the current study, it was again shown that AR 
phosphorylation status is associated with established markers of high risk disease. 
Expression of pARS578 was associated with both increased PSA level (nuclear) and 
high Gleason score (cytoplasmic) at diagnosis. PKC, the predicted kinase 
responsible for phosphorylation of the AR at Ser-578, was also associated with 
increased PSA at diagnosis with high expression in the nucleus. High expression of 
pARS81 is associated the presence of PNI. These findings support those of the AS 
cohort, in which pARS578 was associated with increased PSA at diagnosis and 
presence of PNI, suggesting that pARS578 may be a useful surrogate biomarker of 
high risk clinico-pathological features.  
 
The role of the AR expression in clinical specimens in relation to clinical outcome 
measures has been extensively investigated, with varying results reported. High 
nuclear expression of AR has been associated with decreased disease-specific 
survival in patients with castrate resistant prostate cancer(93). Furthermore, high 
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AR levels were associated with shorter time to biochemical relapse in patients 
undergoing radical prostatectomy (92, 178).  However, conflicting results were 
reported by Sweat et al, who found no association between nuclear AR expression 
in tissue obtained from radical prostatectomy samples from hormone naïve 
prostate cancer patients in relation to clinical progression and survival(179). There 
are a number of factors that are likely to have a role in the differing reported 
findings such as age of specimens, antibody and methods used for detection of the 
AR protein and varying thresholds for stratification into high and low expression 
groups. In addition, the use of total AR quantifies both activated and inactive AR. 
In this study, we investigate the prognostic significance of AR phosphorylated at 
Ser-81 and Ser-578 in addition to total AR.  
 
The prognostic significance of AR serine phosphorylation has been investigated 
previously by ourselves and others (123, 124, 126, 128). We again have 
demonstrated that pARS578 is associated with poor outcome measures, as was found 
in the AS cohort, further supporting the research hypothesis that pARS578 is 
associated with advanced disease. The expression of cytoplasmic pARS578 was found 
to be the marker most commonly associated with poor outcome measures, 
predicting shorter time to biochemical relapse, decreased disease specific survival 
following biochemical relapse and decreased disease specific survival from 
diagnosis. This work will now be validated in a larger cohort of hormone-naïve 
prostate cancer patients to further assess the suitability of pARS578 as a prognostic 
biomarker in prostate cancer.  
 
Nuclear expression of pARS81 is associated with shorter disease-specific survival 
from diagnosis. Cell line work has shown that the AR phosphorylated at Ser-81 has 
a role in AR transcriptional activity, modulation of AR phosphorylation and cell 
proliferation. (115, 117, 118, 180) We have again demonstrated that in prostate 
tissue specimens, pARS81 is associated with poor outcome measures. This supports 
the findings in the AS cohort that demonstrated that cytoplasmic expression of 
pARS81 was associated with decreased time to treatment intervention. 
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As phosphorylation of the AR at Ser-81 and Ser-578 is predicted to occur in 
response to different kinases, we investigated if there was any increased 
prognostic significance when the androgen is phosphorylated at both serine 
residues. Combined high expression of pARS81 and pARS578 is associated with shorter 
disease-specific survival than compared to high expression of pARS81 and pARS578 
independently. These results are potentially of great importance clinically, as it 
highlights a sub-population of patients who may benefit from dual targeted 
therapy with ADT and PKC inhibitors.  
 
A limitation of this study is the small sample number and therefore will now be 
validated in a larger cohort of hormone-naïve prostate cancer patients.  
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Chapter 5 Clinico-pathological parameters of validation prostate 
cancer cohort 
 
Prostate cancer management in the UK is currently based primarily on a limited 
range of tumour factors, namely PSA at diagnosis, Gleason score and clinical stage. 
(51) Whilst risk classification systems are available to clinicians, they are not 
without problem. There remains heterogeneity amongst patients who fulfil the 
criteria of specific risk classification groups. As discussed in the AS chapter and in 
work by other groups, there are patients that despite being defined as low risk can 
experience disease progression, and conversely those with high risk criteria at 
diagnosis may still have indolent disease. (181) Differentiating between those 
patients who can be managed conservatively and those that require radical 
treatment presents a unique challenge in prostate cancer management. (182) A 
clinician’s first priority should be to do no harm. Prostate cancer therefore 
presents clinicians with a difficult decision in deciding the most appropriate 
treatment, with the aim being to minimise overtreatment in indolent disease and 
under-treatment in high risk disease. Clinicians therefore desperately need 
additional tools to allow better risk stratification of patients at diagnosis.  
 
A number of criteria in addition to those used in the NICE guidelines have been 
suggested to optimise risk stratification at diagnosis. The primary Gleason pattern, 
percentage of cancer containing biopsy cores at diagnosis and PNI have been 
shown to independently predict adverse outcomes(165, 183-185). The inclusion of 
these criteria into current risk stratification systems may aid clinicians in directing 
treatment towards those who would receive most benefit. 
 
In addition to tumour factors, systemic inflammation has been increasingly 
recognised as having a role in disease progression in prostate cancer. CRP, a 
marker of systemic inflammation, has been shown to be an independent predictor 
of disease-specific survival in localised prostate cancer. (186) The mGPS, a score 
of systemic inflammation that combines CRP and albumin levels at diagnosis, has 
been shown to be independently associated with adverse outcomes in prostate 
cancer.(187)   
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The aim of the current study is to investigate the role of tumour factors in 
predicting prostate cancer outcomes and validate the findings of the discovery 
cohort in a larger, modern cohort of prostate cancer patients that is more 
reflective of today’s clinical practice. It is anticipated that identification of 
additional risk factors than can be utilised in conjunction with existing risk 
stratification systems could aid in identification of those patients at increased risk 
of adverse outcomes and can therefore direct more aggressive treatment towards 
these patients. In addition, the role of systemic inflammation was investigated in 
this cohort to determine its prognostic value in prostate cancer.  
 
5.1 Patient Demographics  
 
361 patients diagnosed with prostate cancer in 2009 in NHS Greater Glasgow and 
Clyde were included in this study. 243 patients had tissue available for analysis.  
Median follow-up period was 5.2 years (IQR 4.7 – 5.9 years). Patient demographics 
including age at diagnosis, Gleason score, PSA at diagnosis and PSA at relapse were 
recorded and are summarised in Table 5.1. 
Table 5.1 Clinico-pathological characteristics of the cohort 
 
 Clinical Parameter Patients, n (%) 
Age (<70/ ≥70 years) 186 (51.5)/ 161 (44.6) 
Diagnosis PSA (<10/ 10 – 20/ ≥20 ng/ml) 140 (38.8)/ 75 (20.8)/128 (35.5) 
Gleason score (<7/7/>7) 136 (37.7)/114 (31.6)/ 81 (22.4) 
Perineural invasion (no/yes) 201 (55.7)/ 121 (33.5) 
Metastases at diagnosis (no/yes) 275 (76.2)/ 37 (10.2) 
% cores positive for malignancy (<50/≥50) 88 (24.4)/ 128 (35.5) 
Number of patients with missing data is not displayed. Values that do not give a 
sum of 100% is due to data being unavailable 
 
Median age at diagnosis was 69.3 years (IQR 62.8 – 74.7 years). Median PSA at 
diagnosis was 12.6 ng/ml (IQR 6.9 – 35.4 ng/ml). 136 patients had a Gleason score 
of <7 at diagnosis. 37 patients had metastatic disease at the time of diagnosis.  
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Most patients (291 patients) had histological diagnosis confirmed by TRUS biopsy, 
whilst 35 patients were diagnosed following TURP. An incidental finding of 
prostate cancer following prostatectomy as part of radical surgery for non-
prostatic disease was made in a further 6 patients. Two patients were diagnosed 
from biopsy of non-prostate tissue with local invasion of prostate cancer. 
 
51 patients experienced biochemical relapse during follow-up. Median time to 
biochemical relapse was 1.8 years (IQR 1.0 – 2.9). Median PSA at relapse was 8.4 
ng/ml (IQR 3.4 – 21.4 ng/ml).  
 
111 patients died during follow-up. Cause of death was not available for this 
cohort therefore overall survival was used as a clinical outcome measure.  
Median time to death from diagnosis was 3.2 years (IQR 1.9 – 4.6 years). Median 
time to death from biochemical relapse was 1.8 years (IQR 0.7 – 2.9 years).  
53 patients were treated with AS. Patients treated with AS had a median PSA at 
diagnosis of 6.9 ng/ml (IQR 5.3 – 9.9). 44 patients had a Gleason score of 6, the 
remaining patients had a Gleason score of 7. 4 (7.5%) patients died during follow-
up.  Median time to death was 4.0 years. (IQR could not be calculated due to small 
number of deaths). 
5.2 Clinico-pathological parameters related to outcome measures 
 
Time to biochemical relapse was calculated from diagnosis to biochemical relapse. 
High PSA at diagnosis was associated with decreased time to biochemical relapse 
(proportion of patients with biochemical relapse at 5 years, <10 ng/ml 9% vs 10-20 
ng/ml 13% vs >20 ng/ml 33%, HR 2.2, (95% CI 1.5 – 3.1) p=<0.001) (Figure 5.1 A). 
High Gleason score at diagnosis was associated with decreased time to biochemical 
relapse (proportion of patients with biochemical relapse at 5 years, <7 2% vs 7 18% 
vs >7 46%, HR 4.1, (95% CI 2.6 – 6.3) p=<0.001) (Figure 5.1 B). Perineural invasion 
was associated with decreased time to biochemical relapse (proportion of patients 
with biochemical relapse at 5 years, absence of PNI 11% vs presence of PNI 31%, HR 
3.4, (95% CI 1.9 – 6.2) p=<0.001) (Figure 5.1 C). Increased percentage of biopsy 
cores containing cancer was associated with decreased time to biochemical relapse 
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(proportion of patients with biochemical relapse at 5 years, <50% of biopsy cores 
contain cancer 8% vs ≥50% biopsy cores contain cancer 30%, HR 3.7, (95% CI 15 – 
8.9) p=0.002) (Figure 5.1 D). Metastases at diagnosis was associated with 
decreased time to biochemical relapse (proportion of patients with biochemical 
relapse at 5 years, absence of metastases 12% vs presence of metastases 73%, HR 
8.6, (95% CI 4.7 – 15.6) p=<0.001) (Figure 5.1 E).  
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Figure 5.1 Kaplan-Meier Graphs showing clinico-pathological parameters as 
related to time to biochemical relapse 
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A. Kaplan-Meier survival plot showing PSA at diagnosis as related to time to 
biochemical relapse. PSA >10 ng/ml at diagnosis (dotted line) is 
significantly associated with decreased time to biochemical relapse 
B. Kaplan-Meier survival plot showing Gleason score at diagnosis as related to 
time to biochemical relapse. Gleason score >7 at diagnosis (dotted line) is 
significantly associated with decreased time to biochemical relapse 
C.  Kaplan-Meier survival plot showing PNI as related to time to biochemical 
relapse. The presence of PNI at diagnosis (dashed line) is significantly 
associated with decreased time to biochemical relapse  
D. Kaplan-Meier survival plot showing percentage of biopsy cores positive for 
cancer as related to time to biochemical relapse. ≥50% of biopsy cores 
containing cancer at diagnosis (dotted line) is significantly associated with 
decreased time to biochemical relapse 
E. Kaplan-Meier survival plot showing the presence or absence of metastases 
at diagnosis as related to time to biochemical relapse. The presence of 
metastases at diagnosis (dashed line) is significantly associated with 
decreased time to biochemical relapse 
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Time to death from biochemical relapse was calculated from biochemical relapse 
to time to death from any cause. Increased age at diagnosis was associated with 
decreased time to death from biochemical relapse (5-year overall survival from 
biochemical relapse, age <70 years 55% vs age ≥70 years 15%, HR 3.6, (95% CI 1.5-
8.3) p=<0.001). No other clinico-pathological parameters were related to time to 
death from biochemical relapse.   
 
Unfortunately, specific cause of death was not available for this cohort and 
therefore disease-specific survival could not be calculated. Overall survival has 
therefore been used as an end-point in this study. Overall survival was calculated 
from diagnosis to time of death from any cause. Increased age at diagnosis was 
associated with decreased overall survival (5-year survival, age <70 years 84% vs 
age ≥70 years 66%, HR 3.0, (95% CI 2.0-4.6) p=<0.001) (Figure 5.2 A).  
 
High PSA at diagnosis was associated with decreased overall survival (5-year 
survival, <10 ng/ml 87% vs 10-20 ng/ml 79% vs >20 ng/ml 61%, HR 2.0, (95% CI 1.5-
2.6) p=<0.001) (Figure 5.2 B). High Gleason score at diagnosis was associated with 
decreased overall survival (5-year survival, <7 89% vs 7 77% vs >7 53%, HR 2.5, (95% 
CI 1.9-3.2) p=<0.001) (Figure 5.2 C). Perineural invasion was associated with 
decreased overall survival (5-year survival, absence of PNI 81% vs presence of PNI 
67%, HR 1.9, (95% CI 1.2-2.9) p=0.002) (Figure 5.2 D). Increased percentage of 
biopsy cores containing cancer was associated with decreased overall survival (5-
year survival, <50% of biopsy cores contain cancer 87% vs ≥50% biopsy cores contain 
cancer 64%, HR 2.7, (95% CI 1.6 – 5.1) p=<0.001) (Figure 5.2 E). Metastases at 
diagnosis was associated with decreased overall survival (5-year overall survival, 
absence of metastases 81% vs presence of metastases 34%, HR 5.7, (95% CI 3.6-9.5) 
p=<0.001) (Figure 5.2 F).  
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Table 5.2 Univariate analysis of clinico-pathological parameters as related to 
clinical outcome measures 
 
Univariate analysis 
Clinico-pathological 
parameter 
Time to biochemical 
relapse 
 
P value Hazard Ratio 
(95% CI) 
Overall survival 
from biochemical 
relapse 
 
P value Hazard 
Ratio (95% CI) 
Overall survival 
 
 
P value Hazard Ratio 
(95% CI) 
Age  
(<70/ ≥70 years) 
0.113, 1.6, 0.9-2.7 0.001, 3.6, 1.5-8.3 <0.001, 3.0, 2.0-4.6 
Diagnosis PSA  
(<10/ 10 – 20/ ≥20 
ng/ml) 
<0.001, 2.2, 1.5-3.1 0.088, 1.9, 1.0-3.5 <0.001, 2.0, 1.5-2.6 
Gleason score  
(<7/7/>7) 
<0.001, 4.1, 2.6-6.3 0.597, 1.3, 0.6-2.8 <0.001, 2.5, 1.9-3.2 
Presence of PNI   
(no/yes) 
<0.001, 3.4, 1.9-6.2 0.645, 1.2, 0.5-2.7 0.002, 1.9, 1.2-2.9 
% of cores containing 
cancer (<50/≥50) 
0.002, 3.7, 1.5-8.9 0.240, 2.3, 0.5-10.2 <0.001, 2.7, 1.6-5.1 
Presence of 
metastases at 
diagnosis (no/yes) 
<0.001, 8.6, 4.7-15.6 0.204, 1.7, 0.7-3.7 <0.001, 5.7, 3.6-9.5 
 
The clinico-pathological variables were grouped and analysed by Kaplan-Meier 
methods and Cox regression with reference to time to biochemical relapse from 
diagnosis, overall survival from biochemical relapse and overall survival. Patients 
were considered to have biochemical relapse with serum PSA >0.2 ng/ml following 
radical prostatectomy, serum PSA of 2.0 ng/ml above the post treatment nadir 
level following radical radiotherapy or 2-3 consecutive elevations of serum PSA 
above the nadir over intervals greater than 2 weeks following hormone 
treatment. Significant results (p = £0.05) are highlighted in red.  
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Figure 5.2 Kaplan-Meier Graphs showing clinico-pathological parameters as 
related to overall survival 
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A. Kaplan-Meier survival plot showing age at diagnosis as related to overall 
survival. Age ≥70 years (dotted line) is significantly associated with decreased 
overall survival 
B. Kaplan-Meier survival plot showing PSA at diagnosis as related to overall 
survival. PSA >10 ng/ml at diagnosis (dotted line) is significantly associated 
with decreased overall survival 
C. Kaplan-Meier survival plot showing Gleason score at diagnosis as related to 
overall survival. Gleason score >7 at diagnosis (dotted line) is significantly 
associated with decreased overall survival 
D.  Kaplan-Meier survival plot showing PNI as related to overall survival. The 
presence of PNI at diagnosis (dashed line) is significantly associated with 
decreased overall survival  
E. Kaplan-Meier survival plot showing percentage of biopsy cores positive for 
cancer as related to overall survival. ≥50% of biopsy cores containing cancer at 
diagnosis (dotted line) is significantly associated with decreased overall 
survival 
F. Kaplan-Meier survival plot showing the presence or absence of metastases at 
diagnosis as related to overall survival. The presence of metastases at 
diagnosis (dashed line) is significantly associated with decreased overall 
survival 
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5.4 The role of systemic inflammation in prostate cancer 
 
163 patients had a documented CRP level at diagnosis. Median CRP at diagnosis 
was 6 mg/L (IQR 2.3 – 23 mg/L). 282 patients had an albumin level documented at 
diagnosis. Median albumin at diagnosis was 39.5 g/L (IQR 37.0 – 42.0 g/L). The 
modified Glasgow Prognostic Score (mGPS) is a systemic inflammatory prognostic 
scoring system that makes use of serum CRP and albumin at the time of diagnosis 
to inform on prognosis. Patients with both a low CRP (≤ 10 mg/l) and normal 
albumin (≥35 g/l) are assigned a score of 0, patients with only an elevated CRP 
(>10 mg/l) are assigned a score of 1, and patients with both elevated CRP and 
hypoalbuminaemia (albumin <35 g/l) are given a score of 2. Table 5.3 outlines the 
mGPS scoring system.  
Table 5.3 The modified Glasgow Prognostic Score 
 
Markers of inflammation Points allocated 
CRP ⩽10 mg/l and albumin ≥ 35g/l 0 
CRP >10 mg/l 1 
CRP >10 mg/l and albumin <35 g/l 2 
The modified Glasgow Prognostic Score is a systemic inflammatory prognostic 
scoring system the utilises serum CRP and albumin measurements to assign a 
prognostic group.  
 
The mGPS could be calculated in 160 patients.  Twenty-four patients (6.6%) had a 
mGPS of 2 (Table 5.4).  
 
Table 5.4 Markers of systemic inflammation in the cohort 
 
 Marker of inflammation Patients, n (%) 
CRP (£10 mg/L/>10 mg/L) 98 (27.1)/ 65 (18.0) 
Albumin (<35 g/L/≥35 g/L) 38 (10.5)/ 244 (67.6) 
mGPS (0/1/2) 96 (26.6)/40 (11.1)/ 24 (6.6) 
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Number of patients with missing data is not displayed. Values that do not give a 
sum of 100% is due to data being unavailable  
5.4.1 The mGPS related to clinico-pathological parameters 
 
Table 5.5 demonstrates the mGPS as related to clinico-pathological parameters as 
assessed by the Chi square test. High mGPS was associated with high Gleason score 
at diagnosis (p = 0.006), increased PSA at diagnosis (p = 0.015) and the presence of 
metastases at diagnosis (p = 0.001). 
 
Table 5.5 The mGPS as related to clinico-pathological parameters 
 
 The mGPS score  
Clinico-pathological 
parameter 
0 1 2 p-value 
Age  
(<70/ ≥70 years) 
57/38 24/16 9/15 0.930 
Diagnosis PSA  
(<10/ 10 – 20/ ≥20 
ng/ml) 
43/22/28 18/7/15 5/5/14 0.015 
Gleason score  
(<7/7/>7) 
40/31/19 17/12/10 4/6/12 0.006 
Presence of PNI   
(no/yes) 
51/37 25/14 12/10 0.996 
% of cores 
containing cancer 
(<50/≥50) 
19/34 11/15 2/11 0.355 
Presence of 
metastases at 
diagnosis (no/yes) 
80/7 27/7 14/8 0.001 
 
The mGPS was examined for significant relationships with clinical variables using 
the Chi square test. High mGPS was associated with high Gleason score at 
diagnosis, increased PSA at diagnosis and the presence of metastases at diagnosis. 
Statistically significant (p = £0.05) results are highlighted in red.  
 
5.4.2 Markers of systemic inflammation related to clinical outcome measures 
 
High CRP at diagnosis was associated with decreased overall survival (5-year 
overall survival, CRP ≤10 mg/L 74% vs CRP >10 mg/L 58%, HR 1.9, (95% CI 1.1-3.2) 
p=0.015) (Figure 5.3 A). Low albumin at diagnosis was associated with decreased 
overall survival (5-year overall survival, albumin <35 49% vs albumin ≥35 77%, HR 
0.4, (95% CI 0.2-0.7) p=0.001) (Figure 5.3 B). High mGPS score was associated with 
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decreased overall survival (5-year overall survival, score 0 74% vs score 1 70% vs 
score 2 34%) HR 1.8, (95% CI 1.3-2.5) p=0.002) (Figure 5.3 C). Table 5.5 summarises 
the univariate analysis of inflammatory markers as related to clinical outcome 
measures.  
 
Table 5.5 Univariate analysis of inflammatory markers as related to clinical 
outcome measures 
 
Univariate analysis 
Clinico-pathological 
parameter 
Time to 
biochemical 
relapse 
 
P value Hazard 
Ratio (95% CI) 
Overall survival 
from biochemical 
relapse 
 
P value Hazard 
Ratio (95% CI) 
Overall survival 
 
 
 
P value Hazard 
Ratio (95% CI) 
CRP (≤10 mg/L/>10 
mg/L) 
 
0.990, 1.0, 0.5-2.1 0.758, 1.2, 0.4-3.4 0.015, 1.9, 1.1-3.2 
Albumin (<35 
g/L/≥35 g/L) 
 
0.155, 0.6, 0.3-1.2 0.940, 1.0, 0.3-3.2 0.001, 0.4, 0.2-0.7 
mGPS (0/1/2) 
 
0.224, 0.4, 0.8-2.1 0.833, 1.0, 0.5-1.9 0.002, 1.8, 1.3-2.5 
 
The clinico-pathological variables were grouped and analysed by Kaplan-Meier 
methods and Cox regression with reference to time to biochemical relapse from 
diagnosis, overall survival from biochemical relapse and overall survival. Patients 
were considered to have biochemical relapse with serum PSA >0.2 ng/ml following 
radical prostatectomy, serum PSA of 2.0 ng/ml above the post treatment nadir 
level following radical radiotherapy or 2-3 consecutive elevations of serum PSA 
above the nadir over intervals greater than 2 weeks following hormone 
treatment. Elevated CRP, low albumin and high mGPS are all significantly 
associated with decreased overall survival. Significant results (p = £0.05) are 
highlighted in red. 
  
 128 
Figure 5.3 Kaplan-Meier Graphs showing clinico-pathological parameters as 
related to clinical outcome measures 
 
 
 
 
A. Kaplan-Meier survival plot showing CRP level at diagnosis as related to overall 
survival. CRP >10 mg/L at diagnosis (dashed line) is significantly associated 
with decreased overall survival 
B. Kaplan-Meier survival plot showing albumin level at diagnosis as related to 
overall survival. Albumin <35 g/L at diagnosis (solid line) is significantly 
associated with decreased overall survival 
C. Kaplan-Meier survival plot showing mGPS at diagnosis as related to overall 
survival. mGPS of 2 at diagnosis (dotted line) is significantly associated with 
decreased overall survival 
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5.4.3 Multivariate Analysis of Clinico-pathological factors and mGPS related to 
overall survival 
 
The mGPS was combined with age at diagnosis, PSA at diagnosis, Gleason score, 
PNI, percentage of cores positive for cancer and presence of metastases at 
diagnosis in a multivariate cox regression analysis in relation to overall survival. 
Gleason score was independently associated with decreased overall survival (p = 
0.001, HR 2.59, (95% CI 1.4 – 4.6). The remainder of the clinico-pathological 
parameters were not found to be independent with regards to overall survival.  
 
5.5 Discussion 
 
This cohort of patients diagnosed with prostate cancer in 2009 represents a 
modern cohort of prostate cancer patients. As a result, the median follow-up for 
this cohort is only five years. Due to the short follow-up period, there has been a 
relatively small number of events.  In addition, the cause of death for patients was 
not available for this cohort. As a result, overall survival as opposed to disease-
specific survival has been used as a clinical outcome measure. This makes direct 
comparison between the discovery cohort difficult, however, it is anticipated that 
cause of death will be made available in the coming years, and the cohort can be 
reassessed at that time, when the follow-up period will be longer also.  
 
The clinico-pathological characteristics of this cohort reflects the increased use of 
the PSA test in general practice. A survey of UK GPs found that 76% of GPs 
reported performing a PSA test in an asymptomatic patient at least once in the 
preceding three months.(188) The median age of this cohort was 69.3 years, 
compared to 70.1 years in the older cohort. PSA at diagnosis is less and most 
patients are now diagnosed with a Gleason 6 prostate cancer, compared to the 
older cohort, in which median PSA at diagnosis is higher and most patients had 
Gleason 8 or higher disease at the time of diagnosis.  These findings most likely 
reflect the increased use of the PSA test in asymptomatic men in general practice 
in the time period between the two cohorts. A study comparing the use of PSA as a 
screening tool to opportunistic testing found that men diagnosed with prostate 
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cancer in the screening cohort were younger and had lower PSA level at diagnosis 
than compared to those men in the opportunistic cohort. (189) This is in line with 
other studies, which have shown that age and PSA level at diagnosis has been 
falling. (190) 
 
Age at diagnosis has been associated with poor outcome in prostate cancer. 
Several studies have shown that men with advancing age are not only more likely 
to be diagnosed with high risk disease but also to have decreased overall and 
disease-specific survival.(191) A possible reason for this is that elderly patients are 
treated more conservatively. A study of patients in the CaPSURE trial found that 
older men were more likely to receive ADT as first line management. (192) The 
current study supports these findings, with increased age at diagnosis associated 
with decreased overall survival from both diagnosis and biochemical relapse.  
 
Increased PSA and Gleason score have consistently been associated with poor 
outcome measures in prostate cancer.(193-196) High PSA, Gleason score at 
diagnosis and the presence of metastases at diagnosis are all associated with 
decreased time to biochemical relapse and decreased overall survival. In addition, 
Gleason score was found to be an independent marker of overall survival. These 
results validate this cohort as a representative cohort of prostate cancer patients 
that can be utilised for further evaluation of biomarkers.  
 
In addition to the established pathological criteria for risk stratification in 
localised prostate cancer, a number of other pathological parameters have been 
suggested to further determine risk. The percentage of positive biopsy cores has 
been associated with tumour stage and volume, increased risk of disease 
recurrence following radical treatment and decreased disease-specific survival and 
overall survival in localised prostate cancer. (197-199) In the current study, 
patients who were found to have prostate cancer in >50% of the biopsy cores 
obtained had significantly shorter time to biochemical relapse and decreased 
overall survival. This adds to the increasing body of evidence suggesting that 
percentage of positive biopsy cores may have a role in further risk stratification 
alongside established clinical risk factors.  
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As discussed in previous chapters, the role of PNI as a negative prognostic marker 
in prostate cancer has been extensively investigated. Perineural invasion is a 
pathological finding of cancer cells tracking along a nerve within the perineural 
space and is thought to aid the development of extra-prostatic extension. A 
systematic review of the prognostic significant of perineural invasion in prostate 
cancer biopsies concluded that perineural invasion is an important risk factor for 
poor outcome in localised disease, but does not inform on outcome in advanced 
disease. (166) Despite these findings, a survey in 2005 revealed that only 13% of 
urologists thought that the presence of perineural invasion would alter their 
management of patients with prostate cancer. (200) In the present study, 
perineural invasion is significantly associated with increased biochemical relapse 
and decreased overall survival. This is in contrast to the findings of the discovery 
cohort. This may reflect the difference in tissue used in each cohort. Tissue in the 
discovery cohort was obtained from men undergoing TURP or radical 
prostatectomy, whereas the current cohort consists predominantly of tissue 
obtained from TRUS biopsy. A study of 105 radical prostatectomies found that 
there was significant variation in reporting of PNI between pathologists. (175)  As 
such, the Royal College of Pathologists now include reporting on the presence or 
absence of perineural invasion as a core data item for pathology reports of 
prostate biopsy. (201)  
 
Systemic inflammation has been suggested as an alternative adjunct to existing 
risk stratification systems in prostate cancer. Much work has been done 
investigating the role of systemic inflammation in a variety of cancers, however, 
there are limited studies of the role of systemic inflammation in prostate cancer. 
McArdle et al found that elevated CRP was an independent predictor of decreased 
disease-specific survival in both localised and metastatic prostate cancer. (186, 
202) The mGPS score has also been shown to predict survival in prostate cancer. 
(203) Markers of inflammation were available in the current cohort. It was found 
that increased CRP and decreased albumin at diagnosis were associated with 
decreased overall survival. Interestingly, there was no association between time to 
biochemical relapse and markers of systemic inflammation. CRP and albumin are 
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cheap and readily available clinical tests that we have shown can inform on 
outcome in prostate cancer from diagnosis, suggesting that mGPS is a simple, 
accessible tool that can be used in existing clinical practice.  
 
As discussed earlier, a limitation of this cohort is the relatively short period of 
follow-up, due to the recent recruitment of patients. Despite limited follow-up, 
we have demonstrated that PNI and percentage of cores positive can inform on 
survival. Once data is available for disease-specific survival, it is anticipated that 
these findings can be further confirmed and support the increasing body of 
evidence to suggest that these parameters should be included in risk stratification 
tools at diagnosis.   
 
Whilst we have identified a number of alternative clinico-pathological parameters 
that can be utilised alongside existing risk stratification systems, we will now go on 
to investigate the role of molecular markers that could assist in further stratifying 
patients within existing risk categories.  
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Chapter 6 Clinical significance of protein expression in validation 
prostate cancer cohort 
 
One of the major challenges in the management of prostate cancer is 
identification of patients at diagnosis with aggressive disease that require earlier 
treatment and those that have indolent disease and can be managed 
conservatively. With increasing incidence of prostate cancer and rising costs of 
prostate cancer management, it is imperative that treatment is directed to those 
patients who will gain the most benefit. As previously discussed, current methods 
of stratifying patients into risk categories at diagnosis are inadequate and some 
patients fulfilling low or intermediate-risk criteria at diagnosis will develop 
aggressive disease.  
 
In the discovery cohort, it was found that cytoplasmic pARS578 was associated with 
poor outcome measures, predicting shorter time to biochemical relapse, decreased 
disease-specific survival following biochemical relapse and decreased disease-
specific survival from diagnosis. Furthermore, combined high expression of pARS81 
and pARS578 was associated with shorter disease-specific survival than compared to 
high expression of the individual phosphosites alone. 
 
The aim of the current study was to validate the results of the discovery cohort in 
a larger, modern cohort of prostate cancer patients that is more reflective of 
today’s clinical practice. Disease-specific survival was not available for this cohort, 
therefore study outcome measures in this study were time to biochemical relapse 
and overall survival.  
6.1 Protein expression analysis 
 
243 patients had tissue available for IHC. Protein expression in the nucleus and 
cytoplasm was recorded in epithelial tumour cells only. Unfortunately, due to 
technical difficulties and time constraints, protein expression of each antibody 
could not be performed for all patients in the cohort. Expression of all proteins 
was heterogeneous throughout the cells.  
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Protein expression in the specimens was divided into low (≤median) and high 
(>median) for purposes of analysis (Table 6.1). All ICCC values were ≥0.80.  
 
Table 6.1 Protein expression in patients with tissue available 
 
 Patients, n (%) Median 
Histoscore 
(Histoscore units) 
IQR 
(Histoscore 
units) 
AR Nuclear (low/high) 109 (44.9)/ 106 (43.6) 153 120 – 185 
AR Cytoplasmic (low/high) 111 (45.7)/ 104 (42.8) 83 40 - 100 
pARS81 Nuclear (low/high) 98 (40.3)/ 87 (35.8) 170 131 – 200 
pARS81 cytoplasmic (low/high) 95 (39.1)/ 90 (37.0) 100 100 – 120 
pARS578 Nuclear (low/high)  61 (15.9)/ 57 (14.8) 127 102 – 154 
pAR S578 Cytoplasmic (low/high) 61 (15.9)/ 57 (14.8) 130 107 – 163 
PKC Nuclear (low/high) 41 (10.7)/ 41 (10.7) 66 16 – 114 
PKC Cytoplasmic (low/high) 45 (11.7)/ 37 (9.6) 103 55 - 124 
 
The median histoscore for each protein of interest was calculated. Patients were 
grouped into low (≤median) and high expression (>median). The number of 
patients in each group is displayed for each protein.  
Number of patients with missing data is not displayed. Values that do not give a 
sum of 100% is due to tissue being unavailable 
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6.2 Association between PKC expression and expression of pARS578 in 
clinical specimens 
 
In the clinical specimens, nuclear PKC expression was significantly associated with 
pARS578 expression in both the nucleus (c.c. 0.377, p=0.013) and cytoplasm (c.c. 
0.378, p=0.012). There was no association between cytoplasmic PKC and pARS578 
expression. Table 6.2 demonstrates the associations between PKC and pARS578. 
  
Table 6.2 Association between PKC expression and expression of pARS578 at 
both cellular locations in the clinical specimen 
 
 
 
Pearson’s correlation coefficient was used to assess the association between PKC 
expression and expression of pARS578 in the nucleus and cytoplasm. Expression of 
nuclear PKC was significantly associated with pARS578 expression at both locations. 
C.C. denotes Pearson’s correlation co-efficient.Values highlighted in red denotes 
associations with a p value < 0.05  
 
6.3 Expression of pARS81, pARS578 and PKC related to clinico-
pathological parameters 
 
Expression of nuclear pARS578 is significantly associated with age at diagnosis (p = 
0.034). The expression of cytoplasmic pARS578, pARS81 and PKC did not correlate 
with any clinico-pathological parameters.   Table 6.3 demonstrates the expression 
of pARS81, pARS578 and PKC as related to clinico-pathological parameters.
 PKC 
 Nuclear 
p value, C.C 
Cytoplasmic 
p value, C.C 
pAR578 Nuclear 0.013, 0.377 0.154, 0.221 
pAR578 Cytoplasmic 0.012, 0.378 0.069, 0.280 
 136 
Table 6.3 Expression of pARS81, pARS578 and PKC related to clinico-pathological parameters 
 
Expression of pARS81, pARS578 and PKC in the nucleus and cytoplasm was examined for significant relationships with clinical 
variables as shown. Protein expression was divided into high and low groups. Clinical variables were divided into groups and 
the Mann-Whitney U test was performed for statistical analysis. Expression of nuclear pARS578 is significantly associated with 
age at diagnosis. Statistically significant (p = £0.05) results are highlighted in red.
  Nuclear AR S81 Cytoplasmic AR S81 Nuclear AR S578 Cytoplasmic AR  S578 Nuclear PKC Cytoplasmic PKC 
  Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Low 
expression 
High 
expression 
p-
value 
Age               
(<70/>70) 
43/50 44/35 0.218 43/46 44/39 0.539 22/38 29/22 0.034 22/35 29/25 0.112 18/21 13/24 0.332 16/27 15/18 0.471 
Gleason        
(<7/7/>7) 
33/34 21/33 0.708 34/33/19 20/34/24 0.060 20/24/14 12/21/17 0.169 16/24/14 16/21/17 0.707 8/18/10 9/17/11 0.993 11/18/12 6/17/9 0.685 
Diagnosis 
PSA 
(<10/10-
20/>20) 
31/19/43 24/18/37 0.791 33/17/38 22/20/42 0.175 13/15/31 17/8/27 0.489 14/13/29 16/10/29 0.847 10/9/20 4/10/23 0.152 8/9/26 6/10/17 0.638 
PNI                         
(no/yes) 
50/41 33/35 0.424 49/36 34/40 0.142 34/23 27/21 0.726 30/23 31/21 0.756 13/23 20/17 0.126 18/23 15/17 0.801 
% cores 
positive for 
malignancy 
(<50/≥50) 
26/42 20/36 0.773 27/37 19/41 0.227 18/31 13/27 0.678 17/28 14/30 0.557 7/21 6/21 0.810 6/26 7/16 0.319 
Metastases 
(no/yes) 
71/14 58/10 0.766 67/13 62/11 0.841 49/6 38/7 0.494 46/5 41/8 0.335 27/6 30/5 0.665 31/7 26/4 0.574 
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6.4 Expression of pARS81, pARS578 and PKC related to clinical outcome 
measures 
 
Table 6.4 shows the univariate analysis of expression of pARS81, pARS578 and PKC 
related to clinical outcome measures. 
 
Table 6.4 Univariate analysis of expression of pARS81, pARS578 and PKC related 
to clinical outcome measures 
 
Univariate analysis 
Protein expression 
(<median/>median) 
Time to biochemical 
relapse 
P value Hazard Ratio (95% 
CI) 
Overall survival 
 
P value Hazard Ratio (95% 
CI) 
pARS81 Nuclear  
 
0.756, 1.1, 0.5-2.3 0.261, 1.3, 0.8-2.2 
pARS81 Cytoplasmic  
 
0.647, 1.2, 0.6-2.4 0.136, 1.5, 0.9-2.4 
pARS578 Nuclear  
 
0.135, 2.0, 0.8-5.4 0.689, 1.1, 0.6-2.1 
pAR S578 Cytoplasmic  
 
0.037, 2.9, 1.0-8.2 0.076, 1.8, 0.9-3.2 
PKC Nuclear  
 
0.910, 1.1, 0.4-3.2 0.285, 1.4, 0.7-2.7 
PKC Cytoplasmic  
 
0.412, 1.6, 0.5-4.7 0.966, 1.0, 0.5-1.9 
 
Expression of pARS81, pARS578 and PKC in the nucleus and cytoplasm was analysed 
by Kaplan-Meier methods and Cox regression in relation to time to biochemical 
relapse from diagnosis, overall survival from biochemical relapse and overall 
survival. Patients were considered to have biochemical relapse with serum PSA 
>0.2 ng/ml following radical prostatectomy, serum PSA of 2.0 ng/ml above the 
post treatment nadir level following radical radiotherapy or 2-3 consecutive 
elevations of serum PSA above the nadir over intervals greater than 2 weeks 
following hormone treatment. Protein expression was divided into high and low 
groups by the median value. High expression of cytoplasmic pARS578 was associated 
with shorter time to biochemical relapse. Significant results (p = £0.05) are 
highlighted in red. 
 
High expression of cytoplasmic pARS578 was associated with shorter time to 
biochemical relapse (proportion of patients relapsed at 5 years, <median 
expression 12% vs >median expression 32%, HR 2.9 (95% CI 1.0-8.2), p=0.037) 
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(Figure 6.1). No association was observed between pARS81 or PKC and time to 
biochemical relapse.  
 
Figure 6.1 Kaplan Meier Graph showing expression of pARS578 related to time 
to biochemical relapse 
 
 
Kaplan-Meier survival plot showing expression of cytoplasmic pARS578 as related to 
time to biochemical relapse. High cytoplasmic pARS578 (dashed line) is significantly 
associated with decreased time to biochemical relapse 
 
 
High expression of cytoplasmic pARS578 trended towards an association with 
decreased overall survival but did not reach clinical significance (p = 0.076). No 
association was observed between pARS81 or PKC and overall survival.  
 
Due to the short follow-up period and limited number of patients with IHC 
performed for pARS81 and pARS578, overall survival following biochemical relapse as 
related to protein expression could not be calculated in this cohort.  
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6.5 Expression of dual phosphorylation sites on the androgen receptor 
related to outcome measures 
 
The two phosphorylation sites were combined as follows: (i) high pARS81 and high 
pARS578, (ii) high pARS81 or high pARS578 and (iii) low pARS81 and low pARS578 
expression.  
 
High cytoplasmic pARS81 and cytoplasmic pARS578 was associated with decreased 
overall survival (5-year survival, high expression of both proteins 48% vs low 
expression of both proteins 84%, HR 3.5, (95% CI 1.5-8.6) p=0.003) (Figure 6.2 A). 
High nuclear pARS81 and nuclear pARS578 was associated with decreased overall 
survival (5-year survival, high expression of both proteins 58% vs low expression of 
both proteins 89%, HR 3.6, (95% CI 1.2-11.4) p=0.016) (Figure 6.2 B).  
 
Lastly, the expression of total cytoplasmic pARS81 and pARS578 and total nuclear 
pARS81 and pARS578 was investigated in relation to clinical outcome measures. 
Patients were grouped as follows: (i) high total cytoplasmic expression of pARS81 
and pARS578 and high total nuclear expression of pARS81 and pARS578, and (ii) low 
total cytoplasmic expression of pARS81 and pARS578 and low total nuclear expression 
of pARS81 and pARS578. Combined high expression of total cytoplasmic pARS81 and 
pARS578 and high total nuclear expression of pARS81 and pARS578 was associated with 
overall survival (5-year survival, high total expression of both proteins 53% vs low 
total expression of both proteins 88%, HR 4.0, (95% CI 1.0-15.3) p=0.027) (Figure 
6.2 C).  
 
There was no association between combined expression of pARS81 and pARS578 in 
relation to time to biochemical relapse. 
 
Table 6.5 shows the univariate analysis of dual phosphorylation sites as related to 
clinical outcome measures.   
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Table 6.5 Univariate analysis of expression of dual expression of pARS81 and 
pARS578 related to clinical outcome measures 
 
Univariate analysis 
 Time to biochemical 
relapse 
 
P value Hazard Ratio (95% 
CI) 
Overall survival 
 
P value Hazard Ratio (95% 
CI) 
pARS578 cytoplasmic + 
pARS81 cytoplasmic 
 
0.624, 1.4, 0.4-5.7 0.003, 3.5, 1.5-8.6 
pARS578 nuclear + pARS81 
nuclear 
 
0.654, 1.4, 0.3-5.5 0.016, 3.6, 1.2-11.4 
Total cytoplasmic pARS81 
and pARS578 + total nuclear 
pARS81 and pARS578 
  
0.607, 1.5, 0.3-6.6 0.027, 4.0, 1.0-15.3 
 
Dual expression of pARS81 and pARS578 was analysed by Kaplan-Meier methods and 
Cox regression in relation to time to biochemical relapse from diagnosis, overall 
survival from biochemical relapse and overall survival. Patients were considered 
to have biochemical relapse with serum PSA >0.2 ng/ml following radical 
prostatectomy, serum PSA of 2.0 ng/ml above the post treatment nadir level 
following radical radiotherapy or 2-3 consecutive elevations of serum PSA above 
the nadir over intervals greater than 2 weeks following hormone treatment. 
Protein expression was divided into high and low groups. High dual expression of 
pARS81 and pARS578 is associated with decreased overall survival than compared to 
low expression of both phosphosites in all three groupings. Significant results (p = 
£0.05) are highlighted in red.  
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Figure 6.2 Kaplan Meier Graphs showing dual expression of pARS81 and pARS578 
as related to overall survival 
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A. Kaplan Meier survival plot showing overall survival in patients with low 
expression of both cytoplasmic pARS81 and pARS578 (solid line) and high 
expression of both cytoplasmic pARS81 and pARS578 (dashed line). High 
expression of both cytoplasmic pARS81 and pARS578 is associated with 
decreased overall survival than compared low expression of both phosphosites 
B.  Kaplan Meier survival plot showing overall survival in patients with low 
expression of both nuclear pARS81 and pARS578 (solid line) and high expression of 
both nuclear pARS81 and pARS578 (dashed line). High expression of both nuclear 
pARS81 and pARS578 is associated with decreased overall survival than compared 
low expression of both phosphosites 
C. Kaplan Meier survival plot showing overall survival in patients with low 
expression of total pARS81 and pARS578 (solid line) and high expression of total 
pARS81 and pARS578 (dashed line). High total expression of pARS81 and pARS578 is 
associated with decreased overall survival than compared to low total 
expression of pARS81 and pARS578 
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6.6  Discussion 
 
Androgen receptor phosphorylation status has been investigated in this study in 
relation to clinico-pathological parameters and clinical outcome measures with a 
view to verification of the results of the discovery cohort in Chapter 4.  
 
Protein expression in the validation cohort differs to that observed in the discovery 
cohort. The median expression of cytoplasmic pARS578 and PKC was slightly higher 
than nuclear expression for both proteins, which is the inverse pattern to that 
observed in the discovery cohort but similar to that observed in the active 
surveillance cohort. Furthermore, median expression of all proteins observed in 
the validation cohort was higher than that in the discovery cohort, and similar to 
that in the active surveillance cohort. A possible reason for this may be the age of 
the tissue utilised in this study. The TMA for the discovery cohort was constructed 
several years ago and cut slides had been stored for a couple of years prior to use, 
whereas the tissue utilised in the AS and validation cohorts had been cut and 
utilised within a much shorter time period. Despite optimum storage conditions, 
pre-cut slides are exposed to ambient changes in humidity and temperature, which 
can lead to protein degradation through oxidation. (204) A recent study of archival 
breast tissue found the average antigenicity signal from detected biomarkers 
decreased with increasing age of the tissue specimen. (205) The varying expression 
patterns observed between the cohorts are in keeping with this study. Together 
these results suggest that an adjustment for tissue age may be required when 
comparing results from studies using archival tissue of varying age.  
 
Nuclear PKC expression was significantly associated with pARS578 expression in this 
cohort. These results taken with those of the AS and discovery cohorts supports 
PKC being the putative kinase for AR phosphorylation at Ser-578. 
 
Androgen receptor phosphorylation at Ser-578 in the AS and discovery cohorts was 
associated with markers of high-risk disease. These findings could not be verified 
in the current cohort and may be due to the small number of patients available for 
analysis in the validation cohort. Surprisingly, in the current cohort there was a 
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significant association high expression of pARS578 and younger age at diagnosis. This 
finding was not observed in the AS or validation cohort and the relevance of this is 
unclear.  Further analysis should be performed once staining is complete for this 
cohort to verify the results of the earlier cohorts. 
 
As discussed earlier, phosphorylation status of the AR at a number of serine 
residues has been associated with clinical outcome measures. (124, 126, 128) High 
expression of cytoplasmic pARS578 was associated with shorter time to biochemical 
relapse and trended towards an association with decreased overall survival, 
supporting the findings of the discovery cohort. It may be that the use of overall 
survival as an outcome measure in this cohort as opposed to disease-specific 
survival may be masking the true significance of pARS578 expression as a prognostic 
biomarker in prostate cancer. This is particularly relevant in prostate cancer 
patients, who are generally an older population in whom death is more likely from 
all causes. This may reduce the sensitivity of pARS578 expression in identifying those 
patients with high-risk prostate cancer.  Despite this, these findings clearly 
demonstrate that phosphorylation status of AR at Ser-578 is of clinical relevance in 
prostate cancer patients at diagnosis. Completion of IHC staining in this cohort 
should be conducted to confirm these results and should be validated in a multi-
centre prospective cohort before recommending this biomarker for use in clinical 
practice.  
 
The prognostic significance of dual expression of pARS81 and pARS578 was 
investigated in the validation cohort. High dual expression of pARS81 and pARS578 
was significantly associated with decreased overall survival. This result is 
particularly striking when neither phosphorylation site was associated with overall 
survival when assessed independently. These results lend further support to the 
findings of the AS and discovery cohorts, suggesting a synergistic effect when these 
two phosphorylation sites are combined in relation to predicting poor outcome in 
prostate cancer patients. Furthermore, these findings suggest that there is a sub-
population of prostate cancer patients who may benefit from dual targeted 
therapy with ADT and PKC inhibitors. Future work should include cell line studies 
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to assess the response of patients to ADT and PKC inhibitors in relation to pARS81 
and pARS578 expression.  
 
A number of limitations have been identified in this study. Unfortunately, due to 
time constraints, only a limited number of patients had complete staining for all 
antibodies of interest. This work should be completed and reanalysed to verify the 
preliminary results in this cohort. This cohort has a relatively short follow-up 
period and therefore only a small number of events occurred, which is unsurprising 
given the long natural history of prostate cancer. Despite these confounding 
factors, it has still been possible to demonstrate that androgen receptor 
phosphorylation status is relevant to clinical outcomes in prostate cancer patients.  
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Chapter 7 Isolation, propagation and characterisation of primary 
prostate cancer epithelial cell cultures from prostate specimens 
 
Currently, the majority of in vitro prostate cancer research utilises established 
prostate cancer cell lines, the most common of which are LNCaP, PC-3 and 
DU145 cells. (206) Each cell line demonstrates specific characteristics such as AR 
expression and responsiveness to androgens, which corresponds to the clinical 
characteristics of the patient from whom these cell lines were originally 
developed.  Many cell lines are derived from metastatic sites, indicating an 
advanced phenotype. (207) Furthermore, it has been suggested that prostate 
cancer cell lines are often genetically altered by their non-physiological in vitro 
conditions and thus are not truly representative of prostate cancer patients.  
 
Primary prostate cell culture allows the development of a wide phenotypic range 
of prostate cancer cells. Due to the short culture period in many described 
techniques, these primary cells are thought to more accurately reflect the 
characteristics of the patients from whom the cells were derived. Not only can 
primary prostate cell cultures provide models for development of new drug 
treatments, but may also be utilised in personalised medicine to aid in the 
identification of biomarkers to predict which patients will respond best to 
specific treatments.  
 
In this study, we develop a technique for isolation, propagation and 
characterisation of primary prostate cancer cells in 2-D culture from prostate 
specimens.  
7.1 Establishing method for isolation and propagation of primary 
prostate cells 
 
Over a one year period, 36 clinical specimens were collected via TRUS biopsy of 
the prostate and prepared for culture. Several problems were encountered with 
culturing primary prostate epithelial cells including infection, no/poor growth of 
epithelial cells and overgrowth of fibroblasts. A number of changes were made 
to the culture method including the removal of fetal bovine serum from the 
growth medium, minimising the use of Matrigel in cell culture flasks and refining 
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the quantities of growth factors included in the culture medium before 
successfully culturing two patient samples, T288 and T290.   
 
7.2 Patient Characteristics 
 
Two cell cultures were propagated from two patients attending a TRUS biopsy 
list at Glasgow Royal Infirmary in 2015. The patient characteristics are 
summarised in Table 7.1.  
 
The T288 cell culture was obtained from a 56-year-old patient undergoing 
investigation from prostate cancer due to an elevated PSA of 12.3 ng/ml. 
Pathological examination of the other sampled cores obtained at the same time 
revealed a Gleason 3+3 adenocarcinoma of the prostate in 20% of the cores 
sampled, with less than 2% of the cores positive for malignancy. The patient 
went on to have a radical prostatectomy and was confirmed to have a Gleason 
3+3 tumour.   
 
The T290 cell culture was obtained from a 64 year-old patient with a known 
prostate cancer, having being diagnosed with a Gleason 3+3 adenocarcinoma of 
the prostate on a TURP in 2009. The patient was on AS and previous biopsy in 
2012 was negative. Pathological examination of the biopsy cores revealed a 
benign result.  
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Table 7.1 Patient characteristics of primary prostate cell cultures 
 
 Patients 
Clinical Parameter T288 T290 
Age at biopsy 56 64 
PSA at biopsy (ng/ml) 12.3 0.6 
Pathology Adenocarcinoma Benign 
Gleason 3+3=6 - 
% cores positive for 
malignancy 
20% - 
Total tissue malignant <2% - 
HGPIN Yes No 
PNI No - 
Extra-prostatic extension No - 
 
Comparison of the clinico-pathological characteristics of the two patients 
included in this study.  
 
7.3 Flow Cytometry 
 
CK-18, a luminal epithelial cell marker, was used to confirm the presence of 
luminal epithelial cells in the cell culture. CD-90, is a cell surface glycoprotein 
expressed on stem cells and non-lymphoid tissues including fibroblasts, neurons 
and activated epithelial cells but not luminal epithelial cells. 
 
Flow cytometry was performed for T288 and T290 cell cultures. DAPI confirmed 
that 97% of cells in T288 cell culture and 94% of cells in the T290 cell culture 
were alive at time of analysis. Only live cells were analysed for expression of CK-
18 and CD-90. In both cell cultures, the majority of the primary prostate cells 
expressed CK-18 and did not express CD-90. This suggests that most cells 
cultured by this method were luminal prostate epithelial cells. In each cell 
culture, a small number of cells expressed only CD-90, suggesting there was a 
small sub-population of fibroblasts. Table 7.2 demonstrates the expression 
pattern in both cell lines.  
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Table 7.2 Flow cytometry results for primary prostate cell cultures 
 
 
Flow cytometry was used to investigate the expression pattern on CK-18 and 
CD90 in the primary prostate cell cultures. Only live cells were analysed for 
expression of the proteins of interest.  
 
7.4 Gene Expression in Primary Prostate Cell cultures 
 
A panel of genes were selected in order to confirm the presence of prostate 
epithelial cancer cells in the primary cultures. The panel of genes tested include 
AR (androgen receptor), FASN (fatty acid synthase), KLK-3 (kallikrein related 
peptidase 3), GOLM1 (golgi membrane protein 1) and AMACR (alpha-methylacyl-
CoA racemase). Table 7.3 summarises the functions of the gene and typical 
expression pattern in prostate cancer.  
 
  
 T288 T290 
Total cells analysed 32254 32103 
Alive (%) 97.0 93.6 
CK18+/ CD90- (%) 84.3 58 
CK18-/ CD90+ (%) 0.3 1.9 
CK18+/ CD90+ (%) 9.7 29.5 
CK18-/ CD90- (%) 5.6 10.6 
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Table 7.3 Gene expression in prostate cancer 
 
Gene Function Expression in prostate 
cancer 
AR Produces AR protein Increased 
FASN Produces fatty acid synthase Increased 
KLK-3 Produces PSA No significant correlation 
GOLM1 Produces golgi membrane protein 1 Increased 
AMACR Produces alpha-methylacyl-CoA racemase Increased 
 
The function and expression pattern of the genes of interest in prostate cancer 
are detailed.  
 
Levels of mRNA were normalised to those obtained for the housekeeping gene 
ActB. The comparative (ΔΔCt) method was used to quantify relative gene 
expression in two established prostate cancer cell lines (LNCaP and VCaP) and 
the two primary prostate cell cultures compared to a control sample of an 
established benign prostate cell line, PNT2. Results are presented in fold change 
in the target gene relative to ActB endogenous control. A fold change of 1.5 
compared to the control was considered a relevant change in expression.  
Expression of mRNA for all genes of interest from both the prostate cancer cell 
lines and primary prostate cell cultures was increased compared to the benign 
control cell line (Figure 7.2). 
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Figure 7.2 Expression of mRNA in malignant cell lines compared to benign 
control cell line 
 
 
The comparative (ΔΔCt) method was used to quantify relative gene expression 
in two established prostate cancer cell lines (LNCaP and VCaP) and the two 
primary prostate cell cultures compared to a control sample of an established 
benign prostate cell line, PNT2. Results are presented in fold change in the 
target gene relative to ActB endogenous control. A 1.5-fold increase in gene 
expression was considered to be relevant. 
 
AR mRNA expression was highest in the VCaP cell line, where expression was 
increased by 6.1 fold compared to the benign cell line. In the LNCaP cell line, 
expression was increased by 2.7 fold. Expression was increased by 4.1 fold in the 
T290 cell culture and there was a non-relevant increase of 1.4 fold in the T288 
cell culture (Figure 7.2 A).   
 
FASN mRNA expression was highest in the VCaP cell line, where expression was 
increased by 5.0 fold compared to PNT2. Expression was increased by 4.6 fold in 
the T290 cell culture and there was a non-relevant increase in expression of 0.9 
fold in the T288 cell culture (Figure 7.2 B).  
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KLK-3 mRNA expression was highest in the LNCaP cell line, where expression was 
increased by 6.2 fold. Expression was increased by 2.3 fold in the T290 cell 
culture. There was an increase in expression of 1.5 fold in the VCaP cell line and 
a non-relevant increase of 0.9 fold in the T288 cell culture (Figure 7.2 C).  
 
GOLM1 mRNA expression was increased in all cell lines compared to control, 
however, only LNCaP cells showed a relevant increased fold change (1.9) 
compared to control (Figure 7.2 D).  
 
AMACR mRNA expression was highest in the VCaP cell line, where expression was 
increased by 4.3 fold compared to the benign cell line. In the LNCaP cell line, 
expression was increased by 2.1 fold. Expression was increased by 3.3 fold in the 
T290 cell culture and there was a non-relevant increase of 1.1 fold in the T288 
cell culture (Figure 7.2 E).  
 
Table 7.4 summarises the fold change in mRNA expression in each cell line 
compared to the benign control cell line.  
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Table 7.4 Fold change in expression of mRNA in malignant cell lines 
compared to benign control cell line 
 
 Gene 
Cell line AR FASN KLK-3 GOLM1 AMACR 
LNCaP 2.7 2.0 6.2 1.9 2.1 
VCaP 6.1 5.0 1.5 0.8 4.3 
T288 1.4 0.9 0.9 0.4 1.1 
T290 4.1 4.6 2.3 1.3 3.3 
 
The comparative (ΔΔCt) method was used to quantify relative gene expression 
in two established prostate cancer cell lines (LNCaP and VCaP) and the two 
primary prostate cell cultures compared to a control sample of an established 
benign prostate cell line, PNT2. Results are presented in fold change in the 
target gene relative to ActB endogenous control. A 1.5-fold increase in gene 
expression was considered to be relevant. Relevant results are highlighted in 
red.  
 
7.5 Protein expression in primary prostate cell cultures 
 
Protein expression of AR, PSA and pARS578 was assessed in the primary prostate 
cell cultures, T288 and T290, using IF as shown in Figure 7.3. 
 
AR was expressed in both T288 and T290 cell cultures. In the T288 cell culture, 
expression was predominantly cytoplasmic, whereas in the T290 cell culture, 
expression was predominantly nuclear.  
 
PSA is a serine protease expressed by both benign and malignant epithelial cells 
in the prostate. Expression of PSA is regulated by the AR, and is expressed in 
response to androgens activating the AR.  PSA expression was demonstrated in 
both the nucleus and cytoplasm of both primary prostate cell cultures, thus 
confirming that AR is functionally active in both cell cultures.  
 
As the main phosphorylation site of interest on the AR in this body of research 
has been Ser-578, the expression of pARS578 was assessed in the two primary 
prostate cell cultures. Expression of pARS578 was identified in both the nucleus 
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and cytoplasm in both cell cultures. Intensity of staining was greatest in the 
T288 cell culture compared to T290.  
 
Figure 7.3 Protein expression of AR, PSA and pARS578 in primary prostate cell 
cultures 
 
 
 
IF confirms the presence of AR, which is demonstrated to be functional by the 
presence of PSA expression. The protein of interest, pARS578, is also shown to be 
expressed by both primary cell cultures. 
 
7.6 Effect of PKC inhibitors on AR protein expression in prostate cell 
cultures  
 
As shown in Chapter 4, high expression of pARS578 is associated with poor 
outcome measures in hormone-naïve prostate cancer (Figure 4.2). PKC is the 
predicted kinase responsible for phosphorylation of the AR as serine 578. 
Furthermore, PKC expression is significantly associated with pARS578 expression in 
prostate cancer tissue (Table 3.3, 4.3 and 6.2). The effect of PMA, a PKC 
activator, and BIM-1, a highly selective, reversible inhibitor of PKC, on 
expression of AR and pARS578 was therefore investigated.  
 
Expression of AR was increased in the nucleus and cytoplasm of LNCaP cells and 
in the cytoplasm of T288 cells upon treatment with PMA (Figure 7.4B and 7.4D). 
No discernible difference was noted in the PNT2 and VCaP cells (Figure 7.4A and 
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7.4C). On treatment with BIM-1 following stimulation with PMA, there was 
increased nuclear localisation of the AR in the PNT2 and VCAP cells (Figure 7.4A 
and 7.4C). There was decreased expression of AR in LNCaP cells when treated 
with PMA and BIM-1 than compared to PMA alone (Figure 7.4B). No difference 
was observed in the T288 cells treated with PMA and BIM-1 than compared to 
PMA alone (Figure 7.4D).  
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Figure 7.4 Expression of AR in prostate cell cultures following treatment with 
PMA and BIM-1 
  
 
 
 
Cells were incubated in the presence or absence of 10µM BIM-1 for one hour, 
followed by stimulation with 10 nM PMA for one hour. IF was perfomed to assess 
expression of AR in each cell type. 
A. PNT2 cells showed no change in expression of AR upon treatment with PMA. 
On treatment with BIM-1 following stimulation with PMA, there was 
increased nuclear localisation of the AR.  
B. LNCaP cells showed increased expression of AR in both the nucleus and 
cytoplasm upon treatment with PMA. On treatment with BIM-1 following 
stimulation with PMA, there was decreased expression of AR than compared 
to PMA alone.  
C. VCaP cells showed no change in expression of AR upon treatment with PMA. 
On treatment with BIM-1 following stimulation with PMA, there was 
increased nuclear localisation of the AR. 
D. T288 cells showed increased cytoplasmic expression of AR upon treatment 
with PMA. No difference was observed in the cells treated with PMA and 
BIM-1 than compared to PMA alone. 
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Expression of pARS578 was assessed in the established cell lines only. 
Unfortunately, the T288 cell culture stopped growing prior to completion of this 
experiment and therefore it was not possible to study the change in expression 
of pARS578 with drug treatment.  
 
In the PNT2 cells, expression of pARS578 was markedly increased and 
demonstrated increased nuclear localisation upon treatment with PMA (Figure 
7.5A). Expression was also increased in both the LNCaP and VCaP cells in both 
the cytoplasm and nucleus, although with less intensity to that observed in the 
PNT2 cells (Figure 7.5B and 7.5C). On treatment with BIM-1 following stimulation 
with PMA, there was increased cytoplasmic expression of pARS578 than compared 
to nuclear in both the PNT2 and LNCaP cells than compared to PMA alone. No 
discernible difference was demonstrated in the VCaP cells treated with PMA and 
BIM-1 than compared to PMA alone. 
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Figure 7.5 Expression of pARS578 in prostate cell lines following treatment 
with PMA and BIM-1 
 
 
 
Cells were incubated in the presence or absence of 10µM BIM-1 for one hour, 
followed by stimulation with 10 nM PMA for one hour. IF was perfomed to assess 
expression of pARS578 in each cell line. 
A. PNT2 cells showed increased expression of pARS578 and increased nuclear 
localisation upon treatment with PMA. On treatment with BIM-1 following 
stimulation with PMA, there was increased cytoplasmic expression of pARS578 
and decreased nuclear expression of pARS578than compared to cells treated 
with PMA alone 
B. LNCaP cells showed increased expression of nuclear and cytoplasmic pARS578 
upon treatment with PMA. On treatment with BIM-1 following stimulation 
with PMA, there was increased cytoplasmic expression of pARS578 and 
decreased nuclear expression of pARS578than compared to cells treated with 
PMA alone 
C. VCaP cells showed increased expression of nuclear and cytoplasmic pARS578 
upon treatment with PMA. There was no difference in expression pattern 
upon treatment with BIM-1 following stimulation with PMA than compared 
to cells treated with PMA alone 
 
Due to time constraints, the experiments above were only completed once and 
therefore no conclusions can be elucidated.  
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7.6 Discussion 
 
In this study, a method for propagation of primary prostate cells from TRUS 
biopsy tissue was developed. A number of techniques were employed to confirm 
the propagation of a luminal epithelial cell culture and to investigate the 
genotype and phenotype of those cells isolated and propagated.  
 
Flow cytometry has confirmed that this technique allows the isolation and 
propagation of luminal epithelial cells. This is confirmed by the presence of CK-
18, a luminal epithelial cell marker that is absent in basal epithelial cells. (208) 
A small population of cells did not express CK-18, instead expressing CD-90. CD-
90 is a cell adhesion molecule expressed by fibroblasts and has previously been 
shown to be overexpressed by prostate cancer-associated fibroblasts. (209, 210) 
This suggests that the majority of cells cultured by this method are luminal 
epithelial cells, with a small sub-population of fibroblasts or non-luminal 
epithelial cells.  
 
The expression pattern of mRNA from five biomarkers in two prostate cancer cell 
lines and two primary prostate cancer cell cultures compared to a benign 
prostate cell line was investigated to confirm a luminal epithelial prostate 
cancer genotype in the primary prostate cancer cell cultures. 
 
mRNA expression of AR was found to be elevated in all cell lines compared to 
the benign control. It is well recognised that both LNCaP and VCaP cells express 
AR mRNA.(211-213) In keeping with the literature, our results show that AR 
mRNA in VCaP is overexpressed compared to LNCaP. (214)   mRNA expression of 
AR was also demonstrated in both the primary cell cultures. Of particular note, 
the expression of AR mRNA in the T290 cell culture was higher than that 
observed in the LNCaP cell line. Early studies have shown low or no expression of 
AR mRNA in primary prostate cell cultures, which was thought to be due to the 
growth of basal epithelial cells over luminal epithelial cells, which do not 
express AR mRNA (215). More recent studies have developed primary prostate 
cells cultures with AR expression. (216, 217) The expression of AR in the primary 
cell cultures in this study therefore supports the results of the flow cytometry 
suggesting differentiated luminal epithelial primary prostate cells have been 
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grown in this study. This is further supported by the expression of KLK3 mRNA, 
an AR target gene responsible for the production of PSA. The expression of KLK3 
in all four cell lines indicates a luminal, secretory epithelial cell line, as it is 
known that basal epithelial cells do not express the KLK3 gene or PSA. (89, 218) 
Again, it is interesting to note that the T290 cell culture had higher expression 
of KLK3 than VCaP cell line.  
 
Expression of mRNA of FASN, GOLM1 and AMACR was increased in both the 
immortalised prostate cancer cell lines and primary prostate cancer cell cultures 
compared to the beingn prostate control cell line. The increased expression in 
the immortalised prostate cancer cell lines supports the existing body of 
evidence that all three genes have been shown to be overexpressed with a 
malignant genotype. (219-223) Furthermore, the increased expression in the 
primary prostate cancer cell cultures, comparable to that of the immortalised 
prostate cancer cell lines, supports a malignant genotype in these cells. This is 
of particular note in the T290, which despite being benign on pathological 
examination, the prostate epithelial cells expressed a malignant genotype.  
 
It is well recognised that expression levels of mRNA in biological samples do not 
necessarily correlate with protein expression. (224) We therefore sought to 
confirm the presence of AR and PSA protein in the primary prostate cells. Both 
the T288 and T290 were confirmed to express a functional AR, as indicated by 
the expression of PSA. The primary cell cultures were also confirmed to express 
the protein of interest in this study, pARS578, thus indicating that these cells can 
be utilised in future studies to evaluate the use of pARS578 as a biomarker in 
prostate cancer.  
 
The final element of this study investigated the effect of BIM-1, a PKC inhibitor 
on the expression of AR and pARS578 in this study. As we have shown in earlier 
chapters, PKC expression is correlated with pARS578 expression in tissue samples. 
It was hypothesised that treatment of established prostate cell lines with BIM-1 
would decrease expression of pARS578 through inhibition of PKC. As was expected, 
the expression of pARS578 was increased in all three established prostate cell lines 
on treatment with PMA, an upstream activator of PKC. Treatment with BIM-1, a 
PKC inhibitor, resulted in increased expression of pARS578 in the cytoplasm and 
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decreased expression in the nucleus in PNT2 and LNCaP cells. This suggests 
inhibition of nuclear translocation of the AR through inhibition of PKC-dependent 
phosphorylation of the AR. Surprisingly, no difference was observed in the VCaP 
cell line. Whilst these experiments were only conducted once, and therefore no 
definite conclusions can be drawn, these results lend support to the existing 
body of literature that pARS578 plays a role in nuclear-cytoplasmic shuttling. (129)   
 
An obvious limitation of this study is the small sample size. This was due to time 
constraints preventing the collection of further patient tissue for culture. 
Furthermore, as the primary cell cultures stopped growing it was not possible to 
complete all experiments of each patient and those that were conducted were 
only performed once for the same reason. However, despite the small sample 
size, it has been demonstrated that using the techniques described in this thesis 
primary cells can be isolated and propagated from TRUS biopsy samples and 
utilised for future experimentation.  
 
This study describes a technique for the isolation and propagation of primary 
prostate cells from TRUS biopsy. The majority of primary prostate cells 
developed in other studies have originated from radical prostatectomy or 
metastatic tissue, thus producing a bias in the cell cultures developed. TRUS 
biopsy is the gold-standard investigation for the diagnosis of prostate cancer, 
and almost every patient diagnosed with prostate cancer will undergo biopsy. 
This technique allows culture of primary prostate cells from all stages of 
prostate cancer, including those who ordinarily would not undergo surgical 
treatment, such as AS patients and those with metastatic spread at the time of 
diagnosis.  The ability to cultivate primary prostate cancer cells in vitro from an 
initial prostate biopsy, opens the door to further translational research for 
individualised medicine, in the hope that these models will be able to predict 
which patients will have aggressive disease and require earlier treatment and 
response to treatment through the use of biomarkers. Further work needs to be 
conducted to confirm this technique in a larger cohort of patients, including 
correlation with biomarkers expressed in prostate tissue and long-term follow-up 
of patients.  
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Chapter 8 General discussion 
 
Prostate cancer incidence is rising in the UK, with new cases predicted to reach 
75,000 per year by 2035. (1) This is mainly due to the increasing use of the PSA 
blood test in general practice, resulting in the over diagnosis of low risk 
localised prostate cancer that may not have been clinically relevant within the 
patient’s life time. (225) Whilst there are effective treatments available for 
localised disease, there are significant side effects and escalating healthcare 
costs associated with radical treatment. Treatment must therefore be reserved 
for those patients who will gain most benefit. Clinical parameters utilised 
currently are inadequate for differentiating between indolent and aggressive 
disease leading to overtreatment of prostate cancer. Identification of reliable 
prognostic biomarkers that can be utilised at the time of diagnosis to 
differentiate between indolent and aggressive prostate cancer are therefore 
urgently required.  
 
Androgen receptor phosphorylation has been extensively associated with 
prostate cancer development, progression and development of castrate-resistant 
disease. AR phosphorylation status has therefore emerged as a potential 
biomarker in assessment of disease severity. Our group has previously 
investigated several phosphorylation sites on the androgen receptor in relation 
to clinical outcome measures with promising results. (124, 126, 128) The aim of 
this thesis was to assess androgen receptor phosphorylation at serine 578 as a 
potential biomarker that can be used in clinical practice. 
 
PKC is the putative kinase for phosphorylation of the androgen receptor at Ser-
578, as predicted by Scansite 2.0.(130) Previous studies have shown PKC to 
phosphorylate the AR. Site-directed mutagenesis of Ser-578 in a CRPC cell line 
resulted in a 50% decrease in PKC-dependent AR phosphorylation compared to 
wild-type cells. (129) In all cohorts, PKC was significantly associated with 
expression of pARS578 in the clinical specimens. Furthermore, in Chapter 7 it was 
observed that expression of pARS578 in prostate cells appeared to increase on 
treatment with PMA, a potent PKC activator. These results must be interpreted 
with caution as they were only performed once and therefore no definite 
conclusions can be drawn. However, taken together with the results of the 
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clinical cohorts, these findings add to the existing body of evidence that PKC is 
the kinase responsible for androgen receptor phosphorylation at Ser-578.  
 
Androgen receptor phosphorylation at Ser-578 has been linked to increased AR 
transcriptional activity, cell growth, nuclear cytoplasmic shuttling, modulation 
of other AR phosphorylation sites and DNA-repair mechanisms.(129) High 
expression of pARS578 was significantly associated with several clinical markers of 
disease severity including increased PSA, Gleason score at diagnosis and the 
presence of PNI in the AS and/or discovery cohort but was not identified in the 
validation cohort. This suggests that there is potential for pARS578 to be a marker 
of high risk-disease but requires further validation is a larger, multi-centre 
cohort of prostate cancer patients.  
 
The relationship between pARS578 and clinical outcome measures was the 
investigated in three clinical cohorts. There was no association between 
expression of pARS578 and time to intervention in the AS cohort. In the discovery 
cohort however, high expression of cytoplasmic pARS578 was found to be 
significantly associated with time to biochemical relapse, disease-specific 
survival following biochemical relapse and disease-specific survival. High 
cytoplasmic expression of pARS578 was significantly associated with shorter time 
to biochemical relapse and trended towards significance in relation to overall 
survival in the validation cohort. It is possible that due to the short period of 
follow-up in the validation cohort, there are insufficient events to reach clinical 
significance. Survival data will therefore continue to be collected and re-
assessed when 10 year follow-up is available.  Overall, these findings support the 
hypothesis that pARS578 expression is increased in advanced disease and is 
associated with poor outcomes in prostate cancer.  
 
Classical androgen receptor phosphorylation in response to DHT occurs at Ser-81. 
(114, 115) Ser-81 phosphorylation is associated with increased AR transcriptional 
activity and expression of androgen-dependent proteins such as PSA, chromatin-
binding of AR to AREs, nuclear localisation of AR and enhanced cell growth in 
prostate cancer cells. (116-118) As androgen receptor phosphorylation at Ser-578 
occurs via an alternative pathway to that of Ser-81 it was hypothesised that dual 
phosphorylation at these sites may have a synergistic prognostic effect in 
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relation to clinical outcome measures. In all three clinical cohorts, high dual 
expression of pARS81 and pARS578 was associated with poor outcome measures and 
had greater prognostic effect than expression of each phosphosite alone. In 
some cases, this was observed even when the phosphosite was not independently 
associated with poor outcome measures, supporting the research hypothesis that 
expression of AR phosphorylated at these sites may have a cumulative prognostic 
effect. These striking results suggest that there is a sub-population of patients 
who are at significantly increased risk of disease progression and poor outcomes. 
Furthermore, due to the differing mechanisms of phosphorylation at Ser-81 and 
Ser-578, this study identifies a cohort of patients may benefit from dual targeted 
therapy with ADT and PKC inhibitors. 
 
In addition to the above studies, a technique for isolation, propagation and 
characterisation of primary prostate cancer cells from TRUS biopsy specimens 
was developed with a view to providing a potential model for investigation of 
clinical biomarkers and drug discovery. The use of TRUS biopsy to culture 
primary prostate cells is particularly exciting, as most previous techniques use 
tissue obtained from radical prostatectomy or metastatic deposits, which can 
create bias. This technique allows prostate cancer of all disease stages to be 
investigated as TRUS biopsy is performed at diagnosis for virtually every prostate 
cancer patient. This work was only conducted in two patients and therefore 
requires validation in a much larger cohort of patients.  
 
One primary cell culture was used to investigate the effect of PMA and BIM-1 on 
the expression pattern of AR. Whilst this experiment was only conducted once 
and no conclusions can be drawn, it does demonstrate the potential of this 
model for identification of biomarkers to predict response to drug treatments.  
 
Future studies to continue the research conducted in this thesis should include 
validation of the results presented in the clinical cohorts in relation to 
expression of pARS81 and pARS578 and clinical outcome measures. Firstly, the IHC 
staining in the validation cohort should be completed and the results re-analysed 
to fully validate the results of the discovery cohort. In addition, the validation 
cohort should be re-assessed when 10-year survival data is available. Following 
on from this, the prognostic significance of pARS578 alone and in combination 
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with pARS81 should be validated by an independent laboratory with a multi-
centre prospectively collected cohort of prostate cancer patients. As 
phosphoantibodies are known to be unstable, downstream markers should be 
identified using gene expression analysis that could be utilised at surrogate 
markers of pARS81 and pARS578 expression for use in clinical practice.  
 
Future in vitro work should include validation of the primary cell culture 
technique in a larger cohort of prostate cancer patients. Primary cell cultures 
could then be utilised for a number of different research purposes including drug 
discovery, assessing for further biomarkers and 3-d culture.  
 
In summary, the evidence presented in this thesis supports the research 
hypothesis that pARS578 expression on it’s own and in combination with pARS81 are 
markers of high-risk disease and are potential biomarkers for poor prognosis in 
prostate cancer. IHC, the technique employed in the evaluation of expression of 
the proteins of interest in the clinical cohorts in this study, is widely used in 
current clinical diagnostic pathology and therefore is deemed to have potential 
for translation into clinical practice.  
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